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SUMMARY OF THESIS 
This thesis investigates the mechanisms involved in sensory signalling from the mouse urinary 
bladder. Sensory afferent firing is essential in the initiation of the micturition reflex and ultimately 
regulates the cycle of bladder filling and bladder emptying. Whilst bladder contraction and efferent 
function have been studied extensively, the processes that determine afferent signalling remain 
elusive and two distinct pathways are currently thought to underlie mechanotransduction: direct 
gating of mechanosensitive afferents in the bladder wall during bladder stretch, and an indirect 
mechanism via the release of mediators from the urothelium. Understanding more about bladder 
afferent transduction mechanisms may lead to the development of novel treatments for lower 
urinary tract disorders in which symptoms are associated with the filling phase of micturition such as 
overactive bladder and interstitial cystitis.  
Mechanisms underlying bladder mechanosensation were investigated both directly, using an in vitro 
afferent nerve recording technique which allowed the concurrent recording of intravesical pressure 
and afferent nerve activity, and indirectly, examining urothelial mediator release and intracellular 
calcium signalling of urothelial cells and isolated DRG neurons. Using a combination of mechanical, 
pharmacological and genetic tools, a role for P2X, P2Y, TRPV1 and NK2 receptors in influencing 
mechanosensitivity was investigated. 
Experiments employing pharmacological blockade or genetic deletion of the TRPV1 receptor 
implicated TRPV1 in bladder mechanosensitivity. Furthermore, experiments investigating the 
mechanisms of TRPV1 mechanosensitivity determined a role for TRPV1 in modulating purinergic 
responses on afferent nerves and ATP release from the urothelium. These mechanisms are thought 
to combine and underlie the decreased afferent nerve sensitivity to distension observed in TRPV1-/- 
knockout mice. This thesis also suggests that autocrine signalling of the urothelium through P2X and 
P2Y receptors may regulate intracellular calcium levels, an essential component of ATP release from 
the urothelium. Furthermore, a role for tachykinins in mediating mouse detrusor contraction acting 
through NK2 receptors was confirmed. A novel mechanism whereby stimulation of urothelial NK2 
receptors was able to alter urothelial mediator release, and modify afferent nerve activity as a result 
of a change in detrusor function was also elucidated.  
As modulation of bladder compliance and detrusor smooth muscle contraction during bladder 
distension was able to significantly alter afferent nerve discharge, these studies suggest that the 
major stimulus for afferent nerve output from the bladder is direct mechanical stretch of the bladder 
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wall, and that in healthy mice, a lesser component is attributable to secondary indirect mechanisms 
mediated via non-neuronal ATP from the urothelium.  
Further research is necessary to determine the relative contribution of the two mechanosensitivity 
pathways in disease states, as there is significant evidence that a phenotypic switch towards an 
indirect mechanism of mechanosensation could underlie increased sensation and reflex bladder 
symptoms.   
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1.1 ANATOMY OF THE BLADDER 
 
The lower urinary tract (LUT) is composed of the urinary bladder and urethra which work in 
synchrony to provide temporary storage and effective voiding of urine delivered via the ureters from 
the kidneys.  
The urinary bladder is a collapsible muscular organ with openings for the ureters and urethra (Fig 
1.1.1) lined by a mucosal membrane on its luminal aspect and a serosal membrane on its outer 
aspect. The bladder stores urine between periods of emptying called micturition. In humans the 
bladder can hold up to a maximum of around 1000ml of urine if necessary, but a more modest 300-
500ml represents a normal adult micturition volume. The bladder lies posterior to the pubic 
symphysis and when empty it is contained entirely within in the pelvis. The bladder is tethered to 
the pubic and pelvic bones by the pubovesical ligaments which help to maintain a stable position 
within the pelvis. The bladder is composed of functionally and histologically distinct regions.  
Fig  1.1.1 Diagrammatic representation of the lower urinary tract and bladder wall of the human. 
Modified from (Mckinley 2009). 
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Bladder histology 
The bladder, as seen in fig 1.1.2 is composed of numerous layers, the functions of which will be 
described in further detail below. The luminal side of the bladder is composed of the urothelium 
which in turn is composed of stratified epithelial cells arranged into three layers of different cell 
types composing from the apical side: umbrella cells, intermediate cells and basal cells (Lewis 2000). 
Beneath the urothelium is the lamina propria/sub-urothelium which is composed of extensive 
innervations of afferent nerve fibers, dense vasculature and a network of interstitial cells. Together, 
the urothelium and suburothelium are often referred to as the mucosa despite a lack of mucous 
secreting cells. Below the suburothelium is the muscular layer composed of three layers: a large 
circular muscle layer which is enclosed by outer and inner longitudinal muscle. The function of the 
bladder relies on coordinated activity between all the layers of the bladder, and each of these will 
now be described in more detail. 
 
 
 
 
Fig 1.1.2. Cross section of the bladder wall, adapted from (Martini 2001) 
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1.2 THE BLADDER WALL: STRUCTURE AND FUNCTION 
 
Urothelium 
Structure 
The urothelium, when viewed as a cross section is arranged into three layers of different cell types 
composing umbrella cells, intermediate cells and basal cells typically 5-7 cells thick (Lewis 2000). 
Basal cells with a diameter of 5-10μm lie in a single layer attached to a basement membrane, 
intermediate cells are pyriform in shape and vary in size around 20μm but can be arranged in a layer 
that is several cells deep. The superficial apical umbrella cells are large hexagonal shaped cells and 
vary in length between 25 – 250μm based on the degree of bladder stretch (Apodaca 2004).  
 
Barrier function 
The primary function of the urothelium is to serve as a passive diffusion barrier, preventing urine 
contents from entering the blood. There is now compelling evidence the urothelium also performs 
an important role in the detection of mechanical, chemical and thermal stimuli essential to normal 
storage and voiding of urine (Birder 2006; Yoshimura, Kaiho et al. 2008), which will later be 
discussed in detail. The ability of the urothelium to function as an effective barrier is provided 
through a number of specific properties of the umbrella cells including high resistance tight junctions 
(Lewis, Berg et al. 1995), which limit the movement of ions and solutes between cells. The luminal 
surface of umbrella cells has a unique lipid protein membrane structure composed of plaque 
(uroplakins) and hinge regions with a glycosaminoglycan (GAG) layer on the luminal membrane 
(Lewis 2000) which reduces the permeability of the urothelium to small molecules such as water, 
urea and protons.   
 
Accommodation to stretch 
An essential feature of the urothelium is the ability to maintain a barrier function during large 
increases in surface area as the bladder is distended. This is considered to involve two phases; with 
the initial increases in surface area being accommodated by microscopic adjustments of the 
structure as the intermediate and basal cell layers are pushed laterally in an unfolding of the 
epithelium from distinct rugae when empty (Minsky and Chlapowski 1978). A second mechanism 
involves the generation of an expanded umbrella cell membrane from a roughly cuboidal shape to a 
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more flat and squamous morphology. This is due to calcium and cAMP dependent pressure induced 
exocytosis of fusiform/discoid vesicles from within the cells (Truschel, Wang et al. 2002; Wang, 
Truschel et al. 2003). The process of exocytosis encompasses a number of steps which combine to 
accomplish cell surface supply and secretion of biologically relevant molecules.  Vesicles, usually 
preformed,  are trafficked over short distances from within the cell cytoplasm to the apical cell 
membrane, where they first tether, dock and then fuse with the plasma membrane via the 
association of the SNARE complex. The contents of the vesicle are expelled into the exterior whilst 
the vesicle membrane is incorporated into the plasma membrane of the cell, increasing its surface 
area.  This process allows umbrella cells to change shape with a dramatic increase in the apical 
surface area. It has been shown that ATP is released from the urothelium in response to stretch 
(Birder, Nakamura et al. 2002; Sadananda, Shang et al. 2009; Dunning-Davies, Fry et al. 2013) and 
purinergic receptors have been recently implicated in mediating vesicle exocytosis via Ca2+ 
mobilisation or influx (Wang, Lee et al. 2005). Post voiding, the membrane recycles into endosomes 
and the resting shape is recovered. 
 
Sensory function of the urothelium  
The role of the urothelium, as briefly mentioned above, extends beyond a simple barrier function 
and has in recent years been implicated in an important role for visceral sensation. The urothelium, 
which is innervated by afferent and efferent nerves, has been described as having neuronal 
properties due to its ability to respond to an array of chemical messengers often reserved for 
neurotransmission including adenosine triphosphate (ATP), and acetylcholine (ACh). Urothelial cells 
achieve this function via the expression of functional ion channels and receptors normally present 
on nerve endings including purinergic, transient receptor potential (TRP), muscarinic, and nicotinic 
(Birder, Kanai et al. 2001; Stein, Santos et al. 2004; Beckel, Kanai et al. 2005; Mansfield, Liu et al. 
2005; Zarghooni, Wunsch et al. 2007; Streng, Axelsson et al. 2008). The close association of bladder 
afferent nerves to the urothelium, and the above mentioned neuronal properties of these cells have 
supported a theory that urothelial-neural communications occurs and together forms a sensory 
structure. It is also probable that interstitial cells present within the suburothelium (fig 1.1.2) 
contribute to this sensory structure and their roles will also be discussed. Activation of capsaicin 
sensitive primary afferents (CSPANS) has been shown to induce the release of neuropeptides (Maggi, 
Patacchini et al. 1991; Lecci, Giuliani et al. 1997) which have the capacity to influence the urothelium 
and interstitial cells. Stretch and mechanical stimulation of the urothelium in-situ or cultured 
urothelial cells has been shown to stimulate the release of a number of neurotransmitters including 
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NO, ATP, Prostaglandins (PGs), and ACh (Birder, Nakamura et al. 2002; Hanna-Mitchell, Beckel et al. 
2007; Yokoyama, Tanaka et al. 2011; Collins, Daly et al. 2013). The receptors for these 
neurotransmitters and PGs are located on the underlying structures of the bladder, including the 
sensory afferent nerves, detrusor smooth muscle, and interstitial cells, and it is proposed that these 
neurotransmitters may act to modulate bladder sensory output to the spinal cord.  
 
 
 
Fig 1.2.1 Diagrammatic representation of the afferent and efferent innervations of the urinary 
bladder wall, and a hypothetical model of interactions between neuronal and non-neuronal cells 
within the urothelium/sub-urothelium. A number of mediators are released within the urinary 
bladder wall and have the ability to act in either an autocrine or paracrine manner to alter neuronal 
excitability. Abbreviations: ACh, acetylcholine; ATP, adenosine triphosphate; H+, proton, mAChR, 
muscarinic receptor; NKA, neurokinin A; NK2, tachykinin 2 receptor; nAChR, nicotinic receptor; NO, 
nitric oxide; P2X and P2Y; purinergic receptors; trkA, receptor tyrosine kinase A, high affinity receptor 
for nerve growth factor; TRPs, transient potential channels. Modified from Birder (2010). 
 
Interstitial cells 
There is controversy surrounding the nomenclature and organisation of the cells which comprise the 
lamina propria and this is caused by a lack of specific markers and some unusual structural and 
functional characteristics. The electrically active cells of the lamina propria change both in 
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morphology and ultrastructure as they appear closer to the detrusor muscle layer (Wiseman, Fowler 
et al. 2003). As morphological differentiation has not been made, in this thesis they shall be 
encompassed by the term interstitial cells (IC).  
The Interstitial Cells of Cajal (ICC) in the gut act as pacemaker cells, co-ordinating peristaltic 
contractions and facilitating neuromuscular transmission (Sanders and Ward 2007). These spindle-
shaped cells with multiple thin branching processes and expressing markers such as c-kit, and 
connexin-43 (McCloskey 2010) have been identified in the bladder where they are found to form 
two discrete populations of ICs; one such population forms a distinct plexus in the sub-urothelium 
where they are found in close association with afferent nerves (Sui, Rothery et al. 2002; Wiseman, 
Fowler et al. 2003; Fry, Sui et al. 2007). The second population of ICs are found in around the smooth 
muscle layers and are also found to make close structural connections with nerves (Davidson and 
McCloskey 2005; McCloskey, Anderson et al. 2009).  
A specific role for ICs in the bladder has yet to be established but a number of theories have been 
proposed. It has been anticipated that the population of ICs found within detrusor smooth muscle 
may contribute to the spontaneous myocyte activity of the detrusor smooth muscle; although the 
mechanism by which this would occur is still controversial. Gap junctions provide a mechanism for 
direct cell-cell electrical communication and it is thought that the ICs may act as a functional 
synctium linked to the detrusor smooth muscle, influencing contraction (Wiseman, Fowler et al. 
2003). However, despite the electrical activity of ICs, characterised by spontaneous membrane 
current fluctuations which are activated by a rise in intracellular Ca2+ and dependent on Cl- currents 
(Fry, Sui et al. 2007), the calcium transients from detrusor myocytes appear to be independent of IC 
function (Hashitani, Brading et al. 2004; Sui, Wu et al. 2004).   
The extensive gap junctions which couple ICs, allow them to act as a unit to propagate electrical 
activity throughout the sub-urothelial layer, and they are proposed to integrate signals from the 
urothelium with electrical and chemical information from efferent nerves. In providing this service, 
ICs are in a key position in close proximity to sensory afferents and thus have the potential to 
influence the excitability of nerve terminals (Wiseman, Fowler et al. 2003; Sui, Wu et al. 2004), and 
influence afferent transduction.  ATP acting on purinergic receptors (Cheng, Scigalla et al. 2011), and 
ACh via muscarinic receptors (Johnston, Carson et al. 2008) have been shown to initiate intracellular 
Ca2+ transients in ICs, and due to the known release of these neurotransmitters from the urothelium 
and the propinquity of urothelial cells to ICs, it is likely that a functional interaction occurs.  
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Detrusor smooth muscle 
The detrusor smooth muscle consists of a layer of circular muscle which is enclosed by outer and 
inner longitudinal muscle layers. Individual detrusor smooth muscle cells are long, spindle shaped 
cells arranged in bundles surrounded by collagen. The smooth muscle cells contain actin and myosin 
filaments, along with cytoskeletal intermediate filaments and dense bodies containing the 
microfilament protein actinin (Andersson and Arner 2004). 
Detrusor smooth muscle cells elicit an action potential from a resting potential of -50 to -60mV (Sui, 
Wu et al. 2001). The depolarisation phase is mediated via an inward current of Ca2+ via L-type Ca2+ 
channels (Kajioka, Nakayama et al. 2002). ATP-sensitive K+ channels have also been shown to 
influence bladder contractility and cause hyperpolarisation (Bonev and Nelson 1993),  while calcium 
activated K+ channels play a role in the maintenance of the resting potential and in repolarisation of 
the detrusor muscle cell membrane (Montgomery and Fry 1992). 
       
Fig 1.2.2 An example of one of the important intracellular signalling pathways initiated by 
acetylcholine binding to M3 receptors and ATP binding to P2X3 receptors in determining detrusor 
smooth muscle cell contraction. Abbreviations: Ca2+, calcium; CaM, calmodulin; DAG, diacylglycerol; 
IP3, inositol trisphosphate; MLC, myosin light chain; PIP2, phospholipid; PLC, phospholipase-C; RyR, 
ryanodine receptor; SR, sarcoplasmic reticulum. Modified from Fry et al (2010). 
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ACh is released from parasympathetic nerves to initiate contraction of the detrusor whilst 
noradrenaline released from sympathetic neurons cause relaxation. Neurotransmitter release from 
the parasympathetic nerves innervating the detrusor, along with local release of transmitters from 
the urothelium in response to stretch, activates receptors on the detrusor smooth muscle 
membrane. Ligand receptor binding on the cell membrane results in an increase in intracellular Ca2+. 
This is either from extracellular sources, via L-type Ca2+ channels (Kajioka, Nakayama et al. 2002), or 
intracellular; via Ca2+ induced Ca2+ release by ryanodine receptor activation on the sarcoplasmic 
reticulum (Hashitani and Brading 2003), or G-protein coupled IP3 receptor mediated release (Fry, 
Meng et al. 2010). Ca2+ binds to calmodulin in the cytoplasm which is then able to activate myosin 
light chain kinase (MLCK). Activated MLCK phosphorylates the myosin light chain which allows it to 
interact between actin and myosin to cause contraction (fig 1.2.2) (Fry, Skennerton et al. 2002).  
There is evidence for the presence of a number of receptors on the detrusor smooth muscle which 
are thought to have modulator effects on the primarily muscarinic and purinergic components of 
detrusor contraction which will be discussed in further detail below.   
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1.3 NEURAL INNERVATIONS OF THE BLADDER 
 
Micturition pathway 
The function of the urinary bladder is to effectively store and eliminate urine, and is dependent on 
the integration of a complex neural network comprising sympathetic, parasympathetic and somatic 
afferent and efferent pathways from the periphery, spinal cord, brainstem, and cortical regions 
under both voluntary and involuntary control.   
 
Efferent pathways 
The efferent parasympathetic pathway, originating from the sacral spinal cord provides the major 
excitatory input to the urinary bladder. 
Preganglionic cholinergic neurons located in the intermediolateral region of the sacral spinal cord 
(S2 – S4, (laminae v - vii)) project axons as the pelvic nerve to synapse in the pelvic ganglia as well as 
directly into the intramural autonomic ganglia in the bladder wall (Yoshimura, Kaiho et al. 2008). 
Postganglionic neuronal activation is mediated via ACh acting on nicotinic ACh receptors (nAChR) 
(Wang, Orr-Urtreger et al. 2002) but can be influenced by many other receptors including those for 
noradrenaline, the ionotropic P2X and metabotropic P2Y receptors for ATP, as well as various 
peptides (Keast, Kawatani et al. 1990; Tompkins, Girard et al. 2010). Postganglionic axons continue 
as the pelvic nerve and terminate in the detrusor smooth muscle. Terminal regions of 
parasympathetic postganglionic efferents have vesicle filled varicosities capable of releasing 
neurotransmitter to stimulate contraction via the predominant actions of ACh as well as other non-
adrenergic non-cholinergic (NANC) neurotransmitters (de Groat 2006). 
Contraction of the detrusor by ACh is mediated by atropine sensitive M3 receptors despite the 
predominance of M2 receptors in this tissue (Chess-Williams, Chapple et al. 2001; Matsui, 
Motomura et al. 2002). There is an atropine resistant component of excitatory transmission which 
has been shown to be mediated by ATP acting on ionotropic P2X purinoceptors (Burnstock 2001) 
and a number of co-released peptides including vasointestinal peptide (VIP) and neuropeptide Y 
(NPY) which may be inhibitory or excitatory (Andersson and Wein 2004). Although the contribution 
of P2X receptor activation to detrusor contraction appears to be minor in healthy human tissue 
(Ford, Gever et al. 2006), it has been shown that this contribution can dramatically increase in 
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certain bladder pathologies (Bayliss, Wu et al. 1999; O’Reilly, Kosaka et al. 2002; Brady, Apostolidis 
et al. 2004) as well as with age (Yoshida, Miyamae et al. 2004). 
In conjunction with the excitatory input to the detrusor smooth muscle, postganglionic 
parasympathetic efferents have been shown to provide an inhibitory input to the urethral smooth 
muscle in the form of nitric oxide (Andersson and Arner 2004). The efferent sympathetic pathway, 
originating in the thoracolumbar section of the spinal cord (T11-L2) passes to the lumbosacral 
sympathetic chain ganglia and the pelvic plexus, or to short adrenergic neurons in the bladder and 
urethra (de Groat 1997). Sympathetic postganglionic nerves release noradrenaline and provide the 
major excitatory input to the urethra via α1 adrenoceptors and inhibitory input to the detrusor via β 
adrenoceptors (de Groat 2006).  
Preganglionic sympathetic neurons pass to the lumbosacral paravertebral ganglia and the pelvic 
plexus to synapse in the inferior mesenteric ganglia (Birder 2006) via the actions of ACh on nAChR in 
a similar manner to parasympathetic fibers in the pelvic ganglia. Postganglionic axons travel as the 
hypogastric nerve to three major targets where noradrenaline is the principal transmitter released. 
Noradrenaline acts via α1-adrenoceptors on the bladder neck and urethra to stimulate contraction 
(Anderson 1993) whilst also acting via β2 and β3-adrenoceptors on the detrusor to induce relaxation 
(Anderson 1993; Igawa, Yamazaki et al. 1999). Furthermore, it has also been shown that sympathetic 
fibers project to the pelvic ganglia where release of noradrenaline provides inhibition of excitatory 
parasympathetic nerve activity supplying the detrusor (de Groat 2001).   
Efferent innervations of the striated muscles of the external urethral sphincter (EUS) is provided by 
somatic nerves originating from Onuf’s nucleus in the lateral ventral horn of the S2-S4 sacral spinal 
cord (Thor, Morgan et al. 1989). Sphincter motoneurons are carried in the pudendal nerve and 
initiate contraction of the EUS via release of ACh onto nAchR (de Groat 2001; de Groat 2006).  
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Fig 1.3.1 Diagrammatical representation of the neural circuits maintaining continence and 
stimulating micturition in the bladder. Pelvic nerves convey the major afferent innervations of the 
bladder via Aδ- and C-fiber afferents to the lumbo-sacral region of the spinal cord, whilst a smaller 
component of bladder afferent innervations travel in the hypogastric nerve to the thoracolumbar 
region of the spinal cord.  Parasympathetic and sympathetic efferents travel in the pelvic and 
hypogastric nerve respectively. Sacral somatic afferent and efferent innervations to the external 
urethral sphincter are via pudendal nerves. Abbreviations: DRG, dorsal root ganglion; EUS, external 
urethral sphincter; IMG, inferior mesenteric ganglion; MPG, pelvic ganglion. Taken from Ford et al 
(2006) 
 
Afferent Pathways 
Sensory information regarding the state of the lower urinary tract is carried in small myelinated Aδ 
and unmyelinated C-fibers via the pelvic, pudendal and hypogastric nerves to the lumbosacral spinal 
cord. Pelvic and pudendal nerves predominantly have their cell bodies within the dorsal root 
ganglion (DRG) at the level of the sacral spinal cord (S1-S4) whilst hypogastric nerves project via 
DRGs to the thoracolumbar segments (T10-L2) of the spinal cord. Ascending afferent projections 
travel via the lateral and dorsal funiculi and synapse in a number of nuclei in the midbrain and 
brainstem including the periaqueductal grey matter (PAG) (de Groat 1997). These neurons convey 
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information to the pontine micturition centre to initiate the micturition reflex (Blok, Willemsen et al. 
1997). 
Bladder afferents projecting via parasympathetic pathways are essential for maintaining normal 
bladder function. They are found in distinct populations innervating the detrusor smooth muscle, in 
close proximity to blood vessels, in the sub-urothelium and also innervating the urothelium itself 
(Sharkey, Williams et al. 1983; Su, Wharton et al. 1986). The distribution of bladder afferent axons 
has been studied in a number of species and afferent nerves have been classified based primarily on 
conduction velocities, neuropeptide content and their sensitivity to mechanical stimuli: and are 
either high or low threshold. The afferent nerves innervating the urinary tract are composed of 
unmyelinated (C-fiber) axons which comprise approximately 60-70% of total afferent fibers, with the 
remainder consisting of small myelinated (Aδ) fibers (Vera and Nadelhaft 1990; Andersson 2002). 
The majority of bladder dorsal root ganglion (DRG) neurons also contain multiple neuropeptides, 
including calcitonin gene-related peptide (CGRP), substance P, and vasointestinal peptide (VIP) 
(Keast and de Groat 1992; Smet, Moore et al. 1997) and a significant proportion of these are 
capsaicin sensitive (Avelino and Cruz 2000; Avelino, Cruz et al. 2002). Mechanoreceptive afferents 
can also be sub-classified into a larger proportion of low threshold (approx 80%) and fewer high 
threshold (approx 20%) fibers (Sengupta and Gebhart 1994; Shea, Cai et al. 2000). Denervation 
studies have shown that bladder afferent innervations are bilateral with an intermingling of axons 
supplying both contralateral and ipsilateral regions (Gabella and Davis 1998).  
The distribution of axons within the bladder is variable and dependent on the region. Afferent 
innervations of the detrusor is relatively diffuse, but the density of these innervations is uniform 
throughout the bladder (Gabella and Davis 1998; Birder, de Groat et al. 2010). The sub-urothelium 
contains the highest density of axons in the bladder which form a plexus lying just above the basal 
surface of the urothelium. The sub-urothelial plexus is thickest at the bladder neck (Andersson 2002) 
and adjacent urethra, and becomes more diffuse in adjacent regions (Smet, Edyvane et al. 1996; 
Gabella and Davis 1998). There is also a proportion of axons which penetrate the urothelial layer and 
are thought to branch from the sub-epithelial plexus. These fibers, as with those innervating the 
detrusor, are considered to be direct mechanosensors. The afferent nerves of the suburothelium are 
proposed to have a less direct influence on mechanosensitivity but respond to mediators released 
from the urothelium. These afferent are also proposed to have an efferent function related to the 
release of neuropeptides stored in their peripheral varicosities which are released upon excitation 
(Maggi, Patacchini et al. 1991; Smet, Edyvane et al. 1996; Lecci, Giuliani et al. 1997) and are believed 
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to perform a local regulatory role on the underlying structures of the bladder including the 
modulation of afferent nerve excitability (Sculptoreanu and de Groat 2007).    
Classification of sensory neurons within the bladder 
As briefly described, the sensory afferent nerves innervating the bladder belong to different 
functional populations which are thought to underlie their distinct stimulus-response profiles. It has 
been shown that the most important afferents for input into the micturition reflex are those 
travelling in the pelvic nerves to the sacral spinal cord. This is the branch of the micturition pathway 
which will be the focus of this thesis.  
Pelvic afferents consist of small myelinated Aδ fibers with a conduction velocity of ≈11ms-1, and 
unmyelinated C fibers with a conduction velocity of ≤2ms-1. Electrophysiology studies have shown 
that bladder afferents respond to bladder distension (Vlaskovska, Kasakov et al. 2001; Rong, Spyer et 
al. 2002; Daly, Rong et al. 2007) or active contraction. Within these afferents, there was found to be 
a subset that responds to distension but not contraction and were dubbed ‘volume’ receptors 
(Morrison 1999). A number of studies have classified these afferents functionally by their activation 
threshold, and a distinction between a population of low, and high threshold afferents has been 
made based on their response to bladder distension (Rong, Spyer et al. 2002; Zagorodnyuk, Costa et 
al. 2006; Daly, Rong et al. 2007). Although there are inter-experimental differences in the precise 
definitions, low threshold afferents are activated at low intravesical pressures from 3-15mmHg and 
show an increased afferent nerve response as pressures increases up to a point following which, the 
response plateaus (Shea, Cai et al. 2000; Rong, Spyer et al. 2002; Daly, Rong et al. 2007). High 
threshold afferents also respond to an increase in bladder pressures but their activation is initiated 
at a higher threshold and increases past physiological voiding pressures. Populations of Aδ- and C-
fibers respond to both high and low thresholds suggesting there is no correlation between 
conduction velocity and afferent subtype (Sengupta and Gebhart 1994; Shea, Cai et al. 2000). 
Afferent nerve terminals located in the detrusor muscle layers, urothelium and sub-urothelium all 
convey vital information regarding the state of the bladder to the CNS and in this way, control the 
micturition reflex. Traditionally, afferent nerves have been broadly classified as either 
mechanosensitive or chemosensitive fibers. Thus, they either respond to dynamic stretch due to 
physical alterations in the bladder wall, or the actions of chemical stimuli binding to receptors on the 
afferent nerve membrane. It has now been possible to further classify these subtypes based on their 
receptive field as well as the stimuli they respond to. Two research groups have recently proposed 
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different nomenclature for what appears to be essentially a description of the same subtypes of 
afferents and will be discussed in further detail here.  
 
1. Muscle mechanoreceptors  
A consensus that has formed is the location of mechanosensitive afferents which innervate the 
detrusor smooth muscle layers of the bladder. They are powerfully activated by stretch 
(Zagorodnyuk, Costa et al. 2006; Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008) but not by 
stroking with von-frey hairs or chemical compounds such as ATP or capsaicin. Thus they are 
considered pure mechanoreceptors. The proportion of afferents which are muscle 
mechanoreceptors is species dependent, in guinea pig they contributed 15% of total recorded, 
whereas in mouse, that number was around 45% for mixed pelvic and lumbosacral afferents 
(Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). In physiological terms these 
mechanoreceptors are believed to respond to bladder distension by sensing intravesical pressure, 
and by acting as ‘in-series’ tension receptors previously described (Habler, Janig et al. 1993; Shea, 
Cai et al. 2000). It has previously been shown that afferent activity maintains a precise relationship 
with the change in tension of the receptive field of these afferents (Downie and Armour 1992). 
Muscle mechanoreceptors are composed of both low and high threshold components and it has also 
been shown that they can be sensitised by the administration of an inflammatory soup (Xu and 
Gebhart 2008). Removal of the urothelium has no effect on stretch induced firing, which suggests 
that the receptive field for these muscle mechanoreceptors is just that, contained within the muscle. 
 
2. Muscular/urothelial afferents 
The nomenclature of the muscular/urothelial mechanoreceptors is related to their location in the 
bladder, innervating both the detrusor smooth muscle and the sub-urothelium. Considered to be 
similar to the previously reported muscular/mucosa afferents of the pelvic nerve in the distal 
gastrointestinal tract (Brierley, Jones Iii et al. 2004). Unlike muscle mechanoreceptors, removal of 
the urothelium significantly reduces distension induced afferent firing. They respond to both 
mechanical stretch and light von-frey hair stroking and contribute around 30% of the total afferents 
in the bladder wall (Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). Activation is possible 
by ATP (Zagorodnyuk, Gibbins et al. 2007), and thus their location close to the urothelium suggests 
that they might respond to ATP released by urothelial distension (Sadananda, Shang et al. 2009; 
Sadananda, Kao et al. 2012; Collins, Daly et al. 2013). Considered to respond to a lower threshold of 
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stimuli than muscle mechanoreceptors, they are responsive to bladder contractions and most 
probably act as a sub-set of in-series tension receptors (Häbler, Jänig et al. 1993; Shea, Cai et al. 
2000) able to coordinate stretch across the various layers of the bladder wall.  
3. Urothelial afferents  
A subset of urothelial afferents, distinct from muscular/urothelial afferents that make up between 
10-30% of the total afferent discharge was also observed in mouse and guinea pig (Zagorodnyuk, 
Gibbins et al. 2007; Xu and Gebhart 2008). These urothelial afferents are distension insensitive,  but 
activated by mucosal stroking with light von-frey hairs, and can also be activated by various chemical 
stimuli (Zagorodnyuk, Costa et al. 2006; Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008; 
Zagorodnyuk, Brookes et al. 2009). A similar fraction of distension-insensitive (mucosal) afferents 
have been identified in the mouse colon (Brierley, Jones Iii et al. 2004). As with those described in 
the bladder, despite failing to respond to mechanical stretch/distension, these mucosal afferents 
respond to a range of other stimuli including mucosal stroking and probing. It is proposed that these 
afferents may become distension sensitive during inflammation or insult to the bladder and may 
transmit pain sensations. A second class of urothelial mechanoreceptor was also identified by 
zagorodynuk et al, in which these afferents, aside from being insensitive to distension, also fail to 
respond to chemical stimuli. This division of urothelial afferents shares a number of characteristics 
with distension-insensitive afferents previously termed silent nociceptors (Jänig and Koltzenburg 
1990; Habler, Janig et al. 1993) and are described in further detail below. 
 
4. Silent Afferents 
There are a proportion of sensory fibers innervating the viscera which do not respond to high 
intensity mechanical or noxious chemical stimuli. In all recent experiments aimed at elucidating the 
subsets of afferent neurons which mediate afferent nerve discharge, there has been a proportion of 
afferents which are unresponsive to mechanical stimulation, and a proportion of these which are 
unresponsive to chemical stimuli (Shea, Cai et al. 2000; Rong, Spyer et al. 2002; Daly, Rong et al. 
2007; Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). These receptors, as outlined above, 
have been termed ‘silent’ nociceptors. Studies have also shown that sensitisation of previously 
unresponsive afferents is possible (Häbler, Jänig et al. 1990; Rong, Spyer et al. 2002) and thus there 
is evidence for a population of pelvic afferents which under normal conditions are unresponsive to a 
full range of stimuli, and become activated only following acute irritation or inflammation. It is worth 
mentioning that the ability of inflammatory mediators to induce afferent sensitisation is not limited 
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to ‘silent’ afferents but is also seen in both low and high threshold mechanoreceptors (Rong, Spyer 
et al. 2002; Xu and Gebhart 2008). 
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1.4 MECHANISMS OF MECHANOSENSITIVITY 
 
Direct mechanotransduction 
There is a large proportion of bladder mechanosensation which is directly coupled to the mechanical 
forces exerted on the detrusor smooth muscle during distension and is evident by the relationship of 
bladder volume, pressure, or tension with afferent nerve discharge. Direct mechanotransduction has 
been studied in a number of physiological systems and cell types, and numerous molecules and sub-
cellular structures have been shown to mediate mechanical mechanisms into biochemical activity. 
The concept of direct mechanotransduction in visceral afferent nerves is determined by direct gating 
of ion channels in response to mechanical force. For this to occur, an ion channel structure capable 
of responding to a mechanical stimulus must be present at the location where a mechanical stimuli 
is detected (Gillespie and Walker 2001). Currently, the molecular identity of such a channel is elusive, 
but a number of candidates including the epithelial sodium channel (ENaC)/Acid sensing ion channel 
(ASIC)/degenerin Na+ channels, and TRP channels (Sun, Li et al. 2010) are proposed, which have been 
shown to modulate the detection of mechanical stimuli in a number of species (Gillespie and Walker 
2001; Strassmaier and Gillespie 2002; Goodman, Lumpkin et al. 2004). A recent review of direct 
mechanotransduction in the gastrointestinal tract has explored this area (Brierley 2010) and 
concluded that the detection of mechanical stimuli by visceral afferents may be fundamentally 
different to somatic systems.   
The generation of a graded receptor potential in afferent neurons in response to stretch requires the 
gating of a channel, which in the case of physiological bladder filling must be sensitive to incremental 
increases in bladder pressure/muscle stretch and can be rapidly activated to compensate for these 
changes (Brierley 2010), and thus influence the frequency of the action potentials generated. The 
first major hypothesis for direct mechanotransduction relies on the direct distortion of the ion 
channel structure, which can be the result of a change in membrane bilayer tension, a ‘tugging’ of 
the ion channel, physically opening the pore (Hamill and Martinac 2001). The second major 
hypothesis is that of a tethered channel, in which the proteins of the extracellular matrix or 
intracellular cytoskeleton are linked to the stretch activated domains of the ion channel and thus act 
as intermediates to alter tension throughout the entire cell membrane, which results in an opening 
of the channel (Gillespie and Walker 2001; Christensen and Corey 2007).  
One of the main stumbling blocks for determining the methods of direct mechanotransduction in 
the bladder, as described previously, is the heterogeneity of the afferents innervating the different 
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layers of the bladder, and the likelihood of the transduction mechanisms being conserved between 
them.  
Fig 1.4.1 Proposed models by which a putative mechanotransduction channel is gated by mechanical 
stimuli (Brierley 2010). 
Numerous studies have been completed which have elucidated a role for ASIC1, ASIC2, ASIC3, TRPV1, 
TRPV4, and TRPA1 channels in mediating mechanosensitivity in the gastrointestinal tract (Brierley 
2010). However, as many of these channels also contribute to overall afferent sensitivity as well as 
possible roles in other structures of the bladder wall, including the mediator release from the 
urothelium, determining a direct mechanism of action is a particularly gruelling task.  
 
Indirect mechanotransduction 
As described above, there are subsets of afferent neurons which are distension insensitive, but 
express chemoreceptors able to respond to a number of chemical agents, including ATP. An indirect 
mechanism for mechanotransduction involving the interaction of afferent nerves with factors 
released from the surrounding tissues has been postulated. The main pathways thought to underlie 
this, which have been mentioned above, are the release of mediators from the urothelium in 
response to mechanical stretch, the release of neuropeptides from the terminal varicosities of 
afferent nerves, and the ability of interstitial cells to communicate electrically with afferent nerves. 
ATP and ACh are released from the urothelium in response to stretch (Ferguson, Kennedy et al. 1997; 
Hanna-Mitchell, Beckel et al. 2007; Dunning-Davies, Fry et al. 2013) and sub-urothelial afferent 
nerves express purinergic receptors which are stimulated by ATP, including the P2X3 ionotropic 
receptor (Namasivayam, Eardley et al. 1999; Rong, Spyer et al. 2002; Cockayne, Dunn et al. 2005). 
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This mechanism has undergone intense research and is considered to be an important mechanism of 
mechanotransduction in the bladder as P2X3 knockout mice exhibit significant bladder hyporeflexia 
(Cockayne, Hamilton et al. 2000; Vlaskovska, Kasakov et al. 2001). Another possible role for 
urothelially released ATP is the activation of the underlying interstitial cell network which has also 
been shown to express both P2X and P2Y purinoceptors (Sui, Wu et al. 2006; Li, Xue et al. 2013). In 
this model, ATP released from the urothelium is able to induce an exaggerated electrical current in 
interstitial cells, which are able to couple to afferent neurons and influence their excitability.  
 
Fig 1.4.2 Schematic diagram showing a proposed indirect mechanotransduction role for urothelial 
ATP. Bladder distension causes the release of ATP from the urothelium and ATP acts on purinergic 
receptors on the terminal varicosities of bladder afferents, where it may convey mechanosensory 
information to the central nervous system. Taken from Ford et al (2006) 
 
The ability of urothelially released ATP to influence mechanotransduction has been disputed by 
Zagorodyuk and colleagues. They have suggested that the onset of stretch induced afferent 
discharge in the guinea pig rectum is so fast (≈5ms) that it is likely due to a direct mechanism 
(Zagorodnyuk, Lynn et al. 2005). They have also shown that pharmacological blockade of P2X 
receptors or the use of calcium free medium to prevent exocytotic release of transmitters had no 
effect on mechanotransducion in guinea pig bladder (Zagorodnyuk, Costa et al. 2006). Removal of 
the urothelium was also shown to have no effect on stretch induced afferent discharge 
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(Zagorodnyuk, Gibbins et al. 2007). In rebuttal to these claims however, the exocytotic release of 
ATP from the urothelium has been shown to increase following removal of extracellular calcium 
(Matsumoto-Miyai, Kagase et al. 2009), and the stretch sensitive afferents from which they record 
are not those which are thought to depend on this secondary, indirect mechanotransduction 
mechanism.  
As such, this pathway is still an unknown, and this thesis will attempt to clarify some of these issues.  
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1.5 THE MICTURITION REFLEX 
 
Storage phase 
The effective storage of urine is provided through spinal reflexes incorporating parasympathetic, 
sympathetic and somatic afferents from the bladder and urethral sphincters. During urine storage; 
discharge from stretch sensitive afferent nerves innervating the detrusor smooth muscle is low. This 
results in parasympathetic and sympathetic reflexes that aid bladder filling and facilitate continence 
by contracting the internal urethral sphincter (Roberts 2008). The bladder to external urethral 
sphincter reflex, also termed the ‘guarding reflex’, is a result of bladder afferent activation of 
pudendal motoneurons in the sacral spinal cord which stimulate external urethral sphincter 
contractions. The guarding reflex is also under supraspinal regulation, with the pontine storage 
centre in the dorsolateral pons providing descending input which activates pudendal motoneurons 
and increases urethral resistance (de Groat 2006; Yoshimura, Kaiho et al. 2008). There is also 
evidence for reciprocal pudendal afferent inhibition of parasympathetic efferent firing by 
suppression of spinal interneuron activation as well as inhibition of pelvic ganglia (de Groat 2001). 
Parasympathetic afferents travelling in the hypogastric nerve innervate sympathetic fibers 
originating in the thoracolumbar spinal cord which stimulate contraction of the internal urethral 
sphincter and provide inhibition to the pelvic ganglia, thus suppressing parasympathetic efferent 
input to the detrusor smooth muscle (de Groat and Lalley 1972; de Groat and Theobald 1976). The 
inhibitory actions of parasympathetic afferents are removed when firing reaches a threshold 
analogous to a full bladder.     
 
Voiding phase 
The voiding phase of micturition involves a combination of spinal and spinobulbospinal reflexes 
incorporating parasympathetic, sympathetic and somatic pathways. The initiation of the voiding 
phase of micturition is turned on by a threshold level of bladder afferent firing and is mediated by 
activation of the sacral parasympathetic efferent axons to the bladder and urethra in combination 
with inhibition of sympathetic and somatic pathways to the urethral sphincters (de Groat 2006). The 
voiding phase, in contrast to the storage phase, is under voluntary control in adults through 
command of the EUS.  
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The bladder afferents travelling via the pelvic nerve synapse in the spinal cord and the post-synaptic 
neurons travel rostrally to the pontine micturition centre (PMC) in the brainstem (Blok, Willemsen et 
al. 1997). It has been shown that spinal cord injury above the lumbosacral level eliminates voluntary 
control of voiding and results in bladder hyperactivity (Yokoyama, Yoshiyama et al. 2000) and thus it 
is thought that the PMC co-ordinates the afferent sensory information with connections from the 
frontal cortex as well as other forebrain areas (Roberts 2008) to provide voluntary control of 
micturition.  
Activation of spinobulbospinal pathways passing through the PMC stimulates parasympathetic pelvic 
efferents resulting in contraction of the bladder and relaxation of the urethral smooth muscle in 
combination with an inhibition of sympathetic efferent outputs (Drake, Fowler et al. 2010), and an 
inhibition of sphincter activity to give a flow of urine.  
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1.6 PATHOLOGIES OF THE BLADDER 
 
The banner of urinary incontinence or lower urinary tract dysfunction encompasses a range of 
bladder pathologies. These include but are not limited to stress incontinence, urge incontinence, 
overflow incontinence and bladder outlet obstruction, and interstitial cystitis. These pathologies can 
occur individually or in combination whilst also varying extensively in their severity. Urinary 
incontinence has a huge impact on patients’ quality of life and because it is so common, affecting 
approximately 4 million Australians according to the Australian Institute of Health and Welfare, it 
carries an enormous societal and economic burden estimated at AUD $1.5 billion annually. 
The prevalence of bladder dysfunction is not evenly distributed across the population and is 
associated with a number of risk factors including age, pregnancy, and increased body mass index 
(BMI) (Hunskaar, Burgio et al. 2003; Rortveit, Daltveit et al. 2003). Age however is a major 
contributing factor, and, with an aging population the necessity to develop effective treatments, and 
improve quality of life is ever more present.  
 
Overacitve Bladder  
Overactive bladder (OAB) is defined by the International Continence Society (ICS) committee as 
‘urgency, with or without urge incontinence (approximately 30% of patients have incontinence 
Milsom et al (2001)), usually with frequency (voids ≥ 8/day (Wein and Rovner 2002)) and nocturia 
(Abrams, Cardozo et al. 2002) which occurs in the absence of infection or any other obvious 
pathology’. This complex of symptoms is believed to affect approximately 16-17% of the adult (≥40 
years of age) population (Milsom, Abrams et al. 2001; Stewart, Van Rooyen et al. 2003). There is 
some overlap between the symptoms of OAB and interstitial cystitis (IC) except pain is not a defining 
feature of OAB, and therefore points towards a different aetiology. 
As described earlier, during the filling phase of micturition the detrusor smooth muscle relaxes, 
allowing the bladder to fill with urine. OAB is associated with involuntary detrusor overactivity which 
is a urodynamic observation characterised by involuntary detrusor contractions during the filling 
phase, which may be spontaneous or provoked (Abrams, Cardozo et al. 2002). The detrusor, instead 
of exhibiting progressively increasing phasic activity correlating with an increased volume of urine 
and a progressive awareness of bladder distension up to the threshold for voiding, exhibits 
spontaneous contractile activity which causes an immediate rise in intravesical pressure and a desire 
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or ‘urgency’ to void, increased frequency of urination, and often urinary leakage. Overactive bladder 
syndrome can be separated into two main classes dependent on its aetiology:  
 Idiopathic overactive bladder: has no definable cause and is not thought to be mediated by 
an inflammatory response such as that in interstitial cystitis. Most cases of OAB fall into this 
group. 
 
 Neurogenic overactivity bladder: has an obvious neurogenic origin resulting in neurological 
dysfunction or degeneration of the neural pathways controlling micturition such as stroke, 
Parkinsons disease, multiple sclerosis, spina bifida, and spinal lesions, or any other disease 
associated with the nervous system.   
The aetiology of detrusor overactivity is still unknown but is often considered to be multifactoral. A 
major concept now under intense investigation, is that of abnormal afferent firing from the bladder 
wall during the filling phase of micturition. This has been considered in respect to increased 
spontaneous activity of the detrusor myocyte (Andersson 2010), upregulation of C-fiber afferent 
activity and subsequent plasticity (Ouslander 2004), and increased activation of sensory C-fiber 
afferents in the sub-urothelium.  
 
Stress urinary incontinence  
Stress urinary incontinence (SUI) is defined by the ICS as ‘the involuntary leakage of urine during 
increased abdominal pressure, in the absence of detrusor contraction’ (Abrams, Cardozo et al. 2002) 
and is associated with involuntary leakage on everyday effort or exertion, for example sneezing, 
laughing or coughing. SUI is often attributable to a weakening of the urethral sphincters which 
allows urine to escape during periods of increased abdominal pressure. However, peripheral nerve 
dysfunction following damage to the pudendal nerve and weakening of the pelvic floor support 
during childbirth have also been described (Torrisi, Sampugnaro et al. 2007). Thus, pregnancy is a 
major risk factor for SUI and as a result is much more common amongst the female population 
(Luber 2004). SUI also increases definitively with age and although the pathophysiology governing 
this change is less well understood, it is believed to be due to the loss of urethral smooth muscle 
tone. Exercises to strengthen the pelvic floor muscles provide relief for a limited number of patients 
and there is also the option of surgery, but this is associated with increased risk factors and is not a 
viable option for many patients.   
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Overflow incontinence/Bladder outlet obstruction 
Overflow incontinence is often defined as the involuntary loss of urine associated with bladder 
overdistention in the absence of detrusor contractions. This usually occurs as a result of inefficient 
voiding of the bladder which leads to excessive bladder pressure and the potential for urinary 
leakage. This form of incontinence is much more common amongst males and most commonly 
caused by prostate hyperplasia or prolapse of the pelvic organs which, through pressure exerted on 
the urethra, prevents the free flow of urine from the bladder. The current options for relief from 
overflow incontinence are limited and catheterisation remains the predominant method for 
alleviating the symptoms but does not address the root cause.  
 
Painful Bladder Syndrome/Interstitial cystitis 
Interstitial cystitis (IC) is a clinical diagnosis primarily based on symptoms of urgency/frequency and 
especially pain in the bladder. The ICS prefers the term painful bladder syndrome (PBS) and this is 
defined as ‘the complaint of suprapubic pain related to bladder filling, accompanied by other 
symptoms such as increased daytime and night-time frequency, in the absence of proven urinary 
infection or other obvious pathology’ (Abrams, Cardozo et al. 2002). As with most bladder disorders 
the number of people suffering from IC is unclear, but is estimated at approximately 0.5 – 1% of the 
population (Jones and Nyberg 1997). A similar disorder occurs in domestic cats and is known as 
feline interstitial cystitis (FIC).  
An alteration in the barrier function of the urothelium has been linked to the origin of IC. Histological 
analysis of the bladder has shown abnormalities in IC patients (Parsons 2007) which could underlie a 
change in the permeability of the urothelium and the increased access of noxious stimuli to the 
underlying chemosensitive neural network. This is exemplified by the increased pain observed with 
intravesical infusion of potassium in IC patients compared to healthy individuals (Parsons, Greene et 
al. 2005). The expression of inducible nitric oxide synthase was found to be increased in the FIC 
bladder, and increased levels of nitric oxide in mucosal studies have also been linked to altered 
barrier function (Birder, Wolf-Johnston et al. 2005). It could also be hypothesised that damage to the 
urothelium in IC results in an increased release of non-neuronal ATP from the urothelium, which can 
activate sensory afferents that would normally be quiescent. Urine samples from patients with IC 
have higher concentrations of ATP compared to controls, and greater stretch-induced ATP release 
from the urothelium (Sun, Keay et al. 2001). Furthermore, upregulation of P2X3 receptors (Sun and 
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Chai 2004; Tempest, Dixon et al. 2004) has been described in IC patients and alterations of 
purinergic receptor expression in FIC cats (Birder, Ruan et al. 2004).  
Neural plasticity of sub-urothelial nerve fibers is also observed in IC. An increased density of 
peptidergic afferent fibers innervating the bladders of cats and humans with IC has been reported, 
suggesting that abnormal afferent pathways could contribute to this disorder (Pang, Marchand et al. 
1995; Buffington and Wolfe Jr 1998).  This is also correlated to a significant increase in TRPV1 
receptor expression on nerve fibers in IC patients (Mukerji, Yiangou et al. 2006) and this has been 
found to associate to pain scores. This observations are consistent with electrophysiological studies 
in which DRG neurons from FIC cats have abnormal excitability (Sculptoreanu, de Groat et al. 2005).  
There is evidence, therefore, that IC and the pain integral to it, is a result of increased mediator 
release from the urothelium affecting afferent nerve activity. However, there also appears to be a 
significant inflammatory component in the maintenance of this pathology which is not evident in the 
other dysfunctions described here.      
There is a growing consensus that release of a number of chemical mediators, in particular ATP from 
non neuronal sources such as the urothelium and acting on the afferent nerves innervating both the 
urothelium and sub-urothelium has a major part to play and that dysfunction or damage of the 
urothelium is a potential causality.  
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1.7 PURINERGIC RECEPTORS AND ATP 
 
ATP is a universal energy source within cells. In the early 1970’s it was proposed as the 
neurotransmitter responsible for the non-adrenergic, non-cholinergic component of 
neurotransmission (Burnstock, Campbell et al. 1970). The extracellular actions of ATP are mediated 
via a class of membrane bound receptors known as the P2 purinergic receptors (P indicating their 
activation by purines and in some cases pyramidine and the 2 discriminates them from the P1 
receptors which are activated by adenosine). Following identification of ATP as a neurotransmitter, 
two types of P2 receptors were distinguished, P2X and P2Y, based on transduction mechanism 
studies, (Ionotropic P2X receptors and metabotropic P2Y receptors) (Burnstock 2009).  
 
Purinergic receptors 
P2X 
There are seven ionotropic P2X receptors, P2X1-7. All seven P2X receptors have intracellular N- and C- 
termini with protein kinase binding motifs, two transmembrane spanning regions separated by an 
extracellular domain, and an ATP binding site. P2X receptors show 30-50% sequence homology in 
amino acid sequence and are formed by the assembly of multiple subunits (North 2002) giving rise 
to distinct homomeric P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, P2X7 and heteromeric (P2X2/3, P2X1/5, P2X4/6) 
channels.  
 
Upon activation, P2X receptors are permeable to monovalent cations as well as a relatively high 
permeability to calcium. Homomeric P2X channels are distinguishable by their unique activation 
kinetics and their selective responses to a variety of agonist and antagonists. Heteromeric P2X 
channels compose agonist response phenotypes from the various properties of the constituent 
subunits. The endogenous ligand for all P2X receptors is ATP. 
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Fig 1.7.1 Fast (top) and slow (bottom) desensitisation of rat homomeric P2X receptors with ATP 
(30μM), except for P2X7 (1mM) in HEK293 cells. Significant responses and desensitisation are 
observed with all P2X receptor subtypes excluding P2X7. Figure taken from North (2002). 
 
 
 
P2Y 
 
The P2Y-receptor family consists of 8 human subtypes that have been cloned and functionally 
characterised. All eight P2Y receptors are typical G-protein coupled receptors comprising seven 
hydrophobic transmembrane domains connected by three intracellular and three extracellular loops, 
an extracellular N-terminus and intracellular C-terminus. P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors 
all couple to stimulation of phospholipase C and the liberation of intracellular calcium via inistol 
trisphosphate (IP3). In contrast, activation of the P2Y12, P2Y13, and P2Y14 receptors inhibits adenylate 
cyclase activity (von Kügelgen 2006). P2Y receptors are activated by the endogenous ligands ATP, 
ADP, UTP and UDP. P2Y receptors can generally be characterised by their rank order of potency for 
particular agonists as shown in table 1.7.1.  
 
Ectonucleotides 
Purinergic signalling is not only regulated via activation of purinergic receptors, but also through the 
actions of ectonucleotides which rapidly degrade ATP and UTP to their relevant nucleotides. 
Ectonucleotides act to reduce the concentration of ATP and UTP at the receptor, thus preventing 
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overstimulation and desensitisation of receptors (particularly P2X), but through the process of 
breakdown into intermediates such as ADP and UDP, produces a dynamic signalling pathway 
allowing for the activation of diverse subtypes of purinergic receptor. Ectonucleotide breakdown is 
eventually responsible for the termination of the purinergic response.    
Receptor  Endogenous agonist  
P2X1-7 ATP 
P2Y1 ADP ˃ ATP 
P2Y2 UTP = ATP 
P2Y4 UTP ˃ ATP 
P2Y6 UDP ˃˃ UTP ˃ ATP 
P2Y11 ATP ˃ UTP 
P2Y12 ADP ˃˃ ATP  
P2Y13 ADP ˃˃ ATP  
P2Y14 UDP-glucose 
Table 1.7.1 Rank order of potency of P2X and P2Y receptors for endogenous agonists. Adapted from 
Alexander (2011) 
 
Within the bladder it has been found that ectonucleotidases are expressed throughout the bladder. 
Specifically, E-NTPDase enzymes for the metabolism of ATP to ADP and AMP were found in the 
suburothelium and on the basal and intermediate cells of the mouse urothelium (Yu, Robson et al. 
2011). This coupled with the presence of multiple purinergic receptors on the urothelium and 
underlying interstitial cells contributes to the hypothesis that ATP breakdown is not solely for the 
aim of preventing desensitisation, but is an essential component in the synchronisation of purinergic 
signalling. This has become increasingly apparent with recent findings that adenosine exerts a 
powerful negative feedback control of ATP release from the urothelium via P1 receptors (Dunning-
Davies, Fry et al. 2013). 
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Fig 1.7.2 The action of several ectonucleotidases on the metabolism of ATP into ADP, AMP and 
Adenosine. Abbreviations: ectonucleoside triphosphate diphosphohydrolase, (E-NTPDase); 
ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP); (Ecto-5′-NT) Ecto-5′-nucleotidase; (AP). 
Taken from (Fields and Burnstock 2006). 
 
ATP in the bladder 
A more comprehensive review of the actions of ATP will be covered in the relevant results chapters, 
however, whilst running the risk of repetition, a more concise description will be given here.  
ATP has been shown to be co-released with acetycholine from parasympathetic nerve terminals 
innervating the bladder (Burnstock 2009) and acts on purinergic receptors to initiate contraction of 
detrusor smooth muscle. The relative contribution of ATP to nerve-mediated contraction is species 
dependent and in the healthy human bladder it appears to be zero (Andersson and Wein 2004). 
However, an important observation is that in detrusor strips from both male and female patients 
with a range of lower urinary tract disorders, a significant purinergic component emerges (Ford, 
Gever et al. 2006). 
The main focus of this thesis however, is the role of non-neuronal ATP released from the urothelium, 
and this will be discussed further.  
 
ATP release 
The synthesis and storage of ATP within cells is essential to its autocrine and paracrine actions within 
the bladder. ATP is stored at high concentrations, reported to be within the range of 5mM, in 
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secretory vesicles of neurons. It could be assumed that due to the roles of ATP within the bladder, 
these concentrations would be of an equivalent magnitude. Bladder distension, or stretch of the 
urothelial cell layer has been shown to induce ATP release (Ferguson, Kennedy et al. 1997; 
Sadananda, Shang et al. 2009; Collins, Daly et al. 2013) through an intracellular calcium dependent 
(Matsumoto-Miyai, Kagase et al. 2011; Dunning-Davies, Fry et al. 2013), vesicular exocytosis 
mechanism (Knight, Bodin et al. 2002; Birder, Barrick et al. 2003) which is inhibited by botox (Collins, 
Daly et al. 2013). Distension induced urothelial ATP release has been shown to increase in age 
(Yoshida, Homma et al. 2001), models of spinal cord injury, cyclophosphamide induced inflammation, 
and feline interstitial cystitis (Sun and Chai 2002; Khera, Somogyi et al. 2004; Smith, Vemulakonda et 
al. 2005; Smith, Gangitano et al. 2008). ATP is also increased in human luminal samples from 
patients with OAB and ATP has consequently been proposed as a biomarker for this disorder (Cheng, 
Mansfield et al. 2013; Silva-Ramos, Silva et al. 2013). Thus a role for non-neuronal ATP in modulating 
sub-urothelial structures, particularly the afferent nerves in control of mediating the micturition 
reflex has been proposed. 
 
ATP and mechanotransduction 
As mentioned earlier in this introduction, an indirect pathway for the transduction of mechanical 
stimuli from the bladder has been proposed and non-neuronal ATP is central to this hypothesis.  
The concept of ATP as a sensory neurotransmitter was first discussed by Holton et al in 1959 but was 
not accepted as such for a great number of years (Holton 1959). The work of Burnstock et al was 
significant in concluding that ATP in fact was the NANC neurotransmitter release from inhibitory 
nerves in the gut (Burnstock, Campbell et al. 1970). The release of ATP from the urothelium of the 
rabbit in response to hydrostatic pressure was the first to show that ATP was released from non-
neuronal structures and it was postulated that it could stimulate the plexus of nerves lying beneath 
the urothelium (Ferguson, Kennedy et al. 1997), and thus act as a sensory neurotransmitter. This 
work was the basis of the ‘purinergic hypothesis’ put forward by (Burnstock 1999) that distension 
induced ATP release from the urothelium acts on the P2X2 or P2X3 receptors of the sub-urothelial 
sensory afferents to convey information to the CNS  regarding the filling state of the bladder. This 
hypothesis is supported by the release of ATP from the urothelium in response to stretch 
(Sadananda, Shang et al. 2009; Collins, Daly et al. 2013), and immunohistochemical localisation of 
P2X3 receptors on the sub-urothelial afferent nerves (Vlaskovska, Kasakov et al. 2001; Brady, 
Apostolidis et al. 2004; Apostolidis, Popat et al. 2005). 
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A number of functional studies have linked ATP and P2X receptors to bladder mechanosensation, 
and the use of multiunit afferent recording techniques have provided further insight. Briefly, it has 
been observed that pharmacological blockade of P2X3 receptors significantly reduced sensory nerve 
firing (Namasivayam, Eardley et al. 1999) and that knock-out of the P2X3 and P2X2/3 receptors 
significantly attenuate the afferent discharge in response to ramp distension (Vlaskovska, Kasakov et 
al. 2001; Cockayne, Dunn et al. 2005). Importantly, an endogenous role for urothelially released ATP 
has been shown by a decrease in the afferent nerve response with administration of a P2X receptor 
antagonist (Rong, Spyer et al. 2002).  
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1.8 TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 (TRPV1) 
 
The transient receptor potential (TRP) channel family are comprised of 7 structurally related proteins, 
TRPA, TRPC, TRPM, TRPML, TRPP, TRPN and TRPV. The TRPV subfamily currently contains 6 
members, TRPV1-6 (Clapham 2003). All TRP channels are characterised by six-transmembrane 
polypeptide subunits that assemble to form a pore region between transmembrane domains (TM) V-
VI (Minke and Cook 2002) as well as intracellular amino (N-) and carboxyl (C-) terminal cytosolic 
domains. The N-terminus contains at least three ankyrin repeats which are essential to channel 
function (Jung, Lee et al. 2002; Tominaga and Tominaga 2005).  
 
Fig 1.8.1 Extracellular activation and intracellular amino acids involved in TRPV1 function, residues 
believed to be involved in vanilloids binding are in grey. TRP; TRP domain. Phosphatidylinositol (4,5)-
bisphosphate (PiP2) binds to region indicated. Calmodulin (CaM) binds to both C and N termini. A 
indicates the ankyrin domain. Protons act at GLU600 in the extracellular loop as indicated by arrows. 
Protein kinase A (PKA), protein kinase C (PKC), or calcium/calmodulin-dependent protein kinase II 
(CaMKII) phosphorylate Ser (S) or Thr (T) residues as indicated by arrows. Fig taken from Tominaga & 
Tominaga (2005). 
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Activation and desensitisation of TRPV1. 
TRPV1 is activated by vanilloid compounds (such as capsaicin and resiniferatoxin), noxious 
temperature (> 44˚C), and acid (<pH 6.0) and thus has an essential role in the amalgamation of 
noxious stimuli. Endogenous ligands for TRPV1 include the endocannabinoid anandamide (Zygmunt, 
Petersson et al. 1999), and other derivatives of long-chain fatty acids (Ahern 2003; Matta, Miyares et 
al. 2007). Protons have been shown to sensitise the TRPV1 receptor to temperature activation to the 
extent that even moderately acidic conditions (pH ≤ 5.9) activate TRPV1 receptors at room 
temperature (Tominaga, Caterina et al. 1998; Jordt, Tominaga et al. 2000). The threshold for TRPV1 
activation is reduced by inflammatory mediators such as NGF (Chuang, Prescott et al. 2001), 
bradykinin (Chuang, Prescott et al. 2001), and ATP (Tominaga, Wada et al. 2001) through the 
hydrolysis of the phospholipid PiP2.  
Upon activation, the TRPV1 receptor is permeable to both monovalent and divalent cations but 
exhibits higher specificity for divalent ions, and particularly high calcium permeability resulting in 
voltage dependent depolarisation. The calcium component of TRPV1 receptor activation is especially 
important as extracellular calcium is essential for receptor desensitisation (Koplas, Rosenberg et al. 
1997), and thus the dynamic adaption of TRPV1 expression in sensory afferents to continuous or 
repeated stimuli (Rosenbaum, Gordon-Shaag et al. 2004), which is also the proposed mechanism 
involved in TRPV1 mediated analgesia.  
Desensitisation of the TRPV1 receptor is not fully understood but is believed to occur in two stages: 
acute desensitisation, followed by permanent disruption of channel function (Koplas, Rosenberg et 
al. 1997). As mentioned above, an increase in intracellular calcium is essential for TRPV1 
desensitisation, and calmodulin has been suggested to have an important role in this mechanism 
(Rosenbaum, Gordon-Shaag et al. 2004) as well as channel dephosphorylation by calcineurin 
(Mohapatra and Nau 2005). cAMP-dependent protein kinase A has been shown to decrease 
desensitisation by directly phosphorylating TRPV1 (Bhave, Zhu et al. 2002) and replenishment of PiP2 
in the membrane determines recovery of the channel from desensitization (Liu, Zhang et al. 2005). 
These processes are thought to mediate the short term desensitisation of TRPV1, but the long term 
receptor down-regulation that occurs within intravesical administration of capsaicin in the bladder is, 
however, less well understood. A current theory focuses on TRPV1 withdrawal from the cell surface, 
and recent evidence has shown that long-term neuronal disruption occurs through clathrin-
independent internalisation and endocytosis (Sanz-Salvador, Andrés-Borderia et al. 2012).    
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Where are TRPV1 channels found? 
The TRPV1 receptor is found in a number of non-neuronal cells, though its major expression is upon 
peptide-containing thinly myelinated Aδ and unmyelinated C-fibers including DRG neurons. Whilst 
also expressed in the spinal cord and brain of the central nervous system (Winter 2005). Peripheral 
sensory neurons express TRPV1, with most TRPV1 immunolabelling occuring within capsaicin 
sensitive C-fibers but overlaps with CGRP immunoreactivity or isolectin B4 (IB4). There is also limited 
expression of TRPV1 in Aδ-fibers of DRG neurons. In the spinal cord, TRPV1 is predominantly 
expressed on sensory afferent terminals, consistent with C- and Aδ-fiber expression (Guo, 
Vulchanova et al. 1999; Guo, Simone et al. 2001) as well as in trigeminal ganglia (Ichikawa and 
Sugimoto 2001). Interestingly, Meissners corpuscles, responsible for a portion of somatic 
mechanosensation and found within the skin are innervated by TRPV1 immunofluorescent fibers 
(Paré, Elde et al. 2001) suggesting a mechanosensitising role.  
Of major interest to this project is the presence of TRPV1 within the bladder, particularly pertaining 
to those receptors which are likely to influence afferent nerve excitability and discharge. Many 
immunohistochemical studies have demonstrated the presence of TRPV1 in the dorsal root ganglia 
neurons (Hwang, Min Oh et al. 2005) supplying the bladder and on nerve fibers throughout the 
lower urinary tract. There is significant immunoreactivity for the TRPV1 receptor within the bladder, 
the majority of which is reported on non-myelinated C-fibers (Tominaga, Caterina et al. 1998; 
Avelino, Cruz et al. 2002), but also larger diameter A-fibers (Yiangou, Facer et al. 2001; Ost, Roskams 
et al. 2002) present in muscular and suburothelial plexuses. As well as the documented presence of 
TRPV1 within the peripheral endings of sensory afferents there is evidence of TRPV1 
immunoreactivity within interstitial cells (Ost, Roskams et al. 2002), smooth muscle cells (Birder, 
Kanai et al. 2001; Ost, Roskams et al. 2002), and more controversially, the urothelium, where TRPV1 
expression is seen by some (Birder, Kanai et al. 2001; Lazzeri, Vannucchi et al. 2004; Apostolidis, 
Brady et al. 2005) and not by others (Ost, Roskams et al. 2002; Everaerts, Sepúlveda et al. 2009; 
Yamada, Ugawa et al. 2009) with no discernible explanation for the discrepancies apart from 
different immunohistochemical techniques and the use of a number of different species.  
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The role of TRPV1 in the bladder 
Pathophysiology 
A number of studies report a role for TRPV1 in bladder pathophysiology, inflammation, and pain, 
which are thought to be mediated by capsaicin sensitive primary afferent neurons (CSPANS). 
Patients with neurogenic detrusor overactivity show a significant increase in neuronal and urothelial 
TRPV1 immunoreactivity within the bladder (Brady, Apostolidis et al. 2004; Apostolidis, Brady et al. 
2005), and intravesical vanilloid treatment (resiniferatoxin/capsaicin) has been successfully used for 
the treatment of lower unirary tract symptoms associated with sensory urgency and pain including 
idiopathic and neurogenic detrusor overactivity, and interstitial cystitis (De Ridder, Chandiramani et 
al. 1997; Chancellor and de Groat 1999; Silva, Silva et al. 2007). In addition, intravesical application 
of resiniferatoxin in patients with neurogenic detrusor overactivity caused a reduction in 
immunoreactivity for TRPV1 (Brady, Apostolidis et al. 2004; Apostolidis, Brady et al. 2005), 
supporting the idea that the TRPV1 receptor is essential for bladder sensation, particularly in disease 
states. Likewise, in various murine models of inflammation, including cyclophosphamide, acrolein, 
and lippopolysaccharide, the TRPV1 receptor has been shown to be essential in the development of 
mechanical hyperactivity in the bladder, by using either pharmacological blockade (Vizzard 2000; 
Dinis, Charrua et al. 2004), or knockout of the TRPV1 receptor (Charrua, Cruz et al. 2007; Wang, 
Wang et al. 2008). The mechanisms determining this alteration in sensory function, however, are still 
in question.  
 
Physiology 
There is ubiquitous expression of the TRPV1 receptor within the bladder, yet the role of TRPV1 in 
normal bladder function lacks the conclusive role observed in animal and human models of 
inflammation. A role for the TRPV1 receptor in normal bladder mechanosensation has become 
apparent with the use of TRPV1 knockout (TRPV1-/-) mice. Birder et al (2002) showed that TRPV1-/- 
(KO) mice exhibit reduced reflex voiding and spinal cord signalling and it has since been shown that 
TRPV1-/- (KO) mice demonstrate reduced multiunit afferent responses to bladder distension (Daly, 
Rong et al. 2007). TRPV1-/- (KO) mice exhibit blunted responses to jejunal and colorectal distension in 
vitro (Rong, Hillsley et al. 2004; Jones, Xu et al. 2005) which is also attenuated with pharmacological 
blockade of TRPV1.  
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In the bladder, the TRPV1 receptor has been shown to mediate distension induced ATP release from 
the urothelium (Birder, Nakamura et al. 2002; Sadananda, Shang et al. 2009; Dunning-Davies, Fry et 
al. 2013), and thus a role for TRPV1 in mechanosensation mediated via an indirect pathway has been 
proposed.  
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1.9 TACHYKININS 
 
Tachykinin receptors  
The tachykinins are a family of peptides consisting primarily of substance P, Neurokinin A (NKA), and 
Neurokinin B (NKB). It has been well established that tachykinins are present within the central and 
peripheral nervous system. Substance P and NKA are found in the peripheral nervous system, 
confined primarily to primary afferent sensory neurons innervating a number of peripheral 
structures, including the urinary bladder. NKB is mostly found within the spinal cord and central 
nervous system (Mar, Yang et al. 2012). The tachykinin neuropeptides are encoded by the genes TAC 
1 (PPT-A) for substance P and NKA, and TAC 2 (PPT-B) for NKB. Tachykinins are synthesised in the 
endoplasmic reticulum before passing via the Golgi to form the active peptide molecule and 
packaged into secretory vesicles then transported to the nerve terminals (Pennefather, Lecci et al. 
2004). Tachykinins were considered to function entirely as neuropeptides until relatively recently 
when they were identified outside the nervous system (Severini, Improta et al. 2002).   
There are three major classes of tachykinin receptors, known as NK1, NK2 and NK3. Tachykinin 
receptors belong to a family of G-protein coupled receptors consisting of 7 hydrophobic 
transmembrane domains (TM I-VII) with three extracellular and intracellular loops, an extracellular 
amino terminus and a cytoplasmic carboxyl terminus (Maggi 1995). Endogenous tachykinins bind to 
tachykinin receptors with only moderate selectivity. All three tachykinins, substance P, NKA and NKB 
bind to, and act as full agonists for all three tachykinin receptor subtypes but show a defined order 
of potency such that substance P binds preferentially to NK1, NKA preferentially binds NK2, and NKB 
is more selective for NK3 (Mussap, Geraghty et al. 1993; Regoli, Boudon et al. 1994; Maggi and 
Schwartz 1997).  
There is evidence of additional tachykinin receptors and the existence of tachykinin isoforms but 
because there are few pharmacological tools to distinguish them they will not be considered further 
in this thesis.  
 
Why the interest in Tachykinins? 
As mentioned previously, intravesical instillation of vanilloids (capsaicin and resiniferatoxin) show 
positive outcomes when used in the treatment of both idiopathic and neurogenic bladder disorders 
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yet the precise physiology behind their function is far from understood. Capsaicin, and related 
compounds bind to the TRPV1 receptor, expression of which is mostly confined to unmyelinated, 
small diameter primary afferent fibers known to be capsaicin sensitive (CSPANS). High doses of 
capsaicin have the ability to first activate, desensitise and eventually permanently disrupt sensory 
function. This neurotoxic effect of capsaicin on primary afferent neurons is accompanied by a 
significant reduction in tachykinin immunoreactivity (Maggi 1993; Avelino and Cruz 2000; Lecci and 
Maggi 2001). Stimulation of CSPANS with a non-desensitising dose of capsaicin is known to trigger 
the release of tachykinins and the resultant contractile response of the detrusor smooth muscle can 
be blocked by prior administration of tachykinin receptor antagonists (Lecci, Giuliani et al. 1997).  
In general, intravesical instillation of vanilloids like capsaicin and resiniferatoxin produces positive 
effects on bladder symptoms by increasing bladder capacity and decreasing sensations of urgency 
and frequency (Lazzeri, Spinelli et al. 1998; Silva, Rio et al. 2000). It has been proposed that these 
beneficial effects are mediated by changes in the release of endogenous tachykinins. However, the 
precise roles that tachykinin receptors play within the bladder, and particularly their role in sensory 
signalling are yet to be determined.  
 
Where do tachykinins come from? 
Tachykinin neuropeptides are primarily contained within capsaicin sensitive primary afferent 
neurons (Lecci and Maggi 2001; Avelino, Cruz et al. 2002) but there is also building evidence that 
tachykinins are present in capsaicin-insensitive neurons, primarily following inflammation or insult 
(Neumann, Doubell et al. 1996; Hunter, Myers et al. 2000; Carr, Hunter et al. 2002). Tachykinins are 
also present in the enteric nervous system within the gastrointestinal tract (Lomax and Furness 
2000). Tachykinins have been identified in a range of non-neuronal tissue including, but not limited 
to epithelial cells (Chu, Kraft et al. 2000), and immune cells, in which substance P/NKA act as 
mediators of neurogenic inflammation and neuroimmunomodulation (Maggi 1997; Pennefather, 
Lecci et al. 2004). Maggi et al (1988) proposed a mechanism in which CSPANS have a dual role in 
sensory signalling: normal afferent sensory signalling from the nerves to the spinal cord is mediated 
in part by CSPANS, but the sensory stimulus also triggers the peripheral terminals of certain sensory 
neurons to release stored neuropeptides to evoke an effector response as part of an axon reflex, 
which has been termed a sensory ‘efferent’ function. This is supported by more recent experiments 
which have shown that CSPANS synthesise and release substance P and NKA (Hökfelt, Pernow et al. 
2001) and also express the receptors for these neuropeptides (Brechenmacher, Larmet et al. 1998). 
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CSPANS also exhibit enhanced excitatory responses to external stimuli following NK2 receptor 
activation (Sculptoreanu and de Groat 2007; Sculptoreanu, Artim et al. 2009). It is therefore 
proposed that neurokinins may act as an autofeedback modulator of afferent nerve sensitivity.  
 
Expression in the bladder 
In most species, nerves immunoreactive for NKA are found in the detrusor muscle (Burcher, E et al. 
2000; Andersson 2002) but more densely populate the sub-urothelium, encircling intramural ganglia, 
where they are typically co-localised with substance P and CGRP (Smet, Edyvane et al. 1996; Smet, P 
et al. 1997). It has also been suggested that tachykinin-immunoreactive fibers are more abundant in 
the bladder base than in the dome (Maggi 1993). Furthermore, NK2 receptor mRNA has recently 
been observed in cultured suburothelial cells (Bahadory, Moore et al. 2013). 
 
Changes in expression 
In the sub-urothelium of patients with idiopathic detrusor overactivity there is a significant increase 
in tachykinin immunoreactive fibers (Moore K H 1992; Smet, Moore et al. 1997) and it is proposed 
that alterations in micturition are the result of afferent nerve activation via tachykinin receptors in 
the sub-urothelium either directly or via smooth muscle contraction. Callsen-Cencic et al (1997) also 
confirmed bladder projecting DRG neurons which innervate the rat bladder contain tachykinins and 
showed that cystitis induced hyperreflexia caused a significant increase in the number of DRGs 
expressing tachykinins. However, due to the lack of specific action of substance P in the periphery, it 
was proposed that the increase in substance P-immunoreactive bladder afferents in lumbosacral 
regions enhanced activation of the excitatory parasympathetic pathway to the urinary bladder, and 
contributed to the hyper excitability of micturition reflexes in cystitis rats (Callsen-Cencic and Mense 
1997). This provides a mechanism where an ‘efferent’ function of neurokinins released from the 
peripheral endings of these sensory afferent nerves can combine with central effects in the spinal 
cord to promote hyperreflexia.   
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Role in Inflammation and disease 
Alterations in the expression of tachykinin containing afferent nerves and a role in bladder disease 
and inflammation have been thoroughly investigated. Increases in tachykinin immunoreactive 
afferent nerves in the bladder have been observed in human detrusor overactivity (Moore K H 1992; 
Smet, Moore et al. 1997), OAB (Tyagi, Tyagi et al. 2013), and interstitial cystitis patients (Liu, Yang et 
al. 2014). This is also true for animal models of chronic inflammation (Callsen-Cencic and Mense 
1997), ischemia (Azadzoi, Radisavljevic et al. 2008) and diabetic cystopathy (Philyppov, Paduraru et 
al. 2012). Inflammatory markers such as nerve growth factor (NGF) and vascular endothelial growth 
factor (VEGF) have also been implicated in mediating the changes in tachykinin expressing neurons 
(Saban, Davis et al. 2011; Girard, Tompkins et al. 2012), and consequent changes in bladder function 
(Schnegelsberg, Sun et al. 2010; Malykhina, Lei et al. 2012; Liu, Yang et al. 2014). 
These results thus provide a link by which inflammation can induce recruitment of CSPANS and an 
increase in bladder content of tachykinins which is able to influence bladder function. 
 
Contraction and micturition 
Tachykinin neuropeptides have thus been implicated in pathophysiological bladder function, yet the 
site of action of these proposed modulators is still unclear and their role in normal bladder 
physiology has not been elucidated. There has been a distinct lack of experimental research 
concerning tachykinins in the bladder, however, a role for tachykinins in the regulation of detrusor 
smooth muscle tone, release of urothelial mediators, and as modulators of afferent sensitivity as 
briefly described above have all been proposed. 
NKA, acting via the NK2 receptors is the sole tachykinin responsible for stimulating detrusor muscle 
contractions in a number of species (see (Candenas, Lecci et al. 2005) for review) but the NK1 
receptor has also been shown to play a part role in both the rat and guinea pig detrusor contractions 
(Suman-Chauhan, Guard et al. 1990; Longmore and Hill 1992), where NK1 and NK2 receptor 
mediated responses summate. The urothelium has been shown to express mRNA for the NK2 
receptor (Bahadory, Moore et al. 2013), and has also been implicated in NKA mediated effects 
within the bladder through the alteration of mediator release, chiefly nitric oxide and prostanoids 
(Tramontana, Catalioto et al. 2000; Candenas, Lecci et al. 2005). Intravesical instillation of NKA into 
the bladder lumen has also been shown to induce micturition, and it was proposed that these 
actions were secondary to effects mediated via the urothelium (Maggi, Giuliani et al. 1991; Ishizuka, 
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Mattiasson et al. 1995). There is also some evidence to suggest that NKA may also regulate 
interstitial cell excitability and mucosal contractions (Sadananda, Chess-Williams et al. 2008).  
 
Conclusions 
The body of work described above has provided evidence for the roles of ATP and purinergic 
receptors in mediating afferent nerve activity arising from the bladder. Specifically, a role for non-
neuronal ATP released from the urothelium during distension is consistently implicated in the 
activation of indirect mechanosensitive pathways. The ability of this mechanism to influence the 
sensory structure which forms between the urothelium and the underlying sensory afferent nerves 
appears essential to maintaining urinary continence. The P2, TRPV1 and tachykinin receptors, as well 
as sensory neuropeptides expressed within the bladder, have also been shown to have essential 
roles in mediating bladder afferent activity through both the urothelium and sensory afferent nerves 
and this thesis will investigate the coordination of these pathways.      
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1.10 AIMS 
 
The overall aim of this thesis was to gain new information on the mechanisms involved in afferent 
transduction and mechanosensitivity in the bladder, and the contribution of non-neuronal ATP to 
this process. Understanding the sensory structures which control afferent nerve excitability and the 
stimulus for afferent nerve firing provides essential information regarding the micturition cycle, and 
has the potential to reveal future targets for the pharmacological intervention of lower urinary tract 
disorders. This thesis draws on a number of different experimental approaches to address the 
following specific aims. 
 
Specific Aims 
 To elucidate the expression of purinergic receptors by the mouse urothelium, and determine 
their relative contribution to functional responses gauged from increases in intracellular 
calcium that represents an essential component of non-neuronal ATP release. 
 
 Examine the possible functional interaction between TRPV1 and P2X mediated 
mechanosensitivity in bladder afferent nerves, detrusor smooth muscle, urothelial cells and 
isolated DRG neurons using pharmacological blockade and genetic deletion of the TRPV1 
channel.  
 
 Investigate the role of NK1, NK2 and NK3 receptors, and endogenously released tachykinin 
peptides in the control of bladder mechanosensitivity via actions on the detrusor smooth 
muscle, afferent nerves and urothelial cells. The role of the NK2 receptor as a modulator of 
P2X mediated mechanosensitivity was also investigated.   
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 ANIMALS 
 
All experiments were performed using adult male mice on a C57 black background (14-16wk, 25-
30g). TRPV1 wildtype (WT) and knockout (KO) mice with a genetic background of C57/BL6 were 
generated by GlaxoSmithKline (Harlow, UK). Trans-membrane domains 2-4 of the mouse VR1 gene 
(i.e. DNA encoding amino acids 460-555) were replaced by the neo gene (Davis, Gray et al. 2000). 
Mating pairs of TRPV1-/- (KO) and TRPV1+/+ (WT) N1F1 littermates were obtained to generate 
separate colonies of TRPV1 WT and KO mice at the University of Sheffield according to the UK 
Animals (Scientific Procedures) Act 1986. In the course of the study, genotyping was periodically 
performed to confirm the absence of the TRPV1 gene in KO mice. There were no overt differences in 
feeding behaviour, litter size, growth rate and body weight between WT and KO groups.  
For experiments performed in Australia, adult male mice on a C57 black background were also used, 
and obtained through Griffith University animal house in accordance with ethics approved through 
Griffith University Ethics committee #MSC/04/11/AEC. 
All animals were allowed free access to food and water and were humanely killed by cervical 
dislocation in accordance with UK home office regulations covering schedule one procedures whilst 
in the UK and in accordance with Australian ethical committee approval and the guidelines of the 
national health and medical research council of Australia whilst in Australia. 
Tissues obtained from mice were used in all experiments and composed a number of separate 
protocols. These included:  Recording intravesical pressure and afferent nerve activity, harvesting of 
urothelial cells and DRG neurons for calcium imaging, qPCR and immunohistochemistry, and the use 
of the whole bladder for mediator release studies.  
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2.2 IN-VITRO AFFERENT NERVE RECORDING 
 
Following cervical dislocation of mice, an incision in the abdomen was made in order to remove the 
gastrointestinal tract visible superior to the bladder. The animal was cut in two at the level of L2, 
removing vascular connections via the aorta and vena cava, yet ensuring the kidneys and ureters 
remained intact. The tail and hind limbs were removed and the remaining pelvic section consisting 
of bladder, testes, urethra, ureter and kidneys was placed into ice cold Krebs solution whilst being 
transported to the recording chamber. The recording chamber was continually perfused with 
oxygenated (95% O2 and 5% CO2) Krebs-bicarbonate solution (composition, mM: NaCl 118.4, 
NaHCO3 24.9, CaCl2 1.9, MgSO4 1.2, KH2PO4 1.2, Glucose 11.7) at a stable temperature of 35°C to 
maintain functioning tissue.  
Under a dissection microscope (WPI, PZMIII), the ureters were identified and ligated using silk suture 
(US 4/0) to prevent back flow. Excess tissue surrounding the bladder neck was removed to expose 
the pubic symphasis. The pubic symphasis was cut along the rostral/caudal axis of the urethra and 
connective tissue attaching them together was removed. The pelvic bone on either side of the 
urethra was cut away to the point of attachment to the hind legs to provide increased visibility and 
ease of dissection for the pelvic nerves. The urethral ending was cut and a catheter (OD 0.03IN) 
attached to a syringe pump (Genie, Kent, multi-phaserTM model NE-1000) was inserted into the 
bladder and tied in place using silk suture. The bladder was then filled with 0.9% saline to create a 
small amount of pressure in order to pierce the bladder dome with a syringe needle (BD 
microlanceTM, 19G 2”). A double lumen catheter, connected to both a pressure transducer (DTXTM 
plus DT-XX, Becton Dickinson, Singapore), to allow recordings of intravesical pressure, and an 
outflow (two-way) tap was then inserted into the bladder dome through the incision and secured in 
place with silk suture. The open or closed state of the tap allowed control over filling and emptying 
the bladder 
Following catheterisation, bladder nerve bundles containing both pelvic and hypogastric afferent 
nerves exiting the bladder were located around the base of the bladder, proximal to the point at 
which it connects to the urethra. The bladder nerve bundles converge with urethral bundles as they 
run dorsally towards the spinal cord and it is here that they are most easily identified under the 
microscope. Gently removing connective and fatty tissue exposed the nerve bundles which were 
carefully divided into individual strands. A nerve strand was selected and inserted into a suction 
electrode (tip diameter 25-50µm) attached to a Neurolog headstage (NL100, digitimer, Ltd, UK) 
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which allowed the recording of multi-unit afferent nerve activity. The NL100 was connected to an AC 
pre-amp (NL014) allowing the amplification of the nerve signals (x10,000) before they were filtered 
(NL125, band pass filter) and passed through a 50/60Hz electrical noise eliminator (Humbug, Quest 
Scientific) and finally passed via a micro 1401 analogue to digital interface and visualised on a 
computer using Spike 2 software (version 7.1, Cambridge Electronic Design, UK). 
Whole nerve multifiber afferent nerve activity was quantified using the spike 2 software which 
counted the number of action potentials crossing a pre-set threshold.  
 
Fig 2.2.1 Schematic diagram representing an In vitro model for recording intravesical pressure and 
afferent nerve firing of the bladder. The urethral catheter was attached to a syringe pump allowing 
infusion of saline/drugs into the lumen of the bladder. A double lumen catheter inserted into the 
bladder dome was attached to a pressure transducer to allow monitoring of intravesical pressure, as 
well as an outflow tap from which to empty the bladder. Bladder afferent nerve bundles were 
identified, and inserted into a recording electrode. Action potentials were filtered, amplified and 
recorded using computer software. 
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Fig 2.2.2 Photograph of the in-vitro experimental set-up for recording intravesical pressure and 
afferent nerve firing of the bladder. 
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2.3 DATA ANALYSIS 
 
Distension 
Multi unit nerve activity was quantified through Spike software which counted the number of spikes 
that cross a pre-set threshold; with the threshold level for spike counting set depending on the 
parameters to be measured. Further simultaneous analysis quantified the afferent nerve activity in a 
sequential rate histogram. Baseline afferent activity was obtained by averaging the discharge in the 
100 second period prior to the distension. The afferent nerve response during bladder distension 
was calculated by measuring the afferent activity (action potentials/per second) at various 
intravesical pressures (0-40mmHg). These values were then substracted from the baseline firing to 
give a total change in afferent nerve response during distension. 
Baseline firing 
During application of drug without distension of the bladder, baseline firing was calculated by 
measuring the peak response after drug application and then subtracting the mean baseline firing 
(100 seconds) prior to application of the drug.  
Bladder compliance 
Bladder compliance is the ability of the bladder to accommodate the volume within, in relation to 
the intravesical pressure.  
Volume (µl) = Rate (µl/min-1) x Time (s) 
The pressure/volume relationship (compliance) was calculated at various intravesical pressures      
(0-40 mmHg) during bladder filling and determined from the rate of infusion (µl/min_1) and the time 
(s) from the start of the infusion. Compliance was then represented as a pressure-volume XY plot. 
Afferent nerve activity 
Afferent nerve activity is expressed as impulses per second (imp/s−1). Data are expressed as means ± 
S.E.M. Statistical analysis was carried out using either a 2-way ANOVA followed by a Bonferroni 
multiple comparisons post test where necessary or one–way ANOVA/paired students t test and 
significance was set at P< 0.05. (All graphical and statistical analysis used in this thesis was 
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performed using Graph Pad Prism (Version 5.00 for Windows, Graph Pad Software, San Diego 
California USA, www.graphpad.com). 
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2.4 EXPERIMENTAL PROTOCOL 
 
Afferent nerve recordings 
The recording of multiunit nerve preparations was performed whilst the bladder was both at rest 
and under distension.  
Preparation viability 
Before the start of each experiment, the bladder was filled with saline to allow an examination of 
the viability of the experimental preparation. Bladders which did not fill to the set threshold volume 
of 50mmHg indicated that there was a leak in the circuit and sutures needed to be examined before 
the preparation could continue. Secondly, the viability of the nerve contained within the recording 
electrode was also examined. If the nerve failed to elicit a typical reproducible response to 
distension (fig 2.5.2), which is most likely due to damage during the dissection process, then this 
nerve bundle was discarded and a new bundle was inserted into the electrode. After allowing the 
preparation to stabilise for a period of 30 minutes with no volume in the bladder, repeat control 
distensions with isotonic saline (NaCl 0.9%) were performed. To perform control distensions, the 
outflow tap was closed and the syringe driver was set to fill the bladder at either 30 µl/min or 
100µl/min to a final intravesical pressure of 30-40mmHg every 10 minutes, after which, the outflow 
tap was opened and the bladder was allowed to empty. This was repeated until a stable pressure 
and afferent response to bladder distensions was obtained. 
In order to examine the physiology of the bladder, a number of pharmacological agents were applied 
either directly to the outside of the bladder and thus were able to bind the receptors of both the 
muscle and the nerve bundle, or into the lumen of the bladder via the syringe driver. The precise 
protocols relating to the following applications will be explained in further detail within each chapter 
but the general protocols will be explained here: 
 
Intraluminal application of pharmacological agents 
Pharmacological agents were applied to the urothelial surface of the bladder through the syringe 
driver catheter entering via the urethra. All pharmacological agents were diluted in isotonic saline 
and placed in syringes on the syringe pump in place of isotonic saline.  
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These pharmacological agents were applied in two distinct ways and will be clarified for specific 
experiments: either with the outflow tap remained open so the drug passes freely through the 
bladder at a rate of 30µl/min, causing no distension and thus no effect on intravesical pressure, or 
were used in place of isotonic saline to perform bladder distentions.  
Changes in afferent nerve activity were recorded during infusion of the drug as well as pressure and 
afferent nerve activity during or after distensions in the presence of the drug.  
Extraluminal application of pharmacological agents 
To examine both bladder afferent nerve and detrusor muscle responses to the application of 
pharmacological agents, these drugs were applied directly to the extraluminal surface of the bladder. 
This was performed using two different protocols depending on whether the drug was an agonist or 
an antagonist and the pharmacological profile of the drugs being used. In the case of antagonists, 
pharmacological agents were perfused in the extraluminal krebs. 
 Fig 2.4.1 Experimental trace showing stabilisation of detrusor smooth muscle and afferent nerve 
activity following distension to 12mmHg. The Intravesical pressure, and corresponding afferent nerve 
discharge gradually becomes stable in the presence of a set volume after approximately 30minutes.   
 
In many experiments, in order to measure both afferent nerve and intravesical pressure responses 
to pharmacological agents, the bladder was filled to an intravesical pressure of around 12mmHg 
above baseline at a rate of 30ul/min. The infusion of saline was stopped but the outflow tap 
remained closed, and thus maintaining some volume within the bladder. Following a period of 45 
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minutes, which allowed the bladder muscle and neuronal firing to stabilise (fig 2.4.1), agonists were 
applied as a bolus dose from a pipette directly into the bath. Changes in afferent nerve activity were 
recorded during perfusion of the drug as well as pressure and afferent nerve activity during or after 
distensions with the drug. 
 
Isolation and culture of primary urothelial cells 
The method for the isolation of urothelial cells from the mouse bladder was derived from a number 
of previous studies (Birder, Nakamura et al. 2002; Everaerts, Vriens et al. 2010) and optimised for 
use in our laboratory. Following cervical dislocation, bladders were excised from the mouse and 
placed in phosphate buffered saline (PBS) (Gibco®), before the urethra and any excess tissue from 
the serosal side was removed. The bladders were cut longitudinally from the urethral opening and 
pinned flat with the urothelial side facing upwards on a Sylgard® (Dow Corning) coated dish. The 
bladder was washed 3 times in fresh Modified Eagle Medium (MEM) (Gibco®) containing 1% 
Antibiotic-Antimycotic (PSF) solution (Gibco®) and 0.7% HEPES. Bladders were then incubated with 
2.5mg/ml Dispase in MEM for 2hrs at room temperature in the tissue culture hood. The dispase was 
aspirated and the urothelial side of the bladder was gently scraped with a blunt scalpel under a 
dissecting microscope. Removed urothelial cells were immediately placed into 0.5% trypsin-EDTA 
(Gibco®) and then incubated at 37°C for 5-10 minutes or until fully dissociated with gentle trituration 
every few minutes. The trypsin-EDTA was deactivated by addition to MEM with 10% Fetal calf serum 
(FCS) (Gibco®). The cell suspension was then spun at 1500rpm for 15min at 4°C. Media was aspirated 
and the pellet was resuspended in Keratinocyte serum-free media (K-SFM) (Gibco®). Cells were 
washed through a spin at 1500rpm for 15min at 4°C. The media was aspirated and the pellet 
resuspended in fresh K-SFM. The cell suspension was counted and plated on collagen (IV) (Sigma- 
Aldrich Poole,UK) coated coverslips and incubated overnight at 37°C in an atmosphere of 5% CO2- 95% 
O2 for use in both calcium imaging and immunohistochemistry experiments.  
 
Isolation and culture of Dorsal root ganglion neurons 
After cervical dislocation, whole DRG’s from lumbosacral (L6/S2) and thoracolumbar (T11/L2) 
regions were removed. DRG’s were immediately placed in Hanks Balanced Salt Solution (HBSS) (pH 
7.4) (Gibco®) and treated with 2mg/ml papain (Sigma- Aldrich (Poole,UK)) and 0.5mg/ml cystein 
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(Sigma- Aldrich (Poole,UK)) and left to incubate at 37°C for 20 minutes whilst being gently agitated 
before being replaced by HBSS containing 4mg/ml collagenase (Sigma- Aldrich (Poole,UK)) and 
5mg/ml dispase (Sigma- Aldrich (Poole,UK)) and left to incubate at 37°C for 20 minutes whilst being 
gently agitated. Following enzyme treatment, the DRGs were washed with fresh DMEM-F12 
(Invitrogen) culture media containing 10% fetal bovine serum (FBS) (Gibco®) before being 
resuspended in 500µl of fresh DMEM-F12 media. The DRGs were then triturated with a Pasteur 
pipette to release individual DRG neurons, which were counted, and plated onto Matrigel (Sigma- 
Aldrich (Poole,UK)) coated glass coverslips (6 x 16mm). Cells were then incubated in a 5% CO2-95% 
O2 incubator at 37°C for 2 hours. Following incubation, the cells were flooded with DMEM-F12 (1% 
PenStrep, 10% FBS) culture media (Invitrogen) and incubated overnight at 37C in a 5% CO2-95% 
O2 incubator for use in calcium imaging experiments.  
 
Calcium imaging 
Following a 24hr incubation at 37°C, cells attached to coverslips were incubated with 2µM Fura 2 
acetoxymethyl ester (Fura2-AM) (Sigma- Aldrich (Poole,UK)) for 30 min at 37°C in the dark. Fura2-
AM is ratiometric fluorescent dye which diffuses into cells and binds to free intracellular calcium. 
Coverslips were then placed in a washing well containing only media at 37°C before being washed in 
HEPES solution at room temperature and then placed upon the recording equipment. Coverslip 
containing cells were then transferred to a perfusion chamber and mounted on an Epifluorescent 
microscope where they were continually perfused with HEPES buffer at a rate of 1ml/min for 30 
minutes to allow excess Fura2-AM to wash from the cells. Intracellular Ca2+ concentration ([Ca2+]i) 
was measured as the ratio between the fluorescence signal emitted following a 100ms-1 excitation at 
340/350 nm and at 380 nm light. A region of interest (ROI) was placed around all individual cells 
visible within the single view field as well as a blank region where no cells were present to provide a 
baseline light emission reading. After 30 minutes of perfusion with HEPES buffer, cells were 
stimulated for 2-5 minutes with HEPES containing the drug of interest. The drug was then washed 
out by switching the perfusion back to HEPES buffer, finally the cells were stimulated with the 
calcium ionophore ionomycin (5μM) (Sigma- Aldrich (Poole,UK)). Ionomycin was applied as a positive 
control and only positively responding cells were included in the analysis. All calcium imaging was 
performed at room temperature as a heated perfusion system was not available. After correction for 
the individual background fluorescence signals, the ratio of the fluorescence at both excitation 
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wavelengths was calculated and results expressed as a ratio of this fluorescence (Rf). For each 
experimental condition, at least 15 cells in at least three independent experiments were assayed. 
Buffers 
HEPES buffer for DRGs; composition in mM (NaCl 134, KCL 5, HEPES 9.4, glucose 10, CaCl2 2, MgCl2 1). 
HEPES buffer for urothelial cells; composition in mM (NaCl 142, NaHCO3 5, HEPES 10, glucose 16, KCL 
2, CaCl2 2, MgCl2 1, 0.1% bovine serum albumin) (Sigma- Aldrich, Poole, UK) added to the dissolved 
solution. 
Calcium free HEPES buffer for urothelial cells: composition in mM (NaCl 142, NaHCO3 5, HEPES 10, 
glucose 16, KCL 2, MgCl2 3, 0.1% bovine serum albumin added to the dissolved solution. 
All solutions were adjusted to pH 7.4 with NaOH and had an osmolarity of 300-310mosmol/L to 
provide isotonic conditions. 
 
Immunohistochemistry 
Following the culture of urothelial cells for 24hrs on collagen (IV) coated coverslips, surrounding 
culture media was removed and the cells were washed three times with sterile PBS. PBS was 
aspirated and the cells were fixed with 1ml/well cold paraformaldehyde (PFA) (4%) (Sigma- Aldrich 
(Poole,UK)) and left in the fridge for 45 minutes. PFA was removed and the cells were permeabilised 
with 4°C sapponin 0.05% + 2% FBS prepared in PBS (1ml/well) and incubated at 4°C for 45 minutes. 
Following permeabilisation, the sapponin was removed. The primary antibody was prepared in 
saponin +FBS (1/50) and 50µl was applied to each coverslip before being left in the fridge overnight. 
After 24hrs, excess primary antibody was removed with PBS washing (X3). The secondary antibody 
was prepared in PBS + FBS 2% (1/1000) and 50ul was applied to each coverslip and left at room 
temperature in the dark for 2 hours and then washed with PBS (X3). The coverslips were then 
mounted on slides using Vectashield® mounting media (containing Dapi) (Vector Laboratories, UK) 
before being left to dry in the dark and then imaged using a fluorescent microscope. 
Primary antibody for urothelial cells was 1/50 Cytokeratin 7 Clone OV-TL 12/30 monoclonal mouse 
anti-cytokeratin 7 (DAKO) raised in mouse. 
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Secondary antibody used for urothelial cells was 1/1000 Alexa Fluor® 488 green goat anti-mouse 
(Invitrogen) raised in goat.  
 
RT-qPCR  
Extraction of mRNA from PMUC and DRG neurons 
Following isolation of PMUC and DRG neurons from the mouse as per methods described above, 
cells were incubated at 37°C in respective media for 24hrs, all RNA extractions were performed at 
room temperature and following the manufacturer’s instructions for the RNeasy mini kit (Qiagen, 
Australia). Lysis of the cells was performed by addition of buffer RLT (350µl) (1% β-Mercaptoethanol) 
to the cell pellet before being passed repeatedly through a needle (19G) attached to a sterile syringe. 
Ethanol (70%) (350µl) was added to the lysate and mixed by pipetting before transfer to a spin 
column. Following centrifugation, the flow through was discarded and the RNA was now contained 
within the spin column. Further purification of the RNA contained within the spin column was 
achieved through 15s cycles at 10,000rpm with both RW1 and RPE buffers. To elute the RNA, 30µl of 
RNase free water heated to 42°C was added directly to the spin column membrane and centrifuged 
for 1 minute at 10,000rpm. The eluted RNA was then used to repeat this process, ensuring the 
highest possible concentration of RNA in the collection tube.  
RNA was stored at -80°C to prevent decomposition and was all converted to cDNA at the earliest 
possible time point to prevent freeze thaw cycles.  
 
Purity and integrity of the RNA sample 
A NanoDrop 1000 Spectrophotometer (Thermo Scientific) was used to measure the total RNA 
quantity and to assess the purity. Purity of the RNA was determined based on the 260/280 and 
260/230 ratios’ of absorbance. A 260/280 absorbance in the range of 2±0.1 and a 260/230 
absorbance in the range of 2.0-2.2 was considered acceptable and this RNA was then used to 
synthesise cDNA for use in qPCR reactions.  
Total mRNA extraction values from individual mice varied due to the individual variation in size 
between bladders of different mice. RNA extraction from urothelial cells of a single mouse ranged 
from 25-35ng/µL. As such, the point at which mRNA was converted to cDNA provided an opportunity 
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to more easily standardise the quantity of cDNA produced by adding the same quantity (ng) of RNA 
to the cDNA synthesis kit and was standardised at 220ng. 
 
Synthesis of cDNA 
Synthesis of cDNA from RNA was performed using SuperScript III First-Strand Synthesis SuperMix for 
qRT-PCR (Invitrogen). Superscript III is a high performance propriety type of reverse transcriptase 
which is optimised for the synthesis of first-strand cDNA from total RNA as it is not significantly 
inhibited by ribosomal and transfer RNA. For each reaction, 10 µl of 2X reverse transcriptase 
reaction mix (which also contains an RNase inhibitor protein) was added to 2µl of reverse 
transcriptase enzyme mix, containing: oligo(dT)20 (2.5µM), random hexamers (2.5ng/µl), MgCl2 
(10mM) and dNTPs, and then made up to a total of 20µl with a combination of RNA and DEPC-
treated water. The proportion of RNA/H2O was dependent on the concentration of the RNA used, 
with a total of 220ng of RNA from urothelial cells used in each reaction.  
A much larger amount of mRNA was extracted from mouse DRG neurons than urothelium, in the 
range of 190-230ng/µl total RNA. As such, the RNA was diluted by a factor of 1/10 so that similar 
amounts of total mRNA to that obtained for PMUC were used for the conversion to cDNA. 
Following the manufacturer’s instructions, the tube contents were gently mixed and incubated at 
25°C for 10 minutes, 50°C for 30 minutes, and then terminated by heating to 85°C for 5 minutes 
before being immediately chilled on ice. 1µl of E. Coli RNase H was added to the cDNA for 20 
minutes at 37°C before being stored at -80°C for use in qPCR reactions. 
 
Quantitative real-time polymerase chain reaction (qPCR) 
An iQSYBR Green Super Mix (BioRad) was used to amplify the cDNA target genes in the qPCR 
reactions. This supermix includes the SYBR green dye, which binds to the double stranded DNA as it 
is generated by the PCR reaction and allows the product to be quantified. qPCR was performed using 
a Research Rotor-Gene 6000 real time thermocycler (Corbett-Qiagen). The PCR reactions were made 
up to a total of 25µl in each individual 100µl PCR tube (Corbett) and were prepared on -20°C pre-
cooled metal tube carriers. Each PCR tube contained 12.5µl of the iQSYBR Green master mix, 2µl of 
primers (1µl each of forward and reverse) and a mix of cDNA and DEPC treated H2O to make up to 
25µl. Cyclic conditions were set at: 95°C for 12 minutes as an initial hold stage followed by 40 cycles 
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of 95°C for 30s, 59°C for 30s, 72°C for 30s, followed by a melt curve of 0.5°C increments every 30 
seconds from 72-95°C. The number of cycles required to the point that the specific PCR product is 
amplified in a linear way is referred to as the cycle threshold (CT). This is the representation used for 
quantitative analysis, where a single CT difference (Δ CT = 1) represents a two-fold difference in the 
quantity of the target gene. Therefore, after each qPCR reaction, the CT value at linearity was 
determined for each gene and is a representation of relative expression levels of that particular gene. 
Expression levels of each target gene were expressed relative to the housekeeping gene, β-actin, and 
in the case of purinergic receptors, represented as a ratio relative to P2Y1 expression. 
Controls were performed in which no cDNA was added to the reaction mix. 
 
Fig 2.4.2 Example trace of gene amplification during qPCR reactions. The CT is set to the linear phase 
of expression levels.  
 
Primer design and selection 
Oligonucleotide primers were designed from the characterised mouse genome (mus musculus). The 
primers (table 2.4.1) were designed following a strict set of rules ensuring specificity of the primers 
to the gene of interest and purchased from Geneworks (Thebarton, South Australia).  
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Gene   Primer Sequence ‘5 – 3’  Product   Position Tm°C  Chromosome 
P2X1 Forward CAAGTATGCGGAGGACATGG 131bp 1362- 58.4 11 
  Reverse CACACTGAGTCAAGTCCGG   1493 57.8   
P2X2 Forward CCATCAGGTGAAGGACCAGC 118bp 1454- 60.4 5 
  Reverse GCTGGTCAAGAGTGTCCACC   1571 60.6   
P2X3 Forward CAGTGTTCACCAGTGACCAGGC 128bp 1086- 63.6 2 
  Reverse GCCTGTTGAAGGTTCTGCAGCC   1213 64.4   
P2X4 Forward CGTCTGTCACTCTAGAGACGG 202bp 1229- 59.3 5 
  Reverse GGTGCTGTTATGGACGTGTGG   431 61.5   
P2X5 Forward GTAGCCAGAGCTCTTGGCAGG 115bp 1494- 62.8 11 
  Reverse CTCAGAAGCCACATCCTGAGC   1608 60.8   
P2X6 Forward GACCTGCTGCTACTGTATGTGG 104bp 1120- 60.7 16 
  Reverse GGCTCGGTCTATGAACTGTTGG   1226 61   
P2X7 Forward CACATTCGCATGGTGGACCAGC 98bp 1213- 64.5 5 
  Reverse GACAGGTCGGAGAAGTCCATCTGG   1310 64.3   
P2Y1 Forward GTCTCAACAGCTGTGTGGACC 206bp 1598- 61 3 
  Reverse CTCAGGAGCTAGGATCTCGTGC   1803 62   
P2Y2 Forward CACGATGGACTTAGCTCAGAGG 207bp 1864- 60.2 7 
  Reverse CAGGAGGCAGAGATAACAGGC   2070 60.2   
P2Y4 Forward CAGCAGCTATGCAGAGGTAGC 194bp 553- 60.9 X 
  Reverse CCTCTGCCTGCAGTTAGTCC   746 60.1   
P2Y6 Forward GGCAACTGGTCAATTCATGC 150bp 1583- 58 7 
  Reverse CACATCCTGAGATGTCTAGC   1732 55   
P2Y12 Forward GTGTCAACACCACCTCAGCC 149bp 420- 61.1 3 
  Reverse CCTCATTGCCAAGCTGTTCG   568 59.8   
P2Y13 Forward GTTCCTCAAGATCATCATGCCG 210bp 436- 59.4 3 
  Reverse GTGTGACTGACCACCTGATGC   645 61.2   
P2Y14 Forward GTCACGAAGATACAGTGCATGG 131bp 792- 59.4 3 
  Reverse GTGATGGCCGTGTAGAAGACG   922 61   
NK1 Forward GACACTTAGTCTGCCAAGAGC 193bp 3561- 58.7 6 
  Reverse CTCCACATGCTGGATAGAGC   3753 57.8   
NK2 Forward GGATGGTGACATGGCTCAGC 117bp 1879- 61.1 10 
  Reverse GGACAGCTTGCAGACGTTGG   1995 61.8   
NK3 Forward CCTCATTCTCCTAACCATGCC 205bp 1681- 58.1 3 
  Reverse CAGACACCGGATACTTAGAGC   1885 57.6   
TRPV1 Forward CAAGGCTCTATGATCGCAGG 198bp 575- 58.2 11 
  Reverse GAGCAATGGTGTCGTTCTGC   772 59.8   
Table 2.4.1 Primer sequence, product size, gene loci, and Tm for all genes for which RT-qPCR was 
performed. 
 
The mouse genes were identified within unigene through their specific receptor nomenclature. For 
design of the purinergic receptor genes especially, but also for the tachykinin receptors and the 
TRPV1 receptor, it was essential to ensure that these primers were specific for that receptor as a 
large portion of the desired gene is conserved between each of the different receptor isoforms. As 
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such, exon regions were blasted against all other isoforms to identify regions that were specific to 
each receptor before attempting to design the primers (table 2.4.1). All primers were designed 
within exons and were intron spanning. 
 
Urothelium specific information 
For quantifying gene expression in primary mouse urothelial cells a total of 4µl cDNA @ 1/50 dilution 
in DEPC H20 was used and provided linear CT readings within the range of 20-30 PCR cycles. Samples 
were performed in triplicate and statistical analysis was performed to ensure the standard deviation 
was less than 0.16 before accepting results. 
DRG specific information 
Following transcription of DRG cDNA, it was diluted 1/50 with DEPC H2O before being used in qPCR 
experiments. 4µl cDNA @ 1/50 dilution was used to provide linear CT readings of the target genes 
within the range of 20-30 PCR cycles. Samples were performed in triplicate and statistical analysis 
was performed to ensure the standard deviation was less than 0.16 before accepting results. 
 
Urothelial release factors 
The release of acetylcholine (ACh), ATP and prostaglandin E2 (PGE2) was examined using an isolated 
whole bladder preparation. The bladder was catheterised as described previously for afferent nerve 
activity so that intravesical pressure could be measured and the bladder could be filled and emptied 
accordingly. Bladders were constantly perfused at a rate of 30µl/min with the outflow tap open and 
situated in an eppendorf tube in dry-ice for 7 minutes, thus allowing a baseline sample of 
intravesical saline to be collected without stretching of the urothelial layers of the bladder. Following 
collection of a baseline sample, the outflow tap was closed and bladders were filled at a rate of 
either 30µl/min or 100µl/min to a maximal pressure of 40mmHg before perfusion was stopped and 
the outflow tap was open. The tube supplying the outflow tap was removed and placed into an 
eppendorf tube sitting in dry-ice and thus the maximal amount of bladder content would enter the 
eppendorf and be snap frozen to prevent enzymatic degredation within the intravesical supernatant. 
Urothelial mediators were measured both at rest and during stretch in TRPV1-/- (KO) and TRPV1+/+ 
(WT) mice and with the infusion of NKA (300nM) dissolved in saline. 
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The ACh, ATP and PGE2 assays were performed according to the manufacturers’ protocols. Mediator 
concentration in samples was calculated using standard curves constructed from known ACh, ATP or 
PGE2 standards and each plate included a blank which was subtracted prior to analysis.  
 
ATP determination 
Concentrations of ATP release from the bladder lumen were measured using a luminescence based 
ATP Determination Kit (Molecular Probes).  The assay is based on luciferases’ requirement for ATP in 
producing light from the reaction and thus gives a precise reading of the ATP present in the sample 
at the time of the reaction but will not pick up any previously broken down ATP. 
 
Luminescence was measured using a Modulus Microplate Mulitimode Reader (Turner Biosystems, 
California, USA) and ATP content in samples was calculated from a standard curve of luminescence 
plotted using known concentrations of ATP (fig 2.4.3).  
 
 
Fig 2.4.3 Standard curve of luminescence readings to known concentrations of ATP 
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Acetylcholine determination 
Concentration of acetylcholine release from the bladder lumen was measured with an Amplex Red 
ACh/ACh esterase Assay Kit (Molecular Probes). First acetylcholinesterase converts acetylcholine to 
choline. Choline is in turn oxidised to betaine and hydrogen peroxide, which in the presence of 
horseradish peroxidise reacts with amplex red to generate the fluorescent product resorufin.  
Resorufin fluorescence is measured using a Modulus Microplate Mulitmode Reader (Em 590nm) 
(Turner Biosystems, California, USA). As the assay measures the metabolite choline, the assay not 
only calculates the current amount of acetylcholine, but also any acetylcholine that has been broken 
down during the course of sample collection.   
 
Fig 2.4.4 Standard curve of fluorescence readings to known concentrations of ACh. 
 
PGE2 determination 
Concentration of PGE2 was measured using Prostaglandin E2 EIA Kit (Cayman Chemicals). The assay 
uses a 96 well plate coated with goat polyclonal anti-mouse IgG antibodies to which mouse IgG PGE2 
monoclonal antibodies are added. The assay then works by competitive binding between the PGE2 in 
a sample and a PGE2-acetylcholinesterase conjugate (PGE2 Tracer). The binding of the PGE2 Tracer is 
quantified by the addition of an acetylcholinesterase substrate leading to the production of a 
coloured substrate that absorbs strongly at 412nm. Samples and standards were analysed using a 
Modulus microplate reader (420nm) and the intensity of this colour determined is proportional to 
  
64 
 
the amount of PGE2 Tracer bound to the well, which is inversely proportional to the amount of free 
PGE2 present in the well during the incubation.  
 
Fig 2.4.5 Standard curve of spectrophotometer readings and known concentrations of PGE2. Where 
B/B0  is the standard bound/maximum bound. 
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Drugs and Solubility 
All the drugs used in this study are listed in the table below. All drugs were dissolved in dH2O where 
possible, or in DMSO (Sigma), or 70% ethanol (Sigma) to make stock solutions. Stock solutions were 
either diluted in Krebs (for extraluminal application) or saline (for intraluminal application) to the 
final concentration required for individual experiments. For all experiments, a vehicle control was 
used to account for any effects of the solvent. Concentrations of pharmacological agents used in 
each study are described in the relevant experimental protocols section. 
 
Compound Main Action Purchased from Cat No. 
α,β-Methyleneadenosine 5’triphosphate (αβMe-ATP) P2X agonist Sigma Aldrich M6517 
Adenosine 5′-triphosphate (ATP) Purinergic agonist Sigma Aldrich A2383 
Apyrase ATPase enzyme Sigma Aldrich A6410 
Capsaicin TRPV1 agonist Sigma Aldrich M2028 
Capsazepine (CPZ) TRPV1 antagonist Sigma Aldrich C191 
CP99994 NK1 antagonist Tocris Bioscience 3417 
1,1-Dimethyl-4-phenylpiperazinium iodide (DMPP) Nicotinic agonist Sigma Aldrich D5891 
GR159897 NK2 antagonist Tocris Bioscience 1274 
Ionomycin Calcium 
ionophore 
Sigma Aldrich I0634 
Nifedipine L-type Ca
2+
 
channel blocker 
Sigma Aldrich N7634 
NF449 P2X antagonist Tocris Bioscience 1391 
Pyridoxal phosphate-6-azo(benzene-2,4-disulfonic 
acid) tetrasodium salt hydrate (PPADS) 
P2X antagonist Sigma Aldrich P178 
MRS2279 P2Y1 antagonist Tocris Bioscience 2158 
MRS2365 P2Y1 agonist Tocris Bioscience 2157 
MRS2578 P2Y6 antagonist Tocris Bioscience 2146 
MRS2693 P2Y6 agonist Tocris Bioscience 2502 
[Lys5,MeLeu9,Nle10]-NKA(4-10) (NKA) NK2 agonist Tocris Bioscience 3228 
SB222200 NK3 antagonist Tocris Bioscience 1393 
[Sar9,Met(O2)11]-Substance P (Substance P) NK1 agonist Tocris Bioscience 1178 
Senktide NK3 agonist Tocris Bioscience 1068 
Tetrodotoxin (TTX) Na
+
 channel 
blocker  
Tocris Bioscience 1078 
Uridine 5′-triphosphate (UTP) P2Y2/4 agonist Sigma Aldrich U6875 
Table 2.4.2 Summary of the pharmacological agents used in this study 
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2.5 CHARACTERISATION OF AFFERENT NERVE RESPONSES TO 
DISTENSION 
 
 
 
Fig 2.5.1 The afferent nerve and pressure responses to bladder ramp distension. 
A. The rise in intravesical pressure during ramp distension with isotonic saline (0.9%) at 30µl/min to a 
maximal intravesical pressure of 40mmHg. B. Sequential rate histogram portraying the increase in 
whole bladder afferent nerve discharge evoked during saline ramp distension. C.  Raw nerve trace 
depicting the increased afferent activity in response to distension. 
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In normal wildtype preparations, ramp distension provides a progressive increase in intravesical 
pressure and a simultaneous increase in afferent nerve activity (fig 2.5.1). In this study, bladders 
were either filled at a rate of 100µl/min or 30µl/min depending on the experimental protocol, but 
were never distended beyond a threshold of 40mmHg to prevent damage to the bladder wall. There 
were two distinct phases of the bladder response to an increase in volume. In the initial stage (0-
10/15mmHg), there is large increase in volume with a small increase in pressure as the bladder 
muscle is able to accommodate the increase in intraluminal volume. A second stage occurred 
beyond 10-15mmHg in which there is a much larger increase in intravesical pressure for a relatively 
small increase in volume (fig 2.5.1).  
 
 
Fig 2.5.2. Representative trace showing control ramp distensions carried out using isotonic saline at a 
filling rate of 30µl/min to a maximal pressure of 30mmHg. Distensions are performed at 10 minute 
intervals at the start of all experiments to confirm muscle and nerve viability. Nerve and muscle 
responses are stable and reproducible. 
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The whole nerve afferent response to control distension was highly variable between preparations, 
but was very stable within a single preparation. The stability of the afferent response to repeat ramp 
distension was used as a positive control at the start of afferent nerve based experiments and an 
example trace can be seen in fig 2.5.2. The reproducibility of the afferent nerve and compliance 
responses to subsequent ramp distension can be seen in fig 2.5.3.   
 
Fig 2.5.3 Pressure/volume and pressure/nerve responses to three repeat distensions prior to the start 
of an experiment. The compliance and afferent response to distension are reproducible. A, 
pressure/volume relationship during ramp distension at 30µl/min. B, Afferent nerve/pressure 
relationship during ramp distension at 30µl/min. C, pressure/volume relationship during ramp 
distension at 100µl/min. D, afferent nerve/pressure relationship during ramp distension at 100µl/min. 
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2.6 SPONTANEOUS BLADDER CONTRACTIONS 
 
During ramp distension of the bladder with saline, transient increases in intravesical pressure are 
observed as overall pressure increases which are associated with bursts in afferent nerve firing. An 
example of this can be seen in fig 2.6.1. The development of spontaneous contractions during 
distension only occurs when the bladder is distended at a slower rate (30µl/min) and not at faster 
rate of 100µl/min. A closer look at these spontaneous contractions (fig 2.6.2) shows they exhibit 
phasic activity with a consistent amplitude and frequency within an experimental preparation.  
Phasic spontaneous detrusor activity also develops when a bladder is distended to a physiological 
volume of 12mmHg and then left to accommodate the increase in volume (fig 2.6.3). These 
spontaneous contractions observe a similar frequency, but increased amplitude to those observed 
during bladder distension and are also associated with concomitant bursts of afferent discharge.   
 
Fig 2.6.1. Representative trace showing the spontaneous detrusor contractions which occur during 
control ramp distension carried out with isotonic saline at a filling rate of 30µl/min to a maximal 
pressure of 30mmHg. Bursts of afferent nerve activity can be seen within the raw nerve activity, 
corresponding to transient increases in bladder pressure.  
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Fig 2.6.2 A closer look at the interaction between spontaneous detrusor contraction and mean 
afferent discharge during ramp distension at 30µl/min.  
 
 
 
Fig 2.6.3 Spontaneous detrusor contractions and associated afferent nerve activity occurring in a 
bladder distended to 12mmHg and left with saline inside.  
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Fig 2.6.4. Representative trace showing spontaneous detrusor contractions and associated afferent 
nerve activity occurring in a bladder pre-distended to 12mmHg before and after tetrodotoxin (1µM) 
followed by ramp distension with saline.  
 
As can be seen from the trace in fig 2.6.4, spontaneous detrusor contractions persist in the presence 
of tetrodotoxin (1µM). The afferent nerve response to bladder distension is abolished following the 
addition of tetrodotoxin to the bathing solution but has no effect on detrusor contractions when the 
bladder is pre-distended to a set volume or during ramp distension of the bladder at 30µl/min. This 
confirms the hypothesis that spontaneous detrusor contractions are not mediated by neuronal 
activity and appear to be myogenic in origin, potentially mediated by the interstitial cells in the sub-
urothelium which are activated by a rise in intracellular Ca2+ and dependent on Cl- currents 
(Sherrington 1892; Fry, Sui et al. 2007) as opposed to Na+ currents. Spontaneous detrusor activity 
has previously been shown in the isolated whole bladder (Sherrington 1892) and more recent 
studies have shown a level of spontaneous contraction in the whole guinea pig bladder which were 
termed ‘microtransients’ (Drake, Harvey et al. 2003) and also shown to be tetrodotoxin insensitive. 
Prior to recent work elucidating the structural and electrical properties of interstitial cells, these 
were also proposed as the likely mediators of this phenomenon due to its myogenic origin (Gillespie 
2004). 
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2.7 SPONTANEOUS AFFERENT FIRING 
 
During most afferent nerve recording experiments there was a degree of spontaneous afferent 
nerve activity. An example of this can be seen in fig 2.7.1. In some experiments, approximately 2/3, 
large bursts of spontaneous activity are also observed following bladder distension which lasted for 
between 1-5 minutes (fig 2.7.2).  
Fig 2.7.1 Spontaneous afferent discharge in the absence of bladder distension. 
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Fig.2.7.2 Bursts of spontaneous afferent discharge following ramp distension. 
 
The spontaneous baseline firing represented in fig 2.7.1 was recorded when the bladder was empty 
and therefore not subject to any exogenous mechanical stretch. This is consistent with a number of 
other studies which have reported baseline activity in in-vivo experiments in the rat (Sengupta and 
Gebhart 1994; Su, Sengupta et al. 1997) and mouse (Xu and Gebhart 2008), but is in contrast to Rong 
et al (2002) who reported only a small amount of baseline activity in vitro in the mouse and similar 
reports in the rat in vivo (Shea, Cai et al. 2000). In studies which have reported a greater degree of 
baseline firing, the bladder distension is performed to higher intravesical pressures of 80-100mmHg 
whereas studies in which ongoing activity was more sparce, distension was carried out to a much 
lower intravesical pressure (Shea, Cai et al. 2000; Rong, Spyer et al. 2002). However, in the studies 
observed here, the distension pressure and the rate of bladder distension is lower still than the 
studies in the literature and thus seems an unlikely explanation. Fig 2.7.2 represents spontaneous 
bursts in baseline firing following ramp distension of the bladder, the causes of which are unknown. 
It is possible that they could represent the activation of mucosal receptors responsive to light von-
frey hair stimulation (Zagorodnyuk, Costa et al. 2006) responding to contact between mucosal 
surfaces following emptying of the bladder.  
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Above all else, these traces exemplify the importance of recording afferent nerve firing and 
intravesical pressure simultaneously as there are a number of subsets of afferent fibers within the 
bladder which can be discriminated by their activation characteristics. It is likely that bladder 
compliance is dependent upon the intrinsic properties of the detrusor and the urothelium and that 
the accommodation properties of the bladder wall are a major contributor to afferent nerve 
discharge and mechanosensitivity.  
 
More details on experimental design will be given in a brief protocol section within each results 
chapter.  
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CHAPTER 3: PURINERGIC RECEPTORS 
OF THE UROTHELIUM 
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3.1 INTRODUCTION 
 
ATP is an established neurotransmitter in both the peripheral and central nervous systems and 
exerts its diverse effects through actions on both fast acting ionotropic P2X1-7 receptors, and G-
protein coupled P2Y1-14 receptors. Distinguishing P2X receptors is dependent on 
activation/desensitisation kinetics whilst P2Y receptors, although able to respond to ATP, also show 
a distinct rank order of potency for a range of endogenous stimuli, namely ADP, UTP and UDP (table 
1.7.1). Ectonucleotidases, responsible for the metabolism of ATP molecules are also found in the 
suburothelial space and are considered to be essential in fulfilling the complement of adenosine 
based molecular actions within the bladder.  
 
ATP actions in the bladder 
As has been alluded to in many previous studies, ATP plays an essential role in the bladder, and in 
many cases it is considered to be a major stimulus for alterations in mechanosensitivity. Genetic 
deletion of specific purinergic receptors, namely P2X3 and P2X2/3, have been used to show the 
importance of ATP signalling within the bladder. Knockout mice show urinary bladder hyporeflexia, 
with decreased afferent nerve activity, decreased voiding frequency, and increased bladder capacity 
(Cockayne, Hamilton et al. 2000; Vlaskovska, Kasakov et al. 2001; Cockayne, Dunn et al. 2005). In 
similar preparations, also in mice, Rong et al found intravesical αβMe-ATP (a P2X selective agonist) 
increased multifiber discharge and reduced threshold for distension induced firing in high threshold 
C-fiber afferents (Rong, Spyer et al. 2002). These effects were attenuated by an ATP antagonist, 
which also significantly reduced responses in the absence of an exogenous agonist, implicating an 
endogenous source of ATP (Rong, Spyer et al. 2002). These results show that P2X3 and P2X2/3 
receptors are functionally expressed on bladder sensory pathways which enhance afferent nerve 
activity in response to ramp distension as well as responding to exogenous P2X agonists. Importantly, 
a reduction in afferent activity in response to bladder distension was seen with P2X antagonism 
alone, further supporting a role for endogenous release of ATP. Furthermore, namasivayam et al 
showed that desensitisation or antagonism of purinergic receptors also significantly reduced 
afferent nerve responses in rats (Namasivayam, Eardley et al. 1999). Intravesical ATP and αβMe-ATP 
have been observed to induce bladder overactivity in conscious rats (Pandita and Andersson 2002), 
whilst intravesical infusion of purinoceptor antagonists suramin and PPADS can increase bladder 
capacity. Consistent with this role of purinergic receptors in regulating afferent nerve activity and 
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micturition is the presence of P2X3 immunoreactive afferent nerves in the suburothelium of the 
bladder (Vlaskovska, Kasakov et al. 2001; Brady, Apostolidis et al. 2004; Apostolidis, Popat et al. 
2005). In patients with neurogenic detrusor overactivity, a significant increase in P2X3 
immunoreactivity on afferent nerves has been reported (Brady, Apostolidis et al. 2004; Apostolidis, 
Popat et al. 2005). These novel studies also showed that those neurogenic detrusor overactivity 
patients whom responded in a urodynamically positive way to intravesical resiniferatoxin or BOTOX 
treatment, elicited a significant reduction in P2X3 immunoreactive fibers to normal levels. Again, this 
presents evidence to suggest that P2X3 immunoreactive afferents are not only important in normal 
bladder signalling, but may contribute to the manifestation of bladder disorders such as neurogenic 
detrusor overactivty. 
Further evidence of ATP signalling in the bladder comes from purinergic mediated inward currents 
and large transient increases in intracellular Ca2+ in bladder interstitial cells (Sui, Wu et al. 2004; Sui, 
Wu et al. 2006), leading the author to propose that interstitial cells could act as an intermediary 
between ATP released from the urothelium and afferent nerve activation, or through known gap-
junction coupling influence the detrusor smooth muscle cells more directly. A final proposed role for 
ATP within the bladder, over and above its role in parasympathetic mediated stimulation of detrusor 
smooth muscle, is the inducement and proliferation of inflammation through activation of urothelial 
P2Y receptors (Säve and Persson 2010; Kruse, Säve et al. 2012), and a subsequent increase in the 
release of pro-inflammatory cytokines including IL-8 and IL-6. These cytokines most likely play a role 
in maintaining sub-urothelial neuronal excitability, however, as will be described below, an increase 
in urothelial ATP release is observed in many bladder syndromes and the corresponding increase in 
pro-inflammatory cytokines could lead to neuronal sensitisation (Oprée and Kress 2000; Obreja, 
Schmelz et al. 2002; Viviani, Gardoni et al. 2007).  
There is ample evidence to implicate the purinergic system in both normal and abnormal voiding 
reflexes but as the main stimulus for purinergic receptors is ATP, it can be assumed that release of 
this neurotransmitter from a local source is a pre-requisite to these effects.  
 
Non-neuronal ATP release 
Bladder distension, or stretch of the urothelial cell layer in isolation, has been shown to induce ATP 
release (Ferguson, Kennedy et al. 1997; Birder, Nakamura et al. 2002; Sadananda, Shang et al. 2009; 
Sadananda, Kao et al. 2012; Collins, Daly et al. 2013). Whereas the stimulus for ATP release from 
neurons is depolarisation of the pre-synaptic membrane and calcium mediated vesicular release, the 
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major stimulus for ATP release from non-neuronal urothelial cells has been shown to be stretch of 
the bladder wall. This was first shown through the use of isolated tissue mounted in Ussing 
chambers (Ferguson, Kennedy et al. 1997) but has since been shown in both whole bladder 
experiments exposed to ramp bladder distension (Collins, Daly et al. 2013), and mechanical stretch 
of isolated bladder strips (Sadananda, Shang et al. 2009; Sadananda, Kao et al. 2012). ATP release 
has also been observed in urothelial cell culture models using both hypotonic solutions (Birder, 
Barrick et al. 2003; Cheng, Mansfield et al. 2011) and hydrostatic pressure to evoke a mechanical 
response (Olsen, Stover et al. 2011). The mechanism underlying urothelial release of ATP has yet to 
be fully characterised and it has been proposed that there are distinct mechanisms for basal and 
stretch evoked release. The release of urothelial ATP through activation of mechanically-gated 
channels has not been determined since gadolinium and amiloride, agents which block stretch 
activated ENaC and ASIC channels, have been found to have inconsistent effects on ATP release (Knight, 
Bodin et al. 2002; Birder, Barrick et al. 2003; Sadananda, Shang et al. 2009). Du et al (2007) showed that 
intravesical perfusion of 1mM amiloride significantly attenuated ATP release and was proposed as the 
mechanism responsible for a reduced frequency in reflex voiding during cystometry.  However, amiloride 
is also known to antagonise ASIC channels at the concentrations used (Alexander, Mathie et al. 2011) and 
gadolinium is known to inhibit the luciferin-luciferase ATP assay used in these studies (Boudreault and 
Grygorczyk 2002). Thus no firm conclusions regarding the mechanism of direct mechanosensitive ATP 
release can be drawn.  
As with neuronal release of ATP, an essential role for calcium has been proposed in the urothelium. It 
was found that liberation of calcium from the endoplasmic reticulum induces significant ATP release, 
yet blockade of store-operated extracellular calcium entry significantly enhanced distension-induced 
ATP release (Matsumoto-Miyai, Kagase et al. 2011). Thus, stimulation of calcium release from the 
endoplasmic reticulum induces urothelial ATP release, as well as a subsequent inducement of store 
operated calcium entry which suppresses the amount of urothelial ATP released, and thus providing 
a self regulating negative feedback mechanism. This observation has since been corroborated by 
others who have shown that distension-induced ATP release is mediated by a rise in intracellular 
calcium (Dunning-Davies, Fry et al. 2013) and that BAPTA-AM or agents that interfere with internal 
calcium storage block ATP release (Birder, Barrick et al. 2003). Antagonism of the IP3 receptor has 
also been shown to reduce distension-induced ATP release (Matsumoto-Miyai, Kagase et al. 2009). A 
significant role for calcium in urothelial ATP release is supported by considerable evidence for a 
vesicular release mechanism. Crucially, both monensin and brefeldin A, known blockers of vesicle 
formation and trafficking, inhibited calcium-dependent distension evoked ATP release (Knight, Bodin 
et al. 2002; Birder, Barrick et al. 2003). Botulinumtoxin inhibits vesicular exocytosis via cleavage of 
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SNAP-25 and has since been shown to significantly reduce distension evoked ATP release (Smith, 
Vemulakonda et al. 2005; Collins, Daly et al. 2013; Hanna-Mitchell, Wolf-Johnston et al. 2013), 
further indicating that vesicular exocytosis is essential for ATP release. Another school of thought 
relating to vesicular release mechanisms is that it is an increase in hydrostatic pressure that initiates 
discoidal/fusiform vesical exocytosis of ATP during membrane insertion, and that activation of 
purinergic receptors on urothelial cells plays a role in membrane trafficking via calcium signalling 
pathways (Wang, Lee et al. 2005) in order to maintain the barrier function of the urothelium.  
The importance of ATP release has been indicated by alterations in the levels of distension evoked 
release in disease and a significant increase in age (Yoshida, Homma et al. 2001), a known risk factor 
for all lower urinary tract symptoms. In models of spinal cord injury, cyclophosphamide induced 
inflammation, and feline interstitial cystitis, there is a significant increase in distension evoked ATP 
release (Sun and Chai 2002; Khera, Somogyi et al. 2004; Smith, Vemulakonda et al. 2005; Smith, 
Gangitano et al. 2008). In these cases, where tested, instillation of current therapeutic agents such 
as DMSO, heparin, and Botox, resulted in a significant reduction in distension evoked ATP. Botox was 
able to significantly attenuate distension evoked ATP release but had no effect on resting ATP 
release (Smith, Vemulakonda et al. 2005). This led to the proposal that there are two distinct 
mechanisms for ATP release, and only distension evoked release is mediated by exocytosis. This 
grants increased credibility to the prior work of Wang et al (2005) who proposed a role of ATP 
exocytosis in membrane trafficking and the maintenance of the urothelial barrier. 
ATP release is also altered in human luminal samples from patients with OAB and has been proposed 
as a biomarker for OAB detection (Cheng, Mansfield et al. 2013; Silva-Ramos, Silva et al. 2013). 
Increased ATP release is observed in bladder strips from painful bladder, idiopathic detrusor 
overactivity, and neurogenic detrusor overactivity patients exposed to mechanical stretch (Kumar, 
Chapple et al. 2007; Kumar, Chapple et al. 2010). Observations such as these combined with the 
reductions in ATP release seen with Botox treatment, which is concurrent with reduced symptoms 
seen in human patients, afford a role for urothelially released ATP in bladder disease. 
 
Regulation of non-neuronal ATP release 
The control of urothelial ATP release is deemed essential to physiological bladder function and 
therefore must be carefully maintained. It has been shown that acetylcholine is also released in 
response to bladder distension (Yoshida, Inadome et al. 2006) and that acetylcholine binding to the 
urothelium is able to influence ATP release through activation of both nicotinic and muscarinic 
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receptors (Kullmann, Artim et al. 2008; Beckel and Birder 2012; Sui, Fry et al. 2014) via modulations 
in intracellular calcium signalling. This implies that there is a high level of coordination between 
cholinergic and purinergic mechanisms within the urothelium and the mechanism of action of 
currently applied muscarinic antagonists in LUT dysfunction could in fact be altering voiding reflexes 
through actions on non-neuronal ATP release. This could explain why antimuscarinic drugs currently 
used to manage overactive bladder show efficacy during the filling phase of the micturition cycle 
(Andersson and Yoshida 2003). ATP and activation of purinergic receptors has also been shown to 
induce acetylcholine release (Hanna-Mitchell, Beckel et al. 2007) as well as auto-feedback to 
influence ATP release itself (Sun and Chai 2005) which is blocked by the non-selective P2 antagonist 
suramin. The ATP metabolite adenosine, acting through P1 receptors inhibits further ATP release 
and this was proposed to be through inhibition of intracellular calcium liberation (Dunning-Davies, 
Fry et al. 2013). UTP has also been shown to significantly enhance ATP release via intracellular 
calcium pathways (Chopra, Gever et al. 2008; Sui, Fry et al. 2014) indicating that P2Y receptors are 
an essential component of the urothelial purinergic system, whilst αβMe-ATP, which preferentially 
activates P2X1 and P2X3 receptors had no effect on ATP release (Sui, Fry et al. 2014). These urothelial 
P2X receptors are assumed not to have an important role in the autocrine feedback to urothelial 
cells and this is partially verified by Valskovska et al (2001) who showed ATP release was unchanged 
in P2X3 knockout mice. Also consistent with the proposed role of ATP as an auto feedback 
mechanism, is that fast desensitising channels such as P2X1 and P2X3 (North 2002) would not provide 
sustained increases in intracellular calcium during bladder filling in order to maintain 
mechanosensitivity and urothelial integrity.   
 
Purinergic receptor expression in the bladder 
The role of purinergic receptors and their agonists in bladder physiology in health and disease has 
been the focus of intense study for a number of years, and a number of important roles have been 
elucidated. Purinergic receptors have been identified within all major structures of the bladder 
including the detrusor smooth muscle (Andersson and Wein 2004), afferent nerves (Cockayne, 
Hamilton et al. 2000; Vlaskovska, Kasakov et al. 2001), interstitial cells (Wu, Sui et al. 2004; Sui, Wu 
et al. 2006; Cheng, Scigalla et al. 2011) and urothelium (Chopra, Gever et al. 2008; Shabir, Cross et al. 
2013), of which the latter is of particular interest in this study.  
The first study undertaken to identify purinergic receptors in the urothelium was performed using 
immunofluorescence in cats (Birder, Ruan et al. 2004). All seven P2X receptors and P2Y1, P2Y2 and 
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P2Y4 were ubiquitous in both the basal and apical layers throughout the urothelium. A more rigorous 
approach to receptor identification was undertaken by chopra et al (2008). In rat urothelium, qPCR, 
western blotting, immunofluorescence and calcium imaging were undertaken to identify functional 
P2Y receptors. Calcium responses to UTP were found and attributed primarily to activation of P2Y2 
receptors. P2Y4 was not seen with immunofluorescence in the bladder and a band was barely 
detectable in western blot studies. However, P2Y4 mRNA was found to be present within urothelial 
cells (Chopra, Gever et al. 2008), and the P2Y2/4 agonist UTP has since been shown to stimulate a rise 
in intracellular calcium in guinea pig urothelial cells (Sui, Fry et al. 2014). A comprehensive study of 
purinergic expression in human urothelial cells using RT-PCR has recently been published: there was 
minor expression of mRNA for P2X2 but significant expression of P2X4, P2Y1, P2Y2 and P2Y4. A P2Y1 
selective agonist failed to evoke a rise in intracellular calcium in urothelial cells whereas both P2Y2 
and P2Y4 agonists provoked robust calcium responses (Shabir, Cross et al. 2013).  
 
Aims 
The expression and function of purinergic receptors within the urothelium is of particular 
importance in understanding the role of ATP in bladder sensory signalling. As described above, an 
increase in urothelial ATP release and purinergic receptor expression has been shown to correlate 
with alterations in mechanosensation seen in patients with a number of overactive bladder 
syndromes. As the mechanisms of autocrine ATP signalling and ATP induced ATP release are 
deciphered, urothelial purinergic receptors have the potential to provide novel and specific targets 
for the treatment of overactive bladder, and because of their location in the periphery have the 
potential to treat symptoms with minimal adverse effects. Thus, an understanding of the receptors 
present in the urothelium, and their ability to mediate intracellular calcium concentrations is 
essential for mechanistic insight. Characterisation of purinergic receptor expression within urothelial 
cells of the mouse has yet to be performed and elucidation of these mechanisms will be crucial in 
deciphering the precise role of the urothelium in mechanotransduction pathways.  
This chapter will focus on providing functional evidence for purinergic receptors within the 
urothelium.  
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3.2 EXPERIMENTAL PROTOCOLS 
 
Isolation of primary mouse urothelial cells (PMUCs) 
PMUCs were isolated as described in the main methods section. Briefly, following cervical 
dislocation, bladders were excised from the mouse and incubated with 2.5mg/ml Dispase in MEM 
for 2hrs at room temperature. Cells were scraped from the urothelium before being trypsinised (0.5% 
trypsin-EDTA (Invitrogen) at 37°C for 5-10 mins), and resuspended in fresh KSFM media. The cell 
suspension was counted and plated on collagen (IV) (Sigma- Aldrich (Poole,UK) coated coverslips and 
incubated overnight at 37°C in an atmosphere of 5% CO2- 95% O2 for use in both calcium imaging, 
qPCR and immunohistochemistry experiments the following day.  
 
Calcium imaging 
Cells attached to coverslips were incubated with 2µM Fura 2 acetoxymethyl ester (Fura2-AM) 
(Sigma- Aldrich (Poole,UK))  (30 min) at 37°C in the dark. Coverslips were then placed in a washing 
well containing only media at 37°C (30min) before being washed in HEPES solution at room 
temperature and then placed upon the recording equipment. Coverslips containing cells were then 
transferred to a perfusion chamber and mounted on an epifluorescent microscope and continually 
perfused with HEPES buffer at a rate of 1.5ml/min for 30 minutes. Cells for experiments carried out 
in normal calcium containing medium were exposed to the agonist for between 1-3 minutes via 
continual perfusion. If a second dose of agonist was to be applied, a 3 minute washout with HEPES 
was applied and then the agonist at the same concentration for a further 1-3 minutes. Finally the 
cells were stimulated with the calcium ionophore Ionomycin (5μM) (Sigma- Aldrich (Poole,UK)) as a 
positive control. All cells showing a positive response to Ionomycin (5 μM) (Sigma- Aldrich (Poole,UK)) 
exhibited robust responses to purinergic stimulation. Individual cells were easily discriminated based 
on fluorescent intensity under the microscope and for each experimental condition, at least 15 cells 
in at least three independent experiments were assayed. For experiments in nominal calcium 
solution, a period of two minutes was allowed prior to addition of the agonist to allow for the switch 
in solution. For experiments using antagonists, the antagonist was diluted from a stock solution and 
perfused continually in the HEPES for 30 minutes prior to and during the addition of an agonist. To 
ensure that cells were not desensitised to endogenous ATP released from basal cells in culture wells, 
in experiments examining the response of αβMe-ATP, coverslips were incubated with Apyrase 
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(Sigma- Aldrich (Poole,UK), an endonucleotidase able to rapidly metabolise ATP, for 1hr prior to 
being placed on the recording microscope.   
Intracellular calcium was calculated as a ratio between the fluorescent signal at either 340/350 and 
380nm (e.g. Rf 340/380) for responding cells. Results are also expressed as percentage of maximum 
Ionomycin response. 
HEPES buffer for Urothelial cells (Composition in mM (NaCl 142, NaHCO3 5, HEPES 10, Glucose 16, 
KCL 2, CaCl2 2, MgCl2 1) as well as 0.1% BSA added to the dissolved solution. 
HEPES buffer for Urothelial cells: Calcium free in mM (NaCl 142, NaHCO3 5, HEPES 10, Glucose 16, 
KCL 2, MgCl2 3) as well as 0.1% BSA added to the dissolved solution. 
 
Drug Action Concentration 
αβMe-ATP P2X agonist 30µM 
ATP P2 agonist 10nM, 100nM, 1µM, 10µM, 100µM,  1mM 
Apyrase ATPase enzyme 1U-ml¯1 
MRS2279 P2Y1 antagonist 1µM 
MRS2365 P2Y1 agonist 100nM, 1µM, 10µM 
MRS2578 P2Y6 antagonist 1µM, 10µM 
MRS2693 P2Y6 agonist 10µM 
NF449 P2X antagonist 1µM 
PPADS P2X antaogonist 30µM 
UTP P2Y2/4 agonist 100µM, 10µM 
Table 3.2.1 A list of pharmacological tools used in this study. 
 
qPCR 
Full details of qPCR experimental protocols are described in the major methods section. 
mRNA was extracted from PMUCs 24hrs post isolation using Qiagen RNeasy minikit, converted to 
cDNA (superscript III Invitrogen) and frozen at -20°C prior to use in qPCR experiments.  
An iQSYBR Green Super Mix (BioRad) was used to amplify the cDNA target genes in the qPCR 
reactions performed using a Research Rotor-Gene 6000 real time thermocycler (Corbett-Qiagen). 
The PCR reactions were made up to a total of 25µl containing 12.5µl of the iQSYBR Green master mix, 
2µl of primers (1µl each of forward and reverse) and then a mix of cDNA and DEPC treated H2O to 
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make up to 25µl. Cyclic conditions were set at: 95°C for 12 minutes as an initial hold stage followed 
by 40 cycles of 95°C for 30s, 59°C for 30s, 72°C for 30s, followed by a melt curve of 0.5°C increments 
every 30 seconds from 72-95°C. 
Expression levels of each target gene were calculated relative to the housekeeping gene, β-actin, 
and represented here as a proportion of P2Y1 receptor expression. 
 
Gene   Primer Sequence ‘5 – 3’  Product   Position Tm°C  Chromosome 
P2X1 Forward CAAGTATGCGGAGGACATGG 131bp 1362- 58.4 11 
  Reverse CACACTGAGTCAAGTCCGG   1493 57.8   
P2X2 Forward CCATCAGGTGAAGGACCAGC 118bp 1454- 60.4 5 
  Reverse GCTGGTCAAGAGTGTCCACC   1571 60.6   
P2X3 Forward CAGTGTTCACCAGTGACCAGGC 128bp 1086- 63.6 2 
  Reverse GCCTGTTGAAGGTTCTGCAGCC   1213 64.4   
P2X4 Forward CGTCTGTCACTCTAGAGACGG 202bp 1229- 59.3 5 
  Reverse GGTGCTGTTATGGACGTGTGG   431 61.5   
P2X5 Forward GTAGCCAGAGCTCTTGGCAGG 115bp 1494- 62.8 11 
  Reverse CTCAGAAGCCACATCCTGAGC   1608 60.8   
P2X6 Forward GACCTGCTGCTACTGTATGTGG 104bp 1120- 60.7 16 
  Reverse GGCTCGGTCTATGAACTGTTGG   1226 61   
P2X7 Forward CACATTCGCATGGTGGACCAGC 98bp 1213- 64.5 5 
  Reverse GACAGGTCGGAGAAGTCCATCTGG   1310 64.3   
P2Y1 Forward GTCTCAACAGCTGTGTGGACC 206bp 1598- 61 3 
  Reverse CTCAGGAGCTAGGATCTCGTGC   1803 62   
P2Y2 Forward CACGATGGACTTAGCTCAGAGG 207bp 1864- 60.2 7 
  Reverse CAGGAGGCAGAGATAACAGGC   2070 60.2   
P2Y4 Forward CAGCAGCTATGCAGAGGTAGC 194bp 553- 60.9 X 
  Reverse CCTCTGCCTGCAGTTAGTCC   746 60.1   
P2Y6 Forward GGCAACTGGTCAATTCATGC 150bp 1583- 58 7 
  Reverse CACATCCTGAGATGTCTAGC   1732 55   
P2Y12 Forward GTGTCAACACCACCTCAGCC 149bp 420- 61.1 3 
  Reverse CCTCATTGCCAAGCTGTTCG   568 59.8   
P2Y13 Forward GTTCCTCAAGATCATCATGCCG 210bp 436- 59.4 3 
  Reverse GTGTGACTGACCACCTGATGC   645 61.2   
P2Y14 Forward GTCACGAAGATACAGTGCATGG 131bp 792- 59.4 3 
Table 3.2.2 Primer sequence, product size, gene loci, and Tm for purinergic receptors investigated in 
this study. 
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Immunohistochemistry 
PMUCs on collagen coated coverslips were fixed with 1ml/well cold PFA (4%), washed, and 
permeabilised with sapponin (0.05% + FCS 2%) @ 4°C for 45 minutes. The primary antibody was 
prepared in saponin + FBS (1/200) and 50µl was applied to each coverslip before being left in the 
fridge overnight. Cells were washed and the secondary antibody (prepared in PBS + FBS 2% (1/200)) 
was applied (50µl) to each coverslip and left at room temperature in the dark for 2 hours. Coverslips 
were then mounted on slides using Vectashield® mounting media (containing Dapi) (Vector 
Laboratories, UK) before being left to dry in the dark and then imaged using a fluorescent 
microscope. 
Primary antibody for urothelial cells was 1/50 Cytokeratin 7 Clone OV-TL 12/30 monoclonal mouse 
anti-cytokeratin 7 (DAKO) raised in mouse. 
Secondary antibody used for urothelial cells was 1/1000 Alexa Fluor® 488 green goat anti-mouse 
(Invitrogen) raised in goat. 
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3.3 CHARACTERISATION OF PMUC RESPONSES TO ATP 
 
Individual PMUCs within a single experiment responded to ATP (10µM) with variable increases in 
intracellular calcium expressed as a ratio of 340/380nm wavelength emissions (fig 3.3.1). Averaging 
of PMUC responses to ATP (10µM) show that intracellular calcium responses are characterised by 
two phases (fig 3.3.2). There was an initial rapid rise in intracellular calcium followed by a brief rapid 
decay, and a more sustained level of intracellular calcium, which was maintained until ATP was 
removed and a rapid return to baseline calcium levels was observed. This likely represents the 
contribution of a number of different purinergic receptors to the overall response. 
The time course of the responses of PMUCs to increasing concentrations of ATP (10nM-1mM) can be 
seen in fig 3.3.3 (N=6, n=360). PMUCs failed to respond to 10nM and 100nM ATP with an increase in 
intracellular calcium, but increasing doses (1µM, 10µM) elicited significant calcium fluorescence; 
reaching a peak at 100µM with no further increases upon application of 1mM ATP. The 
concentration response relationship to ATP can be seen in fig 3.3.4, where intracellular calcium 
reaches a peak following 100µM ATP with a pEC50 of 3.49±0.77µM (N=6, n =360).  
Confocal images were used to show immunohistochemical staining of PMUCs (fig 3.3.5). Confluent 
urothelial cells expressed cytokeratin 7 (green) in the plasma membrane, with DAPI labelling of the 
nucleus. Light microscope images taken immediately after (A) and 30 minutes following (B) 
urothelial cell placement onto collagen IV coated coverslips (fig 3.3.6) reveal that PMUCs migrate 
towards each other to form a confluent monolayer typical of epithelial cells. The hexagonal 
morphology of the urothelial cells can also be seen following monolayer formation. 
An initial application of ATP (10µM) to PMUCs caused a significant rise in intracellular calcium 
(0.23±0.03, p≤0.0001, N=3, n=67, paired t-test) above baseline, reaching a peak after 
15.3±1.4seconds before exhibiting a slow decline and a return to baseline following agonist washout 
(fig 3.3.7). A subsequent dose of ATP (10µM) to the same cells, following a 3 minute washout with 
krebs solution also initiated a significant rise in intracellular calcium (0.15±0.02). There was a 
significant decline in the maximal response to 10µM ATP between the first and second applications 
(p≤0.0001, N=3, n=67, Wilcoxon matched-pairs signed rank test). The percentage decrease in 
calcium fluorescence (fig 3.3.8) of the second ATP response is equal to 30.5±2.8% of the first. There 
was also a significant change in the kinetics of PMUC responses to ATP (10µM) seen upon repeat 
applications (fig 3.3.9). Initial applications of 10µM ATP reached maximal calcium fluorescence after 
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15.3±1.4 seconds with a significant increase in the time taken to reach peak calcium fluorescence 
upon a subsequent activation (19.50±2.3s) (p≤0.05, N=3, n=67, paired t-test).  
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Fig 3.3.1 Experimental trace showing the variability in individual PMUC intracellular calcium 
responses to ATP (10µM) from a single experiment (n=23). 
 
Fig 3.3.2 Mean±(SEM) change in intracellular calcium levels of PMUCs to ATP (10µM) from a single 
experiment (n=23).  
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Fig 3.3.3 Mean±(SEM) time course response of PMUCs to increasing concentrations of ATP (10nM-
1mM), (N=6, n=360).  
 
Fig 3.3.4 Mean±(SEM) concentration response curve of PMUC intracellular calcium to ATP (10nM-
1mM) (N=6, n=360). Data normalised to % of maximal response. 
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Fig 3.3.5 Immunohistochemistry of cultured PMUCs. Cytokeratin 7 (green) is stained in the plasma 
membrane of urothelial cells. Blue, DAPI, stains the nucleus. Scale bars, 20µm. 
 
 
Fig 3.3.6 Light microscope images of PMUCs immediately following isolation and plating on collagen 
IV coated coverslips (A) and after 30min (B).  
 
Fig 3.3.7 Mean±(SEM) time course of intracellular calcium response of PMUCs to repeat applications 
of ATP (10µM) with washout, (N=3, n=67). 
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Fig 3.3.8 Mean±(SEM) percentage change in PMUC intracellular calcium in response to repeat 
applications of ATP (10µM) with washout (****p≤0.0001, N=3, n=67). 
 
 
Fig 3.3.9 Mean±(SEM) time taken for PMUC to reach peak intracellular calcium in response to repeat 
applications of ATP (10µM) with washout (*p≤0.05, N=3, n=67). 
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3.4 THE ROLE OF EXTRACELLULAR CALCIUM IN PMUC 
RESPONSES TO ATP 
 
Application of 10µM ATP to PMUCs in calcium free HEPES (fig 3.4.1) evoked a significant increase 
(0.16±0.03) in intracellular calcium above baseline (p≤0.0001, N=3, n=62, paired t-test). In the 
absence of calcium, the characteristic two phase change in intracellular calcium seen in control 
experiments (fig 3.4.2) had disappeared, instead replaced by a response which, although still rapidly 
activated, did not exhibit an initial sharp peak, and instead showed a slow decline in response until 
eventually returning to baseline following washout of agonist. A subsequent dose of 10µM ATP also 
caused a significant rise in intracellular calcium (0.16±0.03) above baseline (p≤0.0001, N=3, n=62, 
paired t-test). However, there was no change in the maximal intracellular calcium response to ATP 
between the first and second applications in calcium free HEPES solution (p≥0.05, N=3, n=62, paired 
t-test). 
Maximum intracellular calcium response above baseline to duplicate applications of ATP (10µM) in 
PMUCs in the presence or absence of extracellular calcium are summarised in fig 3.4.2. The peak 
intracellular calcium response to ATP (10µM) was significantly decreased following a prior 
application of ATP at an equal concentration in normal HEPES solution. There was no significant 
change in maximum intracellular calcium responses with duplicate application of 10µM ATP when 
extracellular calcium was removed. There was also no significant difference between the second ATP 
(10µM) response in normal HEPES and those responses seen in calcium free HEPES (p≥0.05, N=3, 
n=62, one-way ANOVA, Bonferroni multiple comparisons post-hoc test). A significant increase in the 
time taken (15.3±1.4s Vs 23.3±1.9s) to reach peak intracellular calcium in response to ATP (10µM) 
was observed in the absence of extracellular calcium (p≤0.01, N=3, n=67, 62, un-paired t test (fig 
3.4.3)) 
Concentration related responses of PMUCs to ATP (10nM-1mM) were observed in the presence and 
absence of extracellular calcium, and responses to maximal doses of ATP (100µM, 1mM) (fig 3.4.4) 
were not significantly different (p=0.4 N=6, unpaired t-test). 10nM and 100nM ATP also failed to 
initiate a rise in intracellular calcium in calcium free HEPES. Changes in responses to ATP (10nM-
1mM) by removal of extracellular calcium are represented by a significant shift to the right on the 
concentration response curve; pEC50 3.49±1.34 Vs 9.5±1.5µM (p=0.013, N=6, unpaired t-test, (fig 
3.4.5)).  
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Fig 3.4.1 Mean±(SEM) time course of intracellular calcium response of PMUCs to repeat applications 
of ATP (10µM) in 0mM Ca2+ HEPES solution with washout, (N=3, n=62). 
  
Fig 3.4.2 Mean±(SEM) peak intracellular calcium increase above baseline for repeated doses of ATP 
(10µM) on PMUCs in normal and calcium free HEPES solution, (**p≤0.01, N=3, n=67, 62).  
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Fig 3.4.3 Mean±(SEM) time taken for PMUC to reach peak intracellular calcium in response to ATP 
(10µM) in the presence and absence of extracellular calcium (**p≤0.01, N=3, n=67, 62)  
 
 
Fig 3.4.4 Mean±(SEM) concentration response curve of PMUC intracellular calcium to ATP (10nM-
1mM) (N=6, n=360, 314) in normal and calcium free HEPES solution.  
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Fig 3.4.5 Mean±(SEM) concentration response curve of PMUC intracellular calcium to ATP (10nM-
1mM) in normal and calcium free HEPES solution. Data normalised to a percentage of maximal 
response. 
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3.5 THE CONTRIBUTION OF P2X IN PMUC RESPONSES TO ATP  
 
The relative expression of purinergic receptor mRNA in PMUCs (fig 3.5.1) revealed P2X2 receptor 
mRNA was expressed in the highest amounts within the urothelium (N=3), whilst mRNA for all other 
purinergic receptors except P2X7 was detected within the urothelium. Of the G-protein coupled P2Y 
receptors, mRNA for the P2Y1 and P2Y2 receptors was highest.  
RT-qPCR provides insight into the mRNA levels of the purinergic receptors within the urothelium, the 
next section of this chapter will provide evidence towards functional receptors for a number of the 
above receptors. 
Application of the P2X agonist αβMe-ATP (30µM) to PMUCs stimulated a significant (p≤0.0001, N=3, 
n=72, paired t-test) increase in intracellular calcium (fig 3.5.2). The calcium response to αβMe-ATP 
(30µM) was characterised by a sharp increase to a peak of 0.31±0.05 above baseline calcium levels, 
reaching a peak following 9±2.8seconds after agonist application, followed by a steady decline in 
response to 45% of the maximum during the 60 second application of the agonist before returning 
back to baseline following washout.  
Prior incubation of the P2X1 receptor antagonist NF449 (1µM) before ATP (10µM) application did not 
block ATP (10µM) induced intracellular calcium increases (fig 3.5.3) and did not significantly 
attenuate maximal responses to ATP (10µM) (fig 3.5.6) (p≥0.05, N=3, n=68, One-way ANOVA, 
Dunnett’s multiple comparisons post-hoc test). However, NF449 (1µM) significantly alters the 
intracellular calcium response profile of ATP (10µM) which exhibits a significantly delayed onset of 
action (fig 3.5.7). The latency of the response to ATP (10µM) following prior incubation of NF449 
(1µM) is shown in fig 3.5.7. The time taken to reach peak intracellular calcium levels in response to 
ATP (10µM) was increased from 15.5±1.4s in control experiments to 29.2±2.1s following NF449 
(1µM) (p≤0.001, N=3, n=68, one way ANOVA, Dunnett’s multiple comparisons post-hoc test). 
Similarly, ATP (10µM) was able to induce an increase in intracellular calcium with prior incubation of 
the P2X antagonist PPADS (30µM) (fig 3.5.4). As with NF449 (1µM), PPADS (30µM) did not 
significantly alter maximal fluorescent responses to ATP (10µM) (fig 3.5.6) (p≥0.05, N=3, n=63, one-
way ANOVA, Dunnett’s multiple comparisons post hoc-test) but showed significant effects on the 
time taken to reach a maximal response to ATP (10µM) (fig 3.5.7). Single cell responses forming an 
experimental trace can be seen in fig 3.5.5 and show an altered calcium response profile when 
compared to control (fig 3.3.2). The time taken to reach peak calcium fluorescence in response to 
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ATP (10µM) was increased from 15.5±1.4s in control to 45.9±2.1s with PPADS (30µM) (p≤0.001, N=3, 
n=68). There was also a significant difference between the time to peak response of ATP (10µM) 
between NF449 (1µM) and PPADS (30µM) treatments (p≤0.001, N=3, n=68, 63, One-way ANOVA, 
Dunnett’s multiple comparisons post hoc-test) (fig 3.5.7). 
These data show that PMUCs cultured over 24hrs are able to respond to P2X stimulation by αβMe-
ATP (30µM) and that the P2X component of ATP (10µM) induced calcium influx can be modified by 
P2X specific antagonists NF449 (1µM) and PPADS (30µM). However, there still remains a large 
proportion of the intracellular calcium response to extracellular ATP and it is proposed that P2Y 
receptors are responsible for these actions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
98 
 
 
Fig 3.5.1 RT q-PCR of purinergic receptors within cultured mouse urothelial cells. Data represented as 
an expression relative to that for the P2Y1 receptor (N=3).  
 
Fig 3.5.2 Mean±(SEM) change in intracellular calcium levels of PMUCs to αβMe-ATP (30µM) (N=3, 
n=72). 
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 Fig 3.5.3 Mean±(SEM) change in intracellular calcium levels of PMUCs to ATP (10µM) in the presence 
of NF449 (1µM) (N=3, n=68). 
 
Fig 3.5.4 Mean±(SEM) change in intracellular calcium levels of PMUCs to ATP (10µM) in the presence 
of PPADS (30µM) (N=3, n=63). 
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Fig 3.5.5 Experimental trace showing individual PMUC intracellular calcium responses to ATP (10µM) 
in the presence of PPADS (30µM). 
 
 
Fig 3.5.6 Mean±(SEM) peak intracellular calcium response of PMUCs above baseline to ATP (10µM) 
in the absence and presence of NF449 (1µM, n=68) or PPADS (30µM, n=63). 
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Fig 3.5.7 Mean±(SEM) time taken for PMUCs to reach peak intracellular calcium in response to ATP 
(10µM) in the presence and absence of NF449 (1µM) (***p≤0.001 Vs control, n=68), and PPADS 
(30µM) (***p≤0.001 Vs control, n=63).  
 
 
Fig 3.5.8 Mean±(SEM) peak intracellular calcium response of PMUCs to ATP (10µM) in the presence 
and absence of NF449 (1µM) (*p≤0.05 Vs control, n=68) and PPADS (30µM) (**p≤0.01 Vs control, 
n=63) 15s after ATP application.  
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3.6 THE CONTRIBUTION OF P2Y RECEPTORS  
 
The specific P2Y receptor agonist UTP (10µM, 100µM) caused a concentration dependent increase in 
intracellular calcium (fig 3.6.1) (N=5, 123, 98). The increase in intracellular calcium initiated by UTP 
(100µM) reaches 63.2% of the maximum to an equivalent concentration of ATP (N=5, n=121).  The 
response profile of UTP (10µM) activation can be seen in the time course response of fig 3.6.2. UTP 
(10µM) initiated a rise in intracellular calcium which was maintained for the duration of agonist 
application and returned to baseline only after the agonist was removed from the bath.  
The time course response to duplicate applications of UTP (10µM), which can be seen in fig 3.6.2, 
shows repeat applications of UTP (10µM) did not show any obvious changes in response profile. As 
well as a similar response profile, the maximum intracellular calcium response to UTP (10µM) was 
not significantly different between first and second responses (fig 3.6.4), (p≥0.05, N=3, n=73, 
Wilcoxon matched-pairs signed rank test). 
The P2Y6 agonist MRS2693 (10µM) caused a small, but significant (p≤0.001, N=3, n=61), paired t-test, 
fig 3.6.6) rise in PMUC intracellular calcium. The effect of P2Y6 activation on intracellular calcium was 
dose dependently antagonised (fig 3.6.5) by a P2Y6 specific antagonist MRS2578: 1µM (7.8±0.3 Vs 
4.0±0.3% ionomycin, p≤0.001, N=3, n=77), and 10µM (7.8±0.3 Vs 2.0±0.3% ionomycin, p≤0.001, N=3, 
n=58, one-way ANOVA, Dunnett’s multiple comparisons post-hoc test).  
The P2Y6 receptor antagonist MRS2578 (10µM) also significantly inhibits UTP (10µM) evoked 
increases in intracellular calcium (fig 3.6.7) (12.9±0.5 Vs 9.4±1.2% ionomycin, p≤0.05, N=4, n=65, 
unpaired t-test).  
The P2Y1 receptor agonist MRS2365 caused a dose dependent (100nM 1µM 10µM) increase in 
PMUC intracellular calcium (fig 3.6.8) (N=4, n=80, 79, 91). The time course of the response of 
MRS2365 (1µM) can be seen in fig 3.6.9. As with UTP (10µM) and the P2Y6 agonist MRS2693 (10µM), 
the intracellular calcium response to MRS2365 did not show desensitisation in the continued 
presence of the agonist, and responses are reduced to baseline only following agonist wash out.  
The P2Y1 receptor antagonist MRS2279 (1µM) was able to significantly attenuate MRS2365 (10µM) 
induced calcium fluorescence (19.5±0.8 Vs 5.3% max ionomycin, p≤0.0001, N=3, n=58, fig 3.6.10), 
and MRS2365 (100nM) (7.3±0.4 Vs 2.4±0.2% ionomycin, p≤0.0001, (N=3, n=74) one-way ANOVA, 
Bonferroni multiple comparisons post-hoc test) 
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Fig 3.6.1 Mean±(SEM) peak increase in intracellular calcium of PMUCs following application of UTP 
(100µM N=5, n=98, 10µM n=123) and ATP (100µM N=5, n=121), (****p≤0.0001 Vs control). 
  
 
Fig 3.6.2 Mean±(SEM) change in intracellular calcium levels of PMUCs to UTP (10µM) (N=5, n=123).  
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Fig 3.6.3 Mean±(SEM) time course of intracellular calcium response of PMUCs to repeat applications 
of UTP (10µM) with washout, (N=3, n=73). 
 
 
Fig 3.6.4 Mean±(SEM) percentage change in PMUC intracellular calcium in response to repeat 
applications of UTP (10µM) with washout (N=3, n=73). 
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Fig 3.6.5 Mean±(SEM) peak increase in intracellular calcium of PMUCs following application of P2Y6 
agonist MRS2693 (10µM) in the absence and presence of P2Y6 antagonist MRS2578 1µM 
(***p≤0.001, N=3, n=77) and 10µM (***p≤0.001 Vs control, N=3, n=58) 
 
 
Fig 3.6.6 Mean±(SEM) change in intracellular calcium levels of PMUCs to P2Y6 agonist MRS2693 
(10µM, N=3, n=61) 
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Fig 3.6.7 Mean±(SEM) peak increase in intracellular calcium of PMUCs following application of UTP 
(10µM) in the absence (n=123) and presence of the P2Y6 antagonist MRS2578 (10µM) (*p≤0.05, N=4, 
n=65). 
 
 
Fig 3.6.8 Mean±(SEM) peak increase in intracellular calcium of PMUCs following application of the 
P2Y1 agonist MRS2365 (N=4, 100nM (n=80), 1µM (n=79), 10µM (n=91). 
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Fig 3.6.9 Mean±(SEM) change in intracellular calcium levels of PMUCs to P2Y1 agonist MRS2365 
(1µM, N=4, n=79).  
 
Fig 3.6.10 Mean±(SEM) peak increase in intracellular calcium of PMUCs following application of P2Y1 
agonist MRS2365 (10µM, n=91, 100nM, n=80) in the absence and presence of the P2Y1 antagonist 
MRS2279 (1µM) (****p≤0.0001 Vs agonist alone, N=3, n=58, n=74) 
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mRNA 
Expression 
Ca2+ 
Response   
mRNA 
Expression 
Ca2+ 
Response 
P2X1 ** ***  P2Y1 *** *** 
P2X2 **** ^^^  P2Y2 ** *** 
P2X3 ** ***  P2Y4 * *** 
P2X4 *** ^^^  P2Y6 * * 
P2X5 *  -   P2Y12 *  -  
P2X6 *  -   P2Y13 **  -  
P2X7 0  -   P2Y14 *  -  
 
Fig 3.6.11 Tabular summary of the experimental data for this chapter. * = (Functional response/gene 
expression), ^ = (Speculative functional response) 0 = (No functional response/gene expression), - = 
(not tested).  
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3.7 DISCUSSION 
 
The data presented in this study reveal the functional presence of purinergic receptors within the 
urothelium of the mouse bladder. Using intracellular calcium imaging, it has been demonstrated that 
PMUCs respond to both P2X and P2Y receptor agonists. Specific agonists and antagonists reveal the 
important role of P2Y receptors, specifically P2Y1, P2Y2 and P2Y4 in mediating urothelial responses to 
endogenous agonists. The results are supported by mRNA expression of purinergic receptors.    
PMUCs were confirmed to be epithelial in origin through staining with cytokeratin 7 and were also 
observed to migrate towards each other following their plating onto collagen coated coverslips 
where they formed a monolayer exhibiting typical hexagonal morphology. The ability of urothelial 
cells to migrate towards each other points to the release of a multitude of factors that enable them 
to communicate with each other, as well as a most probable functional coordination that requires 
their confluence. 
 
ATP induced calcium response 
A number of previous studies have shown functional purinergic receptors and responses to ATP on 
the urothelium (Chopra, Gever et al. 2008; Everaerts, Vriens et al. 2010; Shabir, Cross et al. 2013; Sui, 
Fry et al. 2014). In the present study, urothelial responses to ATP were consistent with previous 
observations of ATP induced increases in intracellular calcium. The ATP response was characterised 
by an immediate sharp increase followed by a slight decrease and sustained intracellular levels of 
calcium in the presence of the agonist. It was shown that PMUCs respond to exogenous ATP with a 
concentration dependent increase in maximum intracellular calcium. Based on the characteristics of 
the response to ATP, a number of things can be inferred. The initial rapid increase in intracellular 
calcium suggests that ionotropic P2X channels contribute to this component of the response through 
influx of extracellular calcium (North 2002). Following a slight decrease, a more sustained level of 
intracellular calcium develops for the remainder of ATP application. Again this indicates a number of 
possible interactions. Ionotropic P2X receptors show marked desensitisation following rapid 
activation (North 2002), and this would be characteristic of the initial desensitisation phase. 
Secondly, there is a sustained level of intracellular calcium with continued ATP application which is 
more characteristic of metabotropic P2Y mediated intracellular calcium liberation through G-protein 
coupling of IP3 (von Kügelgen 2006).  
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The response profile to ATP provides significant clues to the functional capabilities of urothelial cells 
and this discussion will focus on determining the role of P2X and P2Y receptors in initiating a rise in 
intracellular calcium and the potential consequences in relation to bladder function.   
It was found that with repeated applications of sub-maximal doses of ATP, with a short washout 
period, there was a significant reduction in the maximal intracellular calcium response. As 
intracellular calcium levels had returned to baseline prior to a second dose of agonist, it is likely that 
the decrease in response is due to desensitisation of urothelial purinergic receptors responsible for 
calcium influx. This desensitisation significantly reduces the ability of cells to increase intracellular 
calcium levels in response to subsequent ATP and also alters the kinetics of the response, with a 
second dose of ATP taking a significantly longer time to reach peak intracellular calcium levels. 
However, as these results demonstrate, a large proportion of the response remains, suggesting more 
than one population of receptors is responsible for the differential components of the intracellular 
calcium response. As ATP is known to bind to multiple purinergic receptors, the effects observed can 
be most likely attributed to responses of fast desensitising ionotropic P2X receptors (North 2002) 
and metabotropic P2Y receptors, as both of these receptor subtypes have previously been identified 
within the urothelium of a number of other species (Birder, Ruan et al. 2004; Tempest, Dixon et al. 
2004; Chopra, Gever et al. 2008; Sui, Fry et al. 2014).  
To further test the contribution of P2Y receptors in mediating intracellular calcium responses to ATP, 
experiments were performed in the absence of extracellular calcium in an attempt to remove the 
ionotropic P2X component of calcium influx in urothelial cells. PMUCs responded to ATP with a 
significant increase in intracellular calcium even in the absence of extracellular calcium. This provides 
further evidence that there is a large proportion of the urothelial response to ATP which is mediated 
by the liberation of calcium from intracellular stores rather than through membrane bound calcium 
channels, a characteristic of P2Y receptor function. It is also of importance to note that with 
repeated applications of ATP in the absence of extracellular calcium there was no reduction in peak 
response or obvious change in response profile. The ability of urothelial cells to respond to 
continuous or repeated stimuli with an increase in intracellular calcium, the known stimulus for 
distension evoked ATP release from the urothelium (Matsumoto-Miyai, Kagase et al. 2009; 
Matsumoto-Miyai, Kagase et al. 2011), is essential to the proposed physiological role of urothelial 
signalling during bladder distension. This leads to the hypothesis that activation of P2Y receptors are 
an essential component in autocrine signalling of urothelial cells.  
Interestingly, the maximal intracellular calcium increase above baseline in experiments without 
extracellular calcium is almost identical to the maximal response seen following receptor 
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desensitisation in normal HEPES. This further supports the suggestion that the receptors responsible 
for the response to ATP in the absence of extracellular calcium are most likely the same as those 
responsible for the non-desensitised component of ATP induced intracellular calcium rise in normal 
calcium containing solution.  
Further evidence to support multiple populations of purinergic receptors within the mouse 
urothelium is provided by the shift to the right of the concentration-response curve seen in the 
absence of extracellular calcium and a significant increase in the pEC50 for ATP. Interestingly, the 
attenuation in intracellular calcium seen within the pEC50 range of ATP concentrations in calcium 
free HEPES are not seen with higher ATP concentrations. This could imply that at maximal 
concentrations of ATP, ionotropic purinergic activation does not contribute significantly to the levels 
of intracellular calcium within the urothelium. It is hard to determine the importance of these results 
however, as the levels of ATP recorded from bladders at rest and during distension are most 
commonly in the nano and pico-molar range (Vlaskovska, Kasakov et al. 2001; Collins, Daly et al. 
2013; Hanna-Mitchell, Wolf-Johnston et al. 2013) which, as it is diluted into a much larger volume of 
either urine or saline is in no way indicative of the level of ATP released at the level of the urothelial 
cell membrane. Studies into levels of ATP release however, do provide vital information on the 
changes occurring between basal and stretch of the urothelium and in response to exogenous 
stimuli. 
The importance of exogenous ATP mediated intracellular calcium levels within the urothelium is 
implicated by the role of calcium in mediating stretch evoked ATP release (Matsumoto-Miyai, Kagase 
et al. 2009; Matsumoto-Miyai, Kagase et al. 2011; Dunning-Davies, Fry et al. 2013), the ability of ATP 
to induce ATP release (Sun and Chai 2005), and the multitude of interactions that ATP has been 
proposed to mediate in the sub-urothelium relating to mechanosensitivity. Thus, a mechanism by 
which the actions of ATP and its metabolites are able to mediate further ATP release could be an 
additional mechanism contributing to the enhancement in reflex bladder activity observed in a 
number of bladder disorders. 
 
Purinergic Receptor Expression 
RT-qPCR of PMUCs found expression of mRNA for all P2X and P2Y receptors tested except the P2X7 
subtype. P2X1, P2X2 and P2X3 receptors have been shown to be expressed in human urothelium (Liu, 
Xu et al. 2013) whilst P2X7 is selectively expressed on cells of hematopoietic lineage as well as glial 
cells, Schwann cells and astrocytes (Skaper, Debetto et al. 2010). Previous studies investigating P2X7 
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receptor expression in urothelial cells have reported mixed results. Shabir et al (2013) found no 
mRNA expression of P2X7 in human urothelium, whilst an immunohistochemistry study of cat 
urothelium (Birder, Ruan et al. 2004) revealed significant P2X7 staining throughout the basal and 
apical layers of the urothelium. These differences could be attributed to the species used; however, 
as has been suggested recently, there is a large amount of non-specific adsorption of antibodies in 
the urothelium (Yu and Hill 2011) which was exemplified in experiments on TRPV1 expression 
(Everaerts, Sepúlveda et al. 2009) and thus evidence based on immunohistochemistry alone should 
be considered with care. Another possible explanations for this discrepancy could be the presence of 
stromal cells within the urothelium, however, no changes in P2X7 immunoreactivity were observed 
in a model of interstitial cystitis (Birder, Ruan et al. 2004), which has previously been shown to 
induce stromal cell proliferation (Vera, Iczkowski et al. 2008), and thus this seems unlikely.  
The most significantly expressed purinergic receptors from PMUCs were P2X2, P2X4, P2Y1 and P2Y2, 
as well as lesser expression of other purinergic receptor subtypes including P2Y6. This is consistent 
with the results of Chopra et al (2008) who, although only looking at P2Y2 and P2Y4 receptors within 
the urothelium, identified higher expression of P2Y2. The P2Y6 receptor has previously been localised 
to the urothelium of rat bladder using immunofluorescence confocal microscopy (Timóteo, Carneiro 
et al. 2014). In the human urothelium, P2Y1 and P2Y2 mRNA are expressed (Liu, Xu et al. 2013; Shabir, 
Cross et al. 2013), yet interestingly, in cultured cells, expression of P2Y4 receptor mRNA was 
upregulated (Shabir, Cross et al. 2013). As the cells used in the present study were only in culture for 
24hrs post-isolation, and details of days in culture are not provided in other studies, it is assumed 
that the results in this study represent those of a normal urothelial phenotype. Phenotype 
expression has previously been explored in mouse urothelial tissue versus 24hr cultured cells, and 
no differences were observed (Everaerts, Vriens et al. 2010). Another considerable difference 
between the current study and that of Shabir et al (2013) is the precise quantification that is 
afforded to the qPCR techniques of this study as opposed to a qualitative analysis from an agarose 
gel.  
 
Functional P2X receptors 
The expression of P2X2 and P2X4 is consistent with an ionotropic mediated component of the ATP 
response and this was further investigated. αβMe-ATP shows significant specificity for P2X receptor 
subtypes, particularly P2X1 and P2X3. Despite comparatively low mRNA expression levels of these 
receptors, αβMe-ATP was able to induce a significant increase in intracellular calcium. It was 
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observed that the response of PMUCs to αβMe-ATP incurred significant desensitisation during 
agonist application due to the fast activation and deactivation kinetics of this subtype of purinergic 
receptor (North 2002). The actions of αβMe-ATP in the current study are in contrast to those of 
others who found no functional response to αβMe-ATP, however, to obtain the results seen in these 
experiments, it was essential to incubate cells with the ATP’ase apyrase prior to αβMe-ATP 
application to ensure the receptors were not desensitised, a methodology not previously employed 
(Shabir, Cross et al. 2013; Sui, Fry et al. 2014). The emergence of these responses however, provokes 
an important discussion. Due to the continual release of ATP from the urothelium, not only during 
stretch but also whilst at rest, what is the physiological relevance of these responses? Given the 
availability of ectonucleotidases able to rapidly breakdown ATP in the vicinity of the urothelium and 
sub-urothelium (Yu, Robson et al. 2011), there is the possibility that desensitisation of P2X receptors 
is more of a feature when bath application of ATP swamps the ability of ectonucleotidases to 
terminate their action. 
PMUC responses to ATP were also examined in the presence of the P2X receptor antagonists NF449 
and PPADS. It was found that neither NF449 nor PPADS significantly attenuated maximal responses 
to ATP, however, the time taken to reach maximal fluorescence was significantly increased and thus 
a large difference between maximal response to ATP fifteen seconds after application was observed. 
Other attempts to antagonise the P2X component of calcium influx have been attempted, PPADS has 
been shown to attenuate ATP responses but was also found to inhibit UTP responses (Chopra, Gever 
et al. 2008), and ATP responses in calcium free external solution (Shabir, Cross et al. 2013) 
suggesting that PPADS is able to impose non-P2X specific actions. NF449 is highly selective for the 
P2X1 receptor and these experiments provide evidence for a role of the P2X1 receptor in mediating 
urothelial calcium responses to ATP. 
The role of intracellular calcium in distension evoked ATP release has been confirmed (Matsumoto-
Miyai, Kagase et al. 2009; Matsumoto-Miyai, Kagase et al. 2011), and ATP has been shown to 
stimulate further ATP release (Sun and Chai 2005). Nonetheless, the functional importance of the 
initial fast component of ATP induced calcium influx is not known. The ATP induced ATP release 
observed by sun et al (2005) was inhibited by the non-selective purinergic antagonist suramin, and 
ATP release from the urothelium is not affected by αβMe-ATP (Sui, Fry et al. 2014) in mucosal strips 
or following knockout of the P2X3 receptor (Vlaskovska, Kasakov et al. 2001). This conforms to the 
idea that ionotropic receptors would be tonically desensitised in normal urothelial tissues and their 
functional relevance in mediating distension evoked ATP release is limited. In contrast, it has been 
shown that intravesical αβMe-ATP is able to stimulate afferent nerve activity (Rong, Spyer et al. 2002) 
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and was proposed by the author to act either via urothelial cells or directly on afferent nerve 
terminals. The dose of αβMe-ATP used in this study was high, at 1mM, and conclusions about the 
receptors to which it binds are thus not possible. Application of the agonist in this study was also 
accompanied by changes in intravesical pressure, so responses may have been secondary to 
mechanical changes (Rong, Spyer et al. 2002). Intravesical application of 10mM ATP has also been 
shown to induce bladder overactivity via an afferent mechanism (Pandita and Andersson 2002) 
suggesting that ATP is able to stimulate the micturition reflex. Again however, the behavioural 
effects seen by Pandita et al (2002) could either be through direct activation of sub-urothelial 
afferent nerves or mediated through activation of urothelial cells. With application of agonists into 
the lumen of the bladder, it is difficult to draw conclusions either way. Further than this, however, 
due to the dose of agonist used, conclusions about the receptors responsible are still unclear. Based 
on the experiments performed above it would be my hypothesis that the actions of ATP on the 
urothelium are mediated via P2Y receptors.     
 
Functional P2Y receptors 
The observation of ATP-induced rises in intracellular calcium that are independent of extracellular 
calcium would implicate metabotropic P2Y receptors in urothelial ATP responses. The presence of E-
NTPDase ectonucleotides in the urothelial layer (Yu, Robson et al. 2011), which have the ability to 
breakdown ATP to the P2Y1 agonist ADP, and results showing that UTP is able to stimulate release of 
ATP (Chopra, Gever et al. 2008; Sui, Fry et al. 2014) have all provided further credibility to the theory 
that P2Y receptors have an essential role in urothelial function and ATP release. Indeed, as shown in 
table 1.7.1, the ATP metabolite ADP shows greatest affinity for P2Y1 receptors and P2Y2 and P2Y4 
receptors bind both ATP and UTP with equal potency. The P2Y6 receptor, however, although 
showing some affinity for ATP, is preferentially activated by uridine molecules UDP and UTP.  
As previously described, P2Y1, P2Y2, P2Y4 and P2Y6 receptor mRNA is expressed in PMUCs with P2Y1 
and P2Y2 receptor expression highest. The presence of functional P2Y receptors was therefore 
further investigated in the current study. UTP, an agonist at a number of P2Y receptors which shows 
greatest affinity for P2Y2 and P2Y4 was able to stimulate a concentration-dependent increase in 
intracellular calcium. Urothelial responses to UTP showed no desensitisation following repeat 
applications. The ability of UTP to stimulate an increase in urothelial intracellular calcium has been 
observed in other species. In rat cultured urothelial cells, UTP has been shown to stimulate 
intracellular calcium rises (Sui, Fry et al. 2014) via phospholipase C-linked mechanisms which were 
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unaffected by extracellular calcium but significantly attenuated by store depletion (Chopra, Gever et 
al. 2008). UTP-stimulated calcium increases in this study were accompanied by significant and 
reproducible ATP release which has been replicated in guinea pig urothelial strips (Sui, Fry et al. 
2014). In human ureter-derived urothelial cells, functional expression of both P2Y2 and P2Y4 
receptors has been observed (Shabir, Cross et al. 2013).  
Functional responses to highly selective P2Y1 and P2Y6 receptor agonists in PMUCs were observed in 
the present study, and these responses were found to be attenuated by their respective antagonists. 
P2Y1 mediated responses were robust and showed concentration dependency. P2Y6 mediated 
responses were the smallest of all P2Y responses investigated, however, the P2Y6 receptor 
antagonist was also found to significantly attenuate a portion of the calcium response to UTP. The 
P2Y1 receptor has been previously found not to be functionally responsive in ureter-derived 
urothelial cells, although the concentration of agonist used in this study, at 1nM, was significantly 
lower (Shabir, Cross et al. 2013). Despite this, application of a specific P2Y1 antagonist to urothelial 
cells in the current experiments was able to almost abolish the response to the P2Y1 receptor agonist 
and was therefore considered specific to the P2Y1 receptor. This is the only other study that has 
previously examined the role of P2Y1 in urothelial cells and the difference in functional receptors 
could reflect a difference in physiological function as the cells in the study by Shabir et al (2013) 
were derived from the ureters. Ureters have a significant amount of anatomical homology to the 
bladder but do not require the same functions. The ureters are responsible for the transport of urine 
from the kidneys to the bladder, and as such, are only exposed to transient light distension, much 
like the peristaltic waves present in the gastrointestinal tract. Thus, there is less physiological 
evidence for a role by which sustained distension induced release of ATP and the maintenance of 
intracellular calcium concentrations is warranted. Indeed, ureter distension occurs during the 
passage of kidney stones which are extremely painful and perhaps the phenotype of these receptors 
more closely resembles a role of ATP in nociception. 
The function of the P2Y6 receptor has not been previously investigated in isolated urothelial cells and 
thus no comparisons to other studies can be drawn. Activation of the P2Y6 receptor upon the 
urothelium however, has been investigated to some extent. Instillation of a stable UDP analogue 
selective for P2Y6 receptors into the bladder of anesthetised rats increases voiding frequency 
without affecting the amplitude or duration of cystometrically measured bladder contractions. These 
effects were blocked by a P2Y6 antagonist. The UDP analogue also increased ATP in the urine 
(Timóteo, Carneiro et al. 2014).   
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The functional significance of the results presented here have yet to be determined, however, the 
presence of functional purinergic receptors, particularly P2Y is hypothesised to play an essential role 
in micturition. Both ATP and UTP have been shown to induce intracellular calcium increases in 
urothelial cells and consequential ATP release. The sustained increase in intracellular calcium 
observed with UTP and P2Y activation is likely to be of physiological relevance, maybe more so than 
a desensitising response of P2X receptors to ATP, as during mechanosensation of the bladder, 
sensation must be maintained throughout the filling phase up to the threshold for micturition and if 
ATP is a key factor, its release must be continual. ATP and UTP have equal potency at rodent P2Y2 
and P2Y4 receptors and it could be hypothesised that the rise in intracellular calcium with ATP in 
calcium free media is a result of P2Y2 and P2Y4 receptor activation, with a possible small contributing 
role of P2Y6 activation. Unfortunately, there are no selective P2Y2 and P2Y4 antagonists and this 
theory cannot be fully investigated. The P2Y1 receptor is preferentially activated by ADP and ATP, 
and could also play a significant role in extracellular calcium independent ATP mediated urothelial 
responses. Intracellular calcium is a major contributing pathway for ATP release (Matsumoto-Miyai, 
Kagase et al. 2009; Matsumoto-Miyai, Kagase et al. 2011) and increases in intracellular calcium by 
ATP and UTP are accompanied by the release of non-neuronal ATP from the urothelium which is not 
influenced by specific P2X agonists (Sui, Fry et al. 2014) or P2X3 receptor knockout (Vlaskovska, 
Kasakov et al. 2001) but is blocked by the non-selective purinergic antagonist suramin (Sun and Chai 
2005), further supporting a role for urothelial P2Y receptors in mediating this process. The role of 
urothelial ATP has been explored in the bladder and it has been found to be a mediator of detrusor 
smooth muscle contraction, interstitial cell function and afferent nerve excitability and thus the 
ability to mediate these responses through antagonism of P2Y receptors upon the urothelium is a 
particularly attractive pharmacological target.  Indeed, P2Y1 and P2Y2 receptors have been shown to 
be upregulated in the urothelium of interstitial cystitis patients (Liu, Xu et al. 2013) and this is 
accompanied by an increase in urothelial ATP release. 
A secondary hypothesis, supported by evidence in other organs, but not yet explored in the bladder, 
is that UTP, along with ATP is released from the urothelium during mechanical stretch. Mechanically 
released UTP has the potential to act on the ubiquitous P2Y receptors on urothelial and underlying 
cells to potentiate an increase in intracellular calcium and further ATP and UTP release as well as to 
influence mechanosensation. Murine airway epithelial cells exhibit propagation of mechanically 
induced calcium waves which are dependent on mechanically induced UTP release (Homolya, 
Steinberg et al. 2000) and mechanical stimulation of astroma cells has also been shown to release 
UTP (Lazarowski, Homolya et al. 1997). Development of an assay for the quantification of UTP has 
lead to the discovery of UTP release in a number of cells including primary and cultured airway 
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epithelial cells in both resting and mechanically stimulated conditions (Lazarowski and Harden 1999) 
which were increased up to 20 fold using a medium displacement method. Although this was not the 
classical hypotonic stretch that is often used to characterise urothelial cell responses, it supports the 
hypothesis that epithelial cells are capable of releasing UTP and the mechanism for the downstream 
modulation of the micturition reflex is apparent.   
 
Conclusions 
These results have shown for the first time that functional P2Y receptors are present on the mouse 
urothelium and their activation results in significant increases in intracellular calcium. The 
importance of these findings is not yet clear, but the control of urothelial intracellular calcium levels 
is a necessary factor in ATP release, and ATP release is an essential component in the control of 
micturition within the bladder. In addition, the results in this study using primary mouse urothelial 
cells show a number of similarities with the human urothelium and support the use of mice as a 
significant tool in the continued search to determine urothelial cell function.   
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4.1 INTRODUCTION 
 
The TRPV1 receptor is a member of the TRPV subfamily of TRP ion channels permeable to 
monovalent and divalent cations. TRPV1 is activated by vanilloid compounds (such as capsaicin and 
resiniferatoxin [RTX]), noxious temperature (>44˚C), and acid (<pH 6.0) and thus has an essential role 
in the integration of noxious stimuli. The threshold for TRPV1 activation is reduced by inflammatory 
mediators such as NGF, bradykinin (Chuang, Prescott et al. 2001), and ATP (Tominaga, Wada et al. 
2001).  
 
Where is TRPV1 found within the bladder? 
Many immunohistochemical studies have demonstrated the presence of TRPV1 in DRG neurons 
(Hwang, Min Oh et al. 2005) supplying the bladder and on nerve fibers throughout the lower urinary 
tract. There is significant immunoreactivity of the TRPV1 receptor on non-myelinated C-fibers 
(Tominaga, Caterina et al. 1998; Yiangou, Facer et al. 2001; Avelino, Cruz et al. 2002), but also larger 
diameter A-fibers (Yiangou, Facer et al. 2001; Ost, Roskams et al. 2002) present in muscular and 
mucosal plexuses of the bladder. As well as the documented presence of TRPV1 within the 
peripheral endings of sensory afferents, there is evidence of TRPV1 immunoreactivity within the 
interstitial cells (Ost, Roskams et al. 2002), smooth muscle cells (Birder, Kanai et al. 2001; Ost, 
Roskams et al. 2002), and more controversially, the urothelium. TRPV1 expression has been 
described in human urothelial cell cultures (Lazzeri, Vannucchi et al. 2004; Apostolidis, Brady et al. 
2005), but not detected by others (Ost, Roskams et al. 2002).  Expression has also been described in 
rat urothelial cells (Birder, Kanai et al. 2001; Kullmann, Shah et al. 2009) but not in the mouse 
(Yamada, Ugawa et al. 2009; Everaerts, Vriens et al. 2010), which also showed no functional 
response when exposed to TRPV1 agonists. There are a number of factors that might underlie the 
inconsistencies concerning the literature on TRPV1 channels in the bladder. Culturing primary cells 
can have significant effects on gene expression and receptor upregulation. In those studies in which 
functional response to TRPV1 agonists were absent, the culture time tended to be prolonged relative 
to those studies which observed TRPV1 mediated responses. Lack of specificity within commercially 
available TRPV1 antibodies may have also contributed to the controversy (Everaerts, Sepúlveda et al. 
2009) and there is also the distinct possibility that rat and mouse urothelial cells express functionally 
distinct channels. 
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As described in the previous chapter, receptors for ATP are expressed upon urothelial cells. It has 
also been shown that interstitial cells express purinergic receptors, and there is significant 
expression of the homomeric P2X3 receptor on small diameter bladder projecting primary afferents 
(Chen, Akopian et al. 1995; Dunn, Zhong et al. 2001; O’Reilly, Kosaka et al. 2002), which are thought 
to co-localise with TRPV1 (Brady, Apostolidis et al. 2004). Thus there are a number of locations 
within the bladder where receptor co-localisation occurs between TRPV1 and purinergic receptors 
but the significance of this is yet to be fully explored.  
 
TRPV1 in pathophysiology 
The role of the TRPV1 receptor in mediating bladder responses is particularly apparent during 
inflammation, pain, and bladder disorders where pharmacological blockade or knockout of the 
TRPV1 receptor is able to mitigate against mechanical hyperactivity.  
An essential role for the TRPV1 receptor in mediating sensory afferent discharge was provided 
following the observation that intravesical capsaicin and resiniferatoxin are effective for treating 
lower urinary tract symptoms associated with urgency and pain (De Ridder, Chandiramani et al. 1997; 
Chancellor and de Groat 1999). Patients with idiopathic and neurogenic detrusor overactivity (Silva, 
Ribeiro et al. 2002; Silva, Silva et al. 2005) with frequency and urge symptoms (Apostolidis, Gonzales 
et al. 2006; Silva, Silva et al. 2007) show significantly improved sensory urodynamic parameters 
following intravesical resiniferatoxin and capsaicin treatment as well as a significant reduction in 
TRPV1 immunoreactivity within the suburothelium 
Systemic cyclophosphamide or intravesical acrolein can give rise to bladder mechanical 
hyperreactivity in WT, but not in TRPV1-/- (KO) mice despite histological evidence of inflammation 
and cellular damage still being manifest (Wang, Wang et al. 2008). In a lipopolysaccharide model of 
bladder inflammation, bladder overactivity could be induced in wild-type but not TRPV1-/- (KO) mice 
(Charrua, Cruz et al. 2007), while inflammatory changes were similar in WT and TRPV1-/- (KO) mice. A 
distension evoked increase in c-fos in the spinal cord is observed in WT mice but absent in TRPV1-/- 
(KO) mice, consistent with a role for TRPV1 in noxious sensory signalling and pain related to cystitis. 
Vizzard et al (2000) showed that cyclophosphamide induced bladder inflammation significantly 
increased spinal c-fos following distension of the bladder compared to controls and pre-treatment 
with capsaicin significantly reduced the number of Fos-IR cells induced by bladder distension during 
cystitis (Vizzard 2000). Bladder cystitis, spinal c-fos, and increased bladder reflexes in rats treated 
with intraperitoneal cyclophosphamide were significantly attenuated by prior intravesical infusion of 
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resiniferatoxin (Dinis, Charrua et al. 2004). Indeed, Cefalu et al (2009) showed that bladder 
overactivity induced by intravesical citric acid was attenuated following TRPV1 blockade and a study 
using the FIC cat model found functional and morphological changes in DRG neurons sensitive to 
capsaicin only (Sculptoreanu, de Groat et al. 2005; Sculptoreanu, Artim et al. 2009). These results 
support the current concept that TRPV1 is important in bladder inflammation. 
The role of TRPV1 in inflammation and chemical insult is well documented. The precise mediation of 
TRPV1 sensitisation in inflammation is not completely understood but depends on protein kinase A 
and phospholipase C mediated phosphorylation of the receptor (fig 1.8.1). This is thought to occur 
either via inflammatory mediators such as bradykinin, NGF, ATP or PGE2 (Chuang, Prescott et al. 
2001) which activate intracellular messengers, or via the known endogenous activators of TRPV1 
such as noxious temperature (>44˚C), acid (<pH 6.0), and anadamide which potentiate each other 
and open the TRPV1 channel by reducing the heat threshold to normal body temperature levels 
(Nagy, Sántha et al. 2004; Tominaga and Tominaga 2005). TRPV1 expression on DRG neurons is 
significantly increased when cultured in the presence of inflammatory mediators (Avelino and Cruz 
2006). 
These data provide conclusive evidence for the TRPV1 receptor in playing an important role in 
urinary bladder dysfunction.  However, the specific site of action for TRPV1 agonists and antagonists 
is still unknown. While a direct role on afferent nerve terminals is likely there is also a potential 
contribution from other urothelial/sub-urothelial cellular targets as well as the detrusor smooth 
muscle. 
 
The role of TRPV1 within the healthy bladder 
TRPV1 is expressed on bladder afferent neurons in rat (Birder, Kanai et al. 2001; Avelino, Cruz et al. 
2002), human (Yiangou, Facer et al. 2001; Brady, Apostolidis et al. 2004; Apostolidis, Popat et al. 
2005), and mouse (Malykhina, Lei et al. 2012), where a functional response to capsaicin by these 
afferents has been observed (Daly, Rong et al. 2007). Activation of CSPANS has been shown to 
induce an ‘efferent’ function associated with the release of neurokinins which are known contractors 
of detrusor smooth muscle (Maggi, Patacchini et al. 1991) as well as the now known role of capsaicin 
in directly activating afferent nerve terminals.  
The question that still arises, however, is what are the mechanisms for reducing sensory afferent 
firing following TRPV1 desensitisation? It has been reported that systemic administration of 
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capsaicin in adult rats results in the degeneration of 90% of axons innervating the ureter (Chung, 
Schwen et al. 1985), suggesting that the reduction in TRPV1 immunoreactivity and improvement of 
symptoms could be due to neurotoxicity and loss of mechanosensory afferents and not simply 
desensitisation of TRPV1. There are a number of unresolved questions. Can TRPV1 act as a 
mechanosensor to distension and thus denervation of CSPANS leads to direct reduction in 
mechanosensation? Can TRPV1 desensitisation prevent the ‘efferent’ release of neurokinins? Can 
TRPV1 act on non-neuronal targets including the urothelium?  
The role of TRPV1 in normal bladder physiology lacks the conclusive evidence that has accumulated 
for its role in bladder inflammation and pain. However, the widespread distribution of the TRPV1 
receptor within the bladder makes it likely that TRPV1 participates in normal bladder function.  
Evidence of a TRPV1 role in mediating bladder afferent activity has emerged from a number of 
sources. TRPV1-/- (KO) mice have a higher frequency of low-amplitude non-voiding contractions 
during bladder filling and have been reported to have an increase in bladder capacity together with a 
reduction in spinal cord signalling and reflex voiding (Birder, Nakamura et al. 2002). In another study, 
spinal c-fos expression in response to bladder distension was similar in TRPV1-/- (KO) and TRPV1+/+ 
(WT) mice (Charrua, Cruz et al. 2007). This lack of effect is consistent with data from Dinnis et al 
(2004), who observed no effect of capsazepine on bladder reflex activity in normal mice, contrary to 
the effect seen in inflamed bladders (Dinis, Charrua et al. 2004). Daly et al (2007) recorded multiunit 
afferent nerve activity from mice and provide solid evidence of a physiological role for TRPV1. Ramp 
distension of the bladder under physiological conditions causes a graded increase in afferent activity 
which was significantly attenuated by bath application of capsazepine (Daly, Rong et al. 2007). It was 
also found that responses were significantly attenuated in TRPV1-/- (KO) mice, thus confirming a role 
for TRPV1 in afferent signalling.  
These results imply that TRPV1 receptors have an essential role in controlling the normal bladder 
micturition reflex and are not only relevant in times of inflammation and disease. Again however, as 
is the problem with whole animal systems and knockout mice, it is hard to elucidate the specific 
actions of TRPV1 within the bladder and to determine if TRPV1 plays a direct role in 
mechanosensitivity.  
In conjunction with the theory of TRPV1 mediated sensory output, there is also a premise that 
TRPV1 is essential to the initial stages of mechanosensation within the urothelium.  TRPV1 activation 
of cultured urothelial cells has been shown to induce a rise in intracellular calcium and activation of 
an inward cation current (Charrua, Reguenga et al. 2009; Kullmann, Shah et al. 2009). However, as 
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mentioned above, this has not been replicated by other investigators using a mouse model (Xu, 
Gordon et al. 2009; Yamada, Ugawa et al. 2009; Everaerts, Vriens et al. 2010). Importantly in this 
respect, the presence and activation of TRPV1 has also been shown to alter the release of urothelial 
mediators. Capsaicin has been shown to release ATP from rat (Sadananda, Shang et al. 2009) and 
rabbit (Dunning-Davies, Fry et al. 2013) bladder mucosal strips but not porcine bladder (Sadananda, 
Kao et al. 2012). Exogenous vanilloids evoke nitric oxide release from rat bladder strips, which is 
reduced by removal of the urothelium or incubation with capsazepine (Birder, Kanai et al. 2001). 
Also, bladders taken from TRPV1-/- (KO) mice and exposed to TRPV1 agonist failed to show an 
increase in intracellular calcium or nitric oxide release (Birder, Nakamura et al. 2002). Furthermore, 
urothelial ATP release from both whole mouse bladder and cultured urothelial cells was blunted in 
the TRPV1-/- (KO) mice (Birder, Nakamura et al. 2002).  
The role of TRPV1 as a direct mechanosensor to bladder distension has been proposed but has 
proven hard to determine conclusively due to the multiple levels of interaction within the bladder 
wall eg, urothelial release Vs muscle compliance Vs direct afferent discharge and this will be a major 
focus of this study.  
 
Is there a link between TRPV1 and P2X? 
There is evidence that activation of P2X3 sensitive afferents is essential to normal voiding behaviour 
and that there is interaction between purinergic and TRPV1 receptors within the bladder. There is 
also evidence that the effects of TRPV1-/- (KO) can be mediated through interactions with the 
purinergic system, either at the level of the urothelium, or the sensory afferents.  
  
Many reports suggest that endogenous ATP is released from the urothelium during bladder 
distension (Ferguson, Kennedy et al. 1997; Collins, Daly et al. 2013) and acts on sub-urothelial 
afferent nerves to trigger afferent activity. There is significant purinergic receptor expression on 
bladder afferents (Vlaskovska, Kasakov et al. 2001) and this expression is principally P2X on small 
diameter sensory nerves (Chen, Akopian et al. 1995; Bradbury, Burnstock et al. 1998; Burnstock 
2000), with P2X3 receptor immunoreactivity predominantly seen within bladder projecting afferents 
(Cockayne, Hamilton et al. 2000). There is growing evidence of an essential role for the P2X3 receptor 
in normal and pathological bladder function. ATP is significantly involved in the activation of pelvic 
nerve afferents arising from the rat urinary bladder (Namasivayam, Eardley et al. 1999) and has been 
shown, at high concentrations, to initiate bladder overactivity (Pandita and Andersson 2002). The 
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purinergic agonist αβMe-ATP increases afferent discharge in both high-threshold nociceptive and 
low-threshold physiological mechanosensory bladder afferents (Rong, Spyer et al. 2002). P2X3-null 
mice exhibit a marked urinary bladder hyporeflexia, characterized by decreased voiding frequency 
and increased bladder capacity (Cockayne, Hamilton et al. 2000) whilst P2X3
-/- and P2X2/3
-/-
 (KO) mice 
show reductions in bladder afferent firing (Vlaskovska, Kasakov et al. 2001; Cockayne, Dunn et al. 
2005).  
 
Both P2X3 and TRPV1 immunoreactive fibers have been identified on bladder afferents in the sub-
urothelium (Cockayne, Hamilton et al. 2000; Lee, Bardini et al. 2000; Yiangou, Facer et al. 2001) and 
colocalisation of TRPV1 with P2X receptors has been confirmed within a large proportion of dorsal 
root ganglion neurons (Guo, Vulchanova et al. 1999). There is also considerable functional evidence 
that a large proportion of capsaicin sensitive DRG neurons also respond to ATP and αβMe-ATP (Piper 
and Docherty 2000; Dang, Bielefeldt et al. 2005) and co-immunoprecipitation studies demonstrate 
the physical association of TRPV1 and P2X3 receptors on DRG neurons (Stanchev, Blosa et al. 2009).  
P2X3 immunoreactivity on bladder projecting neurons is significantly increased in patients with 
neurogenic detrusor overactivity (Brady, Apostolidis et al. 2004) and is significantly reduced in those 
patients who responded positively to intravesical resiniferatoxin suggesting there is functional 
colocalisation between the TRPV1 and P2X3 receptors on bladder afferent nerve terminals (Brady, 
Apostolidis et al. 2004). Botulinum toxin injected into the bladder wall also reduces both TRPV1 and 
P2X3 immunoreactivity (Apostolidis, Popat et al. 2005), and there is a significant correlation between 
the reduction in TRPV1 and P2X3 immunoreactivity in nerve fibers with the frequency of urgency 
episodes of patients, confirming a sensory role for both receptors.  
Along with a proposed role for TRPV1 and P2X coordination on afferent nerves, there is evidence 
that the TRPV1 receptor is involved in urothelial release of ATP in responses to distension, with 
TRPV1-/- (KO) mice showing a marked reduction in ATP release as described in more detail above. As 
such, it is probable that P2X3 receptors localised on nerves in the suburothelium perform a 
mechanosensory role and we propose that the TRPV1 receptor could play an important role in their 
modulation. 
So far there have been a number of studies investigating the importance of TRPV1 and P2X in 
peripheral control of the micturition reflex. Co-localisation of these receptors within bladder tissues 
raises the possibility that they play an important role in the response to mechanical stimulation and 
the micturition reflex in models of inflammation. As yet there have been no studies investigating a 
sensory transduction role based on a functional interaction between TRPV1 and P2X receptors under 
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non-pathological conditions. This study will investigate the afferent response to P2X stimulation in a 
pelvic afferent nerve model using pharmacological blockade and genetic deletion of the TRPV1 
receptor. This study will go further into examining the role of TRPV1 at both the whole organ level, 
as well as in isolated urothelial cells and DRG neurons to elucidate the interactions alluded to in 
previous studies about the origins and importance of TRPV1 and P2X receptors on bladder function.  
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4.2 EXPERIMENTAL PROTOCOLS 
 
The main methodology is detailed in chapter 2. Here the emphasis is on the specific protocols that 
were employed to address the role of TRPV1 in P2X mediated bladder afferent signalling. 
Intravesical pressure and afferent nerve recording.  
 
Bladder contraction 
In order to measure contractile responses of detrusor smooth muscle and corresponding afferent 
nerve activity, bladders were perfused intravesically with 0.9% saline to a maximum pressure of 
12mmHg following control ramp distensions. The syringe pump was stopped but the outflow tap 
remained closed, keeping a set volume within a slightly distended bladder and the bladder muscle 
was given time to accommodate this volume and become stable (fig 2.4.1). Responses to αβMe-ATP 
(300nM, 1µM, 3µM, 10µM, 30µM, 100µM) were obtained. For contraction responses to compare 
TRPV1+/+ (WT) and TRPV1-/- (KO) mice αβMe-ATP (30µM) and 1,1-Dimethyl-4-phenylpiperazinium 
iodide (DMPP) (100µM) were diluted from stock solutions dissolved in dH20, diluted into krebs 
solution and applied via bolus dose of 900µl to the experimental bath of volume 30ml. In 
experiments in which multiple applications of αβMe-ATP were applied in the same experiment, a 
washout period of 45minutes between each dose ensured receptors were not desensitised. 
 
The responsiveness of bladder afferents to αβMeATP (30µM) was also examined in calcium free / 
high magnesium medium to examine the direct response to afferent nerve stimulation independent 
of bladder contraction. As previously discussed, experiments were set up in a normal calcium 
containing Krebs and were left to equilibrate for 30 minutes. The perfusate was then switched to the 
Ca2+ free medium and preparations were left for a further 30 minutes (NaCl 118mM, KCL 4.75mM, 
NaH2PO4 1.0mM, NaHCO3 25mM, MgSO4 1.2mM, glucose 11mM, EDTA 1mM, Mg
2+ 6mM as used 
previously by (Zagorodnyuk et al., (2006). 
 
Capsazepine (CPZ) (Stock @1mg/ml DMSO) 10µM was diluted in krebs solution and applied via the 
perfusion pump (5ml/min) to the experimental bath for 30min prior to agonist application.  
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Ramp distensions 
All ramp distensions in this study were performed at a rate of 100µl/min to a maximal pressure of 
40mmHg based on pilot experiments and previously published literature (Rong, Spyer et al. 2002; 
Daly, Rong et al. 2007). Repeat ramp distensions at 100µl/min elicit reproducible afferent nerve and 
pressure responses (fig 4.2.1).   
 
Intravesical drug administration 
αβMe-ATP (30µM) or saline control (0.9% saline + vehicle) was infused into the bladder lumen via 
the syringe pump. The syringe pump provided constant infusion of drug or saline at 30µl/min with 
the outflow tap open to prevent bladder distension and in order to ensure that the drug 
concentration was stable during the subsequent ramp distension. Preliminary experiments were 
conducted at higher flow rates but the bladder could not empty at an equivalent rate and thus 
volume, and pressure inside the bladder increased with infusion rates above 30µl/min. Drug infusion 
immediately following the prior control distension for a minimum of 7 minutes before distension 
was repeated with the drug present. 
Periods of control or agonist infusion without bladder distension were analysed for spontaneous 
baseline afferent discharge having calculated that the dead space between the syringe pump and 
the bladder was 120µl and a latency of response would be 4 minutes.    
Fig 4.2.1. Pressure/volume and pressure/nerve responses to three repeat distensions at 100µl/min 
prior to the start of an experiment. The compliance and afferent response to distension are 
reproducible. 
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qPCR 
qPCR experiments were performed as described in the major methods section. DRG neurons and 
PMUC’s were isolated from mice and cultured for 24hrs at 37°C. mRNA was harvested, converted to 
cDNA and RT-qPCR was performed using SYBR-Green fluorescence with the TRPV1 primer at a Tm of 
59°C. 
 
Gene  Sequence ‘5-3’ Product  Position Tm Chromosome 
TRPV1 Forward CAAGGCTCTATGATCGCAGG 198bp 575-772 58.2 11 
 Reverse GAGCAATGGTGTCGTTCTGC   59.8  
Table 4.2.1 Primer sequence, product size, gene loci, and Tm for purinergic receptors investigated in 
this study. 
 
Mediator release 
Mediator release experiments were performed with infusion set at 100µl/min and to a maximal 
pressure of 40mmHg to replicate the conditions in which the afferent nerve recordings were 
performed.  
Basal samples of intraluminal contents were taken during a 7 minute infusion of vehicle/agonist 
@30µl/min with the outflow tap open to prevent a build up of volume and bladder pressure, the 
outflow tube was placed into a sterile eppendorf tube placed on dry-ice to prevent post-hoc 
degradation of substrates. Immediately following ramp distensions, the syringe pump was stopped 
and the outflow catheter was placed into a sterile eppendorf tube placed in dry-ice to collect the 
intravesical contents whilst the bladder was left to empty passively.  
Intravesical contents from basal and distension (stretch) in control and drug treated preparations 
were assayed for ATP (Molecular Probes® A22066) and ACh (Molecular Probes® A12217) using 
commercially available kits. Unknowns were calculated from a standard curve of known 
concentrations with blank values subtracted.   
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Calcium imaging 
The calcium imaging protocol is described in more detail in the major methods chapter.  
Calcium imaging was performed using an excitation wavelength of 510nm light and ratios were 
calculated from emissions at 350/380nm or 340/380nm with background fluorescence deducted. 
ATP concentrations used in urothelial concentration-response curves were 1mM, 100µM, 10µM, 
1µM, 100nM 10nM using serial dilutions. αβMe-ATP (30µM) and Ionomycin (5µM) were diluted 
from stock into HEPES solution and applied using a gravity perfusion system at a rate of 1.5ml/min 
for 60s and 5 minutes respectively. Data are presented as a ratio of fluorescence Rf (350/380), or Rf 
(340/380), N= number of experiments, n= number of cells.  
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4.3 THE CONTRIBUTION OF TRPV1 TO BLADDER AFFERENT 
NERVE ACTIVITY 
 
As the bladder filled with saline there was a graded increase in intraluminal pressure and a 
concurrent increase in the afferent nerve firing. The results in fig 4.3.1 show that the afferent nerve 
response to distension in TRPV1-/- (KO) mice was significantly reduced compared to age matched WT 
control mice (p≤0.01, n=9, Two-way ANOVA, Bonferroni multiple comparisons post-hoc test). This 
difference in afferent nerve firing becomes more apparent as the pressure is increased above 
10mmHg and suggests a mechanism whereby the TRPV1 receptor is involved in mediating a small 
component of the afferent nerve responses to distension. The compliance of the detrusor smooth 
muscle to an increase in volume was unaffected by TRPV1 knockout (fig 4.3.2). Peak afferent 
discharge was found to occur at the highest distension pressure for all preparations. 
There is a variable degree of spontaneous afferent nerve firing when the bladder was empty with 
occasional bursts of firing. In experiments in which such spontaneous activity was present, there was 
a trend for reduced levels of firing in the TRPV1-/- (KO) mice but this failed to reach statistical 
significance (fig 4.3.3, fig 4.3.4).    
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Fig 4.3.1 Mean±(SEM) pressure/nerve relationship within the bladder when distended with saline at 
a rate of 100µl/min in TRPV1+/+ and TRPV1-/- mice (**p≤0.01, n=9). 
 
 
Fig 4.3.2 Mean±(SEM) pressure/volume relationship within the bladder when distended with saline at 
a rate of 100µl/min in TRPV1+/+ and TRPV1-/- mice (n=9). 
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Fig 4.3.3 Mean±(SEM) peak baseline spontaneous afferent activity recorded over 100s whilst the 
bladder was empty in TRPV1+/+ and TRPV1-/- mice (n=7). 
 
 
Fig 4.3.4 Mean±(SEM) peak baseline spontaneous afferent activity recorded during 100s whilst the 
bladder was empty in TRPV1+/+ and TRPV1-/- mice (n=7). 
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4.4 THE ROLE OF TRPV1 IN P2X MEDIATED AFFERENT 
SIGNALLING 
 
Bladder afferent nerves respond to the purinergic agonist αβMe-ATP with an initial sharp increase in 
afferent nerve discharge (fig 4.4.1) which immediately begins to decrease in amplitude even in the 
continued presence of the agonist. Afferent nerve responses were concentration-dependent with a 
pEC50 of 7.57±0.5µM (n=6). An experimental trace from a typical experiment in which increasing 
concentrations of αβMe-ATP were applied to the bladder can be seen in fig 4.4.2. Upon application 
of αβMe-ATP there was also a concurrent contraction of the detrusor smooth muscle. This data 
confirms that the smooth muscle and afferent nerves serving the bladder are sensitive to activation 
by purinergic agonists.   
Application of a single dose of bath applied αβMe-ATP (30µM) initiates a significant increase in 
afferent nerve activity (fig 4.4.3). The afferent response to αβMe-ATP is characterised by an initial 
rapid component followed by a period of more sustained firing before returning to baseline over 2-3 
minutes which is accompanied by a corresponding detrusor smooth muscle contraction as indicated 
by an increase in intravesical pressure (fig 4.4.4). The responses to αβMe-ATP (30µM) were 
reproducible with sufficient time allowed between agonist administrations to allow receptor 
resensitisation (Fig 4.4.4). Maximum responses (fig 4.4.5), and time course profiles (fig 4.4.3) to 
αβMe-ATP (30µM) were not significantly different for the two additions of agonist (p≥0.05, n=9, two 
way ANOVA, Bonferroni multiple comparisons post-hoc test). 
Afferent nerve firing during the αβMe-ATP (30µM) response time course was significantly 
attenuated in TRPV1-/- (KO) mice compared to WT littermates (p≤0.0001, n=9: Two-way ANOVA, 
Bonferroni multiple comparisons post-hoc test) (fig 4.4.6). These results suggest that TRPV1-/- (KO) 
mice have reduced afferent nerve sensitivity to purinergic stimulation. In order to examine this 
interaction further, the time course responses to purinergic agonists in WT mice were also examined 
in the absence and presence of the TRPV1 receptor antagonist capsazepine (10µM) (fig 4.4.7). 
Capsazepine (10µM) significantly reduced the duration of the responses to αβMe-ATP (30µM) in a 
similar manner to that seen in the knockout (p≤0.0001 n=9: Two-way ANOVA, Bonferroni multiple 
comparisons post-hoc test). An experimental trace showing αβMe-ATP induced afferent nerve firing 
and detrusor contraction before and following capsazepine (10µM) in WT mice can be seen in fig 
4.4.8. 
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Peak responses to αβMe-ATP in TRPV1+/+ (WT) and TRPV1-/- (KO) mice with capsazepine are 
summarised in fig 4.4.9. Bath applied αβMe-ATP (30µM) caused a significant rise in afferent nerve 
activity reaching a peak of 136.8±30.8imp s-1 (n=9) in control (WT) mice. The response to αβMe-ATP 
(30µM) was significantly reduced in TRPV1-/- (KO) mice (47.4±16.6imp s-1 p≤0.05, n=9) similar to that 
seen with prior capsazepine (10µM) incubation (63.16±27.8imp s-1 p≤0.05, n=9, one-way ANOVA 
Bonferroni multiple comparisons post-hoc test) 
These results indicate that there is a significant decrease in purinergic evoked afferent nerve 
discharge, both in terms of magnitude and duration of the responses, with either pharmacological 
blockade or genetic knock-out of the TRPV1 receptor. 
Further analysis of the data for αβMe-ATP responses indicated that there is also a change in the 
kinetics of the afferent nerve discharge (fig 4.4.10). Bath applied αβMe-ATP (30µM) induces peak 
afferent nerve firing in WT mice after 18±3.2s. TRPV1-/- (KO) mice (64.4±10.4s p≤0.001, n=9) and WT 
mice with capsazepine (10µM) (51.1±11.6s p≤0.05, n=9, one-way ANOVA, Bonferroni multiple 
comparisons post-hoc test) showed a significant increase in the time taken to reach peak afferent 
activity.  
These results indicate there is a functional link between the TRPV1 receptor and purinergic evoked 
afferent nerve responses in the mouse bladder. In order to examine this interaction further it was 
first essential to investigate if this was due to a general change in neuronal excitability, or if it is a 
specific interaction between the TRPV1 and P2X receptors. 
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Fig 4.4.1 Mean±(SEM) concentration-response curve of afferent nerve activity to αβMe-ATP (300nM-
100µM, n=6).  
 
 
Fig 4.4.2 Experimental trace showing afferent nerve activity in response to increasing concentrations 
of αβMe-ATP. A 45 minute washout was allowed between each successive dose to prevent receptor 
desensitisation. 
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Fig 4.4.3 Mean±(SEM) afferent nerve activity over the duration of the response to repeated 
applications of αβMe-ATP (30µM) in TRPV1+/+ (WT) mice from the same experiment (n=9). 
 
Fig 4.4.4 Experimental trace showing the reproducibility of afferent nerve and intravesical pressure 
responses to repeat application of αβMe-ATP (30µM) in control mice. These experiments were 
performed in a bladder predistended to 12mmHg in order to accurately measure intravesical 
pressure responses.  
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Fig 4.4.5 Mean±(SEM) peak afferent firing in response to repeat application of αβMe-ATP (30µM) in 
control mice (n=9). 
 
Fig 4.4.6 Mean±(SEM) afferent nerve activity over the duration of the response to applications of 
αβMe-ATP (30µM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (****p≥0.0001, n=9).  
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Fig 4.4.7 Mean±(SEM) afferent nerve activity over the duration of the response to αβMe-ATP (30µM) 
in TRPV1+/+ (WT) mice in the presence and absence of capsazepine (10µM) (****p≥0.0001, n=9).  
 
 
 Fig 4.4.8 Experimental trace showing afferent nerve and intravesical pressure responses to repeat 
application of αβMe-ATP (30µM) in control mice prior to and following incubation with the TRPV1 
antagonist capsazepine (10µM).These experiments were performed in a bladder predistended to 
12mmHg in order to accurately measure intravesical pressure responses. Note that while afferent 
response is attenuated, the pressure profile is similar after capsazepine. 
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Fig 4.4.9 Mean±(SEM) peak afferent nerve responses to αβMe-ATP (30µM) in TRPV1+/+ (WT) in the 
presence and absence of capsazepine (10µM), and TRPV1-/- (KO) mice. (*p≤0.05 compared to 
TRPV1+/+, n=9). 
 
 
Fig 4.4.10 Mean±(SEM) time taken to reach maximum afferent nerve impulse frequency in response 
to αβMe-ATP (30µM). (**p≤0.01, *p≤0.05 compared to TRPV1+/+, n=9). 
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4.5 IS THE EFFECT OF TRPV1 COUPLED TO P2X MEDIATED 
AFFERENT FIRING? 
 
To determine if the decreased afferent responses to αβMe-ATP were due to a general change in 
neuronal excitability, peak afferent nerve response to the nicotinic agonist DMPP (100µM) in 
TRPV1+/+ (WT) and TRPV1-/- (KO) mice were examined (fig 4.5.1). DMPP (100µM) applied to bladders 
from WT mice caused a significant increase in peak afferent firing 139.1 ± 46.1imp s-1 (n=12). 
Knockout of the TRPV1 receptor had no significant effect on the peak afferent response to DMPP 
157.2±52.3imp s-1, (p≥0.05 n=7, unpaired t-test). The maintenance of nicotinic evoked afferent 
responses in both TRPV1+/+ (WT) and TRPV1-/- (KO) mice suggest that changes seen in purinergic 
activation of bladder afferent nerves by removal or blockade of the TRPV1 receptor are not due to a 
general decrease in afferent nerve excitability.  
As shown above, increases in afferent nerve firing following αβMe-ATP (30µM) occur with a 
concurrent contraction of the detrusor smooth muscle which is known to influence afferent activity. 
In order to determine if the changes in afferent nerve firing due to pharmacological blockade or 
knock-out of the TRPV1 receptor are a result of altered detrusor muscle activity, the detrusor 
contraction responses were also examined. There was no significant difference in the contraction 
responses of TRPV1+/+ (WT) and TRPV1-/- (KO) mouse bladders (fig 4.5.2), as measured by a change in 
intravesical pressure (12.4±1.6 Vs 12.06±1.3mmHg p≥0.05, n=9). Similarly, capsazepine (10µM) also 
failed to alter contraction responses to αβMe-ATP (30µM) in TRPV1-/- (KO) mice 12.06±1.3 Vs 
12.5±3mmHg (p≥.005, n=4, One-way ANOVA, Bonferroni multiple comparisons post-hoc test). The 
results from fig 4.3.2 also show that there is no change in the compliance of the detrusor smooth 
muscle in TRPV1-/- (KO) mice. 
These results suggests that any changes in afferent nerve discharge are not as a result of a change in 
detrusor muscle activity and can be attributed to changes associated with afferent nerve firing.  
A further test of this hypothesis was to remove the smooth muscle contraction component of the 
αβMe-ATP response. This was achieved by repeating experiments in a calcium free krebs solution 
with or without capsazepine (10µM) (fig 4.5.3). A significant reduction in the peak afferent nerve 
response to αβMe-ATP (30µM) was still observed following capsazepine (10µM) in calcium-free 
buffer (86.6±16.3imp-s Vs 53.6±10.8imp-s, p≤0.05, n=7, unpaired t-test).  
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The results suggest that there is a significant interaction between a functional TRPV1 receptor and 
the purinergic component of afferent nerve activity. There is no difference in the contraction 
responses of the detrusor smooth muscle and thus the interaction is likely to be at the level of the 
afferent nerves. These experiments have concentrated on the application of bath applied purinergic 
agonists, however, with relevance to a more physiological difference, the alterations in afferent 
nerve responses to distension in TRPV1 KO mice seen in fig 4.3.1 could theoretically occur from a 
number of sources in any part of the bladder wall.  
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Fig 4.5.1 Mean±(SEM) Peak afferent nerve response to bath applied nicotinic agonist DMPP 
(100µM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (n=7).  
 
 
Fig 4.5.2. Mean±(SEM) Peak intravesical pressure responses to αβMe-ATP (30µM) in TRPV1+/+ 
(WT) and TRPV1-/- (KO) mice with or without capsazepine (10µM). (n=9, 9, 9, 4)  
 
  
  
143 
 
 
Fig 4.5.3 Mean±(SEM) peak afferent nerve responses to bath applied αβMe-ATP (30µM) in a calcium 
free modified krebs solution with or without capsazepine (10µM). (*p≤0.05, n=7). 
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4.6 THE EFFECT OF INTRAVESICAL αβMe-ATP ON AFFERENT 
NERVE ACTIVITY 
 
The following experiment observed the effects of intravesical perfusion of αβMe-ATP (30µM) on 
spontaneous afferent activity. Intravesical perfusion of αβMe-ATP (30µM) significantly increased 
spontaneous afferent firing (p≤0.05, n=6, paired t-test, fig 4.6.2). The experimental trace in fig 4.6.1 
shows an example of the relationship between the raw nerve activity and the rate histogram of 
afferent nerve activity imp/s¯¹. There is an increase in afferent nerve activity with no change in 
intravesical pressure.  The afferent nerve response profile is different from that with bath 
application of αβMe-ATP (30µM) and could represent diffusion across the urothelial barrier, or 
secondary actions following receptor binding on urothelial cells.  
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Fig 4.6.1 Experimental trace representing the effects of intravesical instillation of αβMe-ATP (30µM) 
on baseline spontaneous afferent activity. The upper trace is a rate histogram of nerve activity 
(imp/s-1), the middle trace is the raw nerve activity, and the bottom trace shows intravesical pressure.  
 
 
  
Fig 4.6.2 Mean±(SEM) average baseline spontaneous afferent activity recorded over 100s prior to, 
and following intravesical instillation of αβMe-ATP (30µM) (*p≤0.05, n=6). 
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4.7 UROTHELIAL AND DRG RESPONSES IN TRPV1+/+ (WT) AND 
TRPV1-/- (KO) MICE 
 
The following experiments have explored further the idea that a variety of cell types could be 
contributing to the interaction between TRPV1 and mechanosensitivity seen in fig 4.3.1. Specifically, 
these experiments were conducted to explore on the one hand the possibility of a functional 
contribution of TRPV1 in urothelial cells and on the other hand to examine the sensitivity of DRG 
neurons from TRPV1+/+ (WT) and TRPV1-/-  (KO) mice in isolation from the urothelium.  
Relative mRNA expression of the TRPV1 receptor in isolated PMUCs and DRG neurons is shown (fig 
4.7.1). mRNA for the TRPV1 receptor is expressed in both PMUCs and DRGs. However, the levels of 
expression were significantly greater in DRG neurons than for PMUCs (p≤0.01, n=3, unpaired t-test).  
In order to investigate the role of the TRPV1 receptor in responses to the purinergic agonist ATP in 
urothelial cells, a concentration response curve of primary mouse urothelial cells to ATP (10nM-
1mM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice was constructed (fig 4.7.2). Data normalised to 
percentage of maximal response show PMUCs respond in a concentration-dependent manner to the 
purinergic agonist ATP with an pEC50 values of 3.49±0.77µM and 4.2±0.74µM in TRPV1+/+ (WT) and 
TRPV1-/- (KO) respectively (N=6, n=360, 470). There was no significant difference between pEC50 
responses to ATP of urothelial cells from TRPV1+/+ (WT) and TRPV1-/- (KO) mice and no change in the 
concentration of ATP required to elicit a maximal intracellular calcium response (100µM).  While the 
sensitivity to ATP was similar between TRPV1+/+ (WT) and TRPV1-/- (KO) mice, the magnitude of the 
calcium-signal was different. Calcium fluorescence data is presented (fig 4.7.3) showing that PMUC’s 
from TRPV1-/- (KO) mice have a significantly potentiated response to ATP (p≤0.001, N=6, n=360, 470, 
two-way ANOVA, Bonferroni multiple comparisons post-hoc test) indicating that the TRPV1 receptor, 
or lack thereof, is able to influence purinergic signalling in PMUCs. Paradoxically, the calcium-
response is greater in the absence of TRPV1. 
The presence of a functional TRPV1 receptor within PMUCs was further tested by measuring 
intracellular calcium responses to the application of the TRPV1 agonist capsaicin (1µM) (fig 4.7.4). 
PMUCs did not show a rise in intracellular calcium in response to capsaicin (1µM) despite responses 
to application of ATP being observed (N=3, n=57).  
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Further investigation into the role of the TRPV1 receptor in mediating bladder distension responses 
was achieved through analysis of the luminal contents for ATP and acetylcholine prior to, and 
following bladder distension.   
The effect of bladder distension on the release of acetylcholine (Fig 4.7.5) shows a consistent release 
of acetylcholine from the bladder at rest (basal) and a non-significant increase in release during 
bladder distension (0.35±0.13µM, basal Vs 0.50±18µM stretch). Knock-out of the TRPV1 receptor 
had no effect on the release of acetylcholine at rest or during bladder distension. Basal: 0.36±0.11 
(KO) Vs 0.35±0.13 (WT), Stretch: 0.57±.11 (KO) Vs 0.50±18µM (WT) (p≥0.05 compared to WT basal 
and stretch, n=6, two-way ANOVA, Bonferroni multiple comparisons post-hoc test).  
The effect of bladder distension on the release of ATP (fig 4.7.6) shows ATP is released into the 
bladder lumen at low levels during rest, and at significantly higher levels during distension (2.5±0.3 
Vs 14.4±3.4nM p≤0.001 n=6) in TRPV1+/+ (WT) mice. In TRPV1-/- (KO) mice, there was no difference in 
basal release of ATP (2.5±0.3 Vs 3.1±0.8nM) but a significant decrease in stretch evoked ATP release 
from the bladder into the lumen when compared to WT mice (14.4±3 Vs 4.1±0.9nM p≤0.01 n=6, 
one-way ANOVA, Bonferroni multiple comparisons post-hoc test). The results show that knock-out 
of the TRPV1 receptor was able to significantly inhibit distension evoked ATP release.  
Pelvic DRG neurons were able to respond to αβMe-ATP (30µM) with a variable increases in 
intracellular calcium (fig 4.7.8) which rose rapidly to a peak before a swift reduction in response 
towards baseline. The individual cell responses and variability can be seen in fig 4.7.7. Application of 
αβMe-ATP (30µM) to DRGs caused desensitisation of receptors on DRG neurons as shown by the 
significant reduction following repeat application of αβMe-ATP following a 5 minute washout in 
HEPES. The second response to αβMe-ATP shows a 69.5±5% reduction in maximal response 
(p≤0.0001, N=4, n=32, Wilcoxon matched-pairs signed rank test, fig 4.7.9).  
The measurement of intracellular calcium levels within DRG neurons (fig 4.7.10) showed that DRG 
neurons from WT mice respond to the TRPV1 agonist capsaicin (300nM) with an increase in 
intracellular calcium which varied considerably between individual cells. DRG neurons from TRPV1-/- 
(KO) mice failed to respond to capsaicin (300nM). DRG neurons from both TRPV1+/+ (WT) and TRPV1-
/- (KO) responded to ATP (100µM) with an increase in intracellular calcium. These results confirm the 
knockout of the TRPV1 receptor by removing the response to extracellular capsaicin (300nM) and 
that a proportion of pelvic DRG neurons are sensitive to both TRPV1 and purinergic agonists. 
In order to investigate the hypothesis that there is a functional link between TRPV1 and P2X 
receptors on the afferent neurons innervating the bladder, and that this link is responsible for 
  
148 
 
reduced afferent discharge in distension responses as well as responses to αβMe-ATP (30µM) in the 
in-vitro afferent model, isolated DRG neurons from TRPV1+/+ (WT) and TRPV1-/- (KO) mice were 
exposed to αβMe-ATP (30µM) and the peak intracellular calcium response was measured (Fig 
4.7.12). Data was normalised to percentage of maximum ionomycin induced calcium influx to 
overcome intra-experimental variability. There was no significant difference in maximal αβMe-ATP 
(30µM) induced calcium influx in DRG neurons 24.4±2.4% Vs 28.1±3.2% in WT and KO mice 
respectively (p≥0.05, N=12, n=80, unpaired t-test).  
Further analysis of the DRG neurons responding to αβMe-ATP showed that the percentage of DRG 
neurons responding to αβMe-ATP (30µM) was significantly reduced in TRPV1-/- (KO) mice compared 
to TRPV1+/+ WT (Fig 4.7.13) (59.4±4.9 Vs 36.3±4.1%, p≤0.01, N=12, unpaired t-test). The total 
number of responding Vs non-responding cells was 80/132 (WT) Vs 80/234 (KO).  
These results suggest there is a decreased overall response to purinergic receptor activation in 
TRPV1-/- (KO) mice when compared to TRPV1+/+ WT through a significant decrease in the total 
number of DRG neurons activated by αβMe-ATP.  
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Fig 4.7.1 Mean±(SEM) expression of TRPV1 receptor mRNA relative to β-actin (ΔCT/CT) in PMUCs and 
DRG neurons (n=3) (***p≤0.001, n=3). 
 
 
Fig 4.7.2 Mean±(SEM) concentration response curve of PMUC intracellular calcium to ATP (10nM-
1mM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (N=6, n=360, 470). Data normalised to % of maximal 
response. 
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Fig 4.7.3 Mean±(SEM) concentration response curve of PMUC intracellular calcium to ATP (10nM-
1mM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (****p≤0.0001, N=6, n=360, 470).  
  
 
Fig 4.7.4 Mean±(SEM) change in intracellular calcium levels of PMUCs to capsaicin (1µM) and ATP 
(10µM) (N=3, n=57). 
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Fig 4.7.5 Mean±(SEM) intraluminal acetylcholine release from bladders at rest and at a maximum 
distension of 40mmHg with saline (0.9%) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (n=6). 
 
 
Fig 4.7.6 Mean±(SEM) intraluminal ATP release from bladders at rest and at a maximum distension 
of 40mmHg with saline (0.9%) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (n=6). 
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Fig 4.7.7 Experimental trace showing the variability in individual DRG neurons intracellular calcium 
responses to αβMe-ATP (30µM) from a single experiment in TRPV1+/+ (WT) mice (n=8). 
 
 
Fig 4.7.8 Mean±(SEM) time course of intracellular calcium response of DRG neurons to repeat 
applications of αβMe-ATP (30µM) with 3 minute washout (N=4, n=32). 
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Fig 4.7.9 Mean±(SEM) percentage change in DRG neuron intracellular calcium in response to repeat 
applications of αβMe-ATP (30µM) with 3 minute washout in TRPV1+/+ (WT) mice (****p≤0.0001, N=4, 
n=32).  
 
 
Fig 4.7.10 Mean±(SEM) time course of intracellular calcium response of DRG neurons to capsaicin 
(300nM) and ATP (100µM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice  (N=3, n=18).  
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Fig 4.7.11 Mean±(SEM) percentage change in DRG neuron intracellular calcium in response to αβMe-
ATP (30µM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice  (N=12, n=80). 
 
 
Fig 4.7.12 Mean±(SEM) peak increase in intracellular calcium of DRG neurons following application 
of αβMe-ATP (30µM) in TRPV1+/+ (WT) and TRPV1-/- (KO) mice (N=12, n=80). 
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Fig 4.7.13 Mean±(SEM) percentage of DRG neurons responding to αβMe-ATP (30µM) per experiment 
from TRPV1+/+ (WT) and TRPV1-/- (KO) mice (**p≤0.01, N=12, n=80) 
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4.8 DISCUSSION 
 
How does TRPV1 affect normal bladder responses to distension? 
As the bladder fills, an increase in afferent nerve discharge is observed with a concurrent increase in 
intravesical pressure.  The initial increase in pressure is accompanied by a sharp increase in afferent 
nerve activity, which plateaus once the pressure exceeds the physiological voiding threshold.  
The first observation obtained in experiments comparing TRPV1-/- (KO) and TRPV1+/+ (WT) mice was a 
significant decrease in the afferent nerve response to ramp distension in KO animals. Importantly, 
this was not accompanied by a change in detrusor muscle compliance. There is experimental 
evidence to support a role of TRPV1 as a direct mechanotransducer of bladder afferent discharge 
generated using a variety of experimental approaches and different animal models, yet no 
consensus has been reached on how this is achieved mechanistically. 
There are many reports supporting a role of TRPV1 as a mediator of reflex bladder activity. Using an 
anesthetised rat model, Cefalu et al (2009) showed that intravenous administration of a novel TRPV1 
antagonist increased micturition threshold volume. Reflex voiding during bladder filling under 
anaesthesia and c-fos spinal signalling were reduced in TRPV1-/- (KO) mice (Birder, Nakamura et al. 
2002), supporting a role for TRPV1 in the afferent input to micturition pathways. Cystometrograms 
obtained during anesthesia showed more frequent non-voiding contractions, and large amplitude 
voiding contractions were completely absent in 45% of TRPV1-/- (KO) mice (Birder, Nakamura et al. 
2002). Charrua et al (2009) showed that reflex bladder activity in anaesthetised rats and mice was 
transiently suppressed following duodenal administration of a TRPV1 antagonist. Further, in excised 
rat bladders capsazepine applied to the serosal side decreased autonomous contractile activity in 
response to filling (Gevaert, Vandepitte et al. 2007) suggesting a direct role of TRPV1 without 
connection to spinal reflex mechanisms. These results support a role for TRPV1 as a mediator of 
detrusor contraction but fail to provide conclusive evidence for an afferent role during distension. 
Evidence for this comes from the reduction in c-fos signalling during bladder filling in TRPV1-/- (KO) 
mice (Birder, Nakamura et al. 2002). However, it has since been shown that the contribution of 
capsaicin sensitive C-fibers to distension may be unmasked during anaesthesia (Cheng and de Groat 
2004) and thus these results must be interpreted with care. TRPV1 knockout or the central 
application of TRPV1 antagonists in many of these studies also limits the emphasis that can be 
placed on peripheral mechanosensory actions, as TRPV1 is known to be present in central processes. 
It has also been shown that cutaneous mechanosensation is apparently normal in   TRPV1-/- (KO) 
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mice (Caterina, Leffler et al. 2000) and therefore a direct mechanotransduction role of TRPV1 
afferents and stretch/tension detection in the muscle seems unlikely. Furthermore, studies show 
that knockout of the TRPV1 receptor has no effect on bladder contractions (Charrua, Cruz et al. 
2007), or bladder capacity and voiding pressure (Wang, Wang et al. 2008) in anaesthetised mice. 
This was also shown to be the case in anesthetised rats (Dinis, Charrua et al. 2004) with no change in 
reflex activity in normal bladders with capsazepine administration.  
The most compelling evidence for a role of TRPV1 in mechanosensation comes from the work of 
Daly et al 2007. In a similar preparation to the one described here, it was shown that bath 
application of the TRPV1 antagonist capsazepine caused a significant attenuation of afferent 
discharge in TRPV1+/+ (WT) mice and that afferent responses to ramp distension were similiarly 
attenuated in TRPV1-/- (KO) mice compared to WT, without a change in bladder compliance. Thus, 
there is a consensus that the TRPV1 receptor is involved in mechanosensation within the mouse 
bladder. However, as mentioned above and in reference to the physiology of the bladder wall, there 
are a number of proposed sites for this action, including direct influences on afferent nerve 
sensitivity, detrusor smooth muscle contractility, and urothelial mediator release. The results of this 
chapter have focussed on elucidating the mechanisms of this interaction.   
It is also important to note that although the present data show a significant change in 
mechanosensation with knockout of the TRPV1 receptor, there is still a major component of afferent 
firing during distension that remains. This is consistent with previous cystometric studies showing 
that reflex responses to bladder distention were attenuated as opposed to abolished in TRPV1-/- (KO) 
mice and in WT mice treated with TRPV1 antagonists (Birder, Nakamura et al. 2002; Cefalu, Guillon 
et al. 2009; Charrua, Cruz et al. 2009). There are a number of different mechanisms contributing to 
the activation of bladder afferent nerves, and tension/contraction of the detrusor smooth muscle is 
considered a major component of mechanosensation. However, the experiments in this thesis and 
those by Daly et al (2007) provide firm evidence that the TRPV1 receptor is involved in bladder 
mechanotransduction via afferent nerves, and that this is not a result of changing bladder 
compliance. A theory arising from this thesis is that P2X receptors on sensory afferent nerves 
responding to urothelial ATP released during distension, interact with TRPV1 as a key component of 
mechanosensation. The hypothesis that TRPV1 may be able to mediate afferent excitability to P2X 
stimulation through coexpression of TRPV1 and P2X on sensory afferents has been further expored.  
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Does TRPV1 mediate P2X evoked afferent activity? 
There is convincing evidence to suggest that P2X3 sensitive afferent nerves are essential to normal 
bladder function. There is also evidence that P2X3 receptors co-localise with TRPV1 on bladder 
afferent nerves (Dang, Bielefeldt et al. 2005), and there are also reports which support an interaction 
between purinergic receptors and TRPV1 on DRG sensory neurons (Piper and Docherty 2000; 
Stanchev, Blosa et al. 2009). The aim of this section is to discuss the interactions between TRPV1 and 
P2X within mouse bladder afferent nerves and determine the location of this interaction.  
To investigate further the hypothesis that TRPV1 may mediate afferent sensitivity to P2X receptors, 
contraction and afferent nerve responses to the P2X receptor agonist αβMe-ATP were examined in 
TRPV1+/+ (WT) and TRPV1-/- (KO) mice, with or without the TRPV1 antagonist capsazepine. The results  
showed that bladder afferent nerves responded to αβMe-ATP in a concentration-dependent manner 
with an increase in afferent nerve activity and a concurrent contraction of the detrusor smooth 
muscle. It was observed, that in the presence of the TRPV1 antagonist capsazepine, and in TRPV1-/- 
(KO) mice, the afferent response to αβMe-ATP was significantly reduced. It could be proposed based 
on these results, that the sensitivity of P2X receptors on afferent nerves is modulated by TRPV1, and 
that the decrease in mechanosensitivity seen during ramp distensions in TRPV1-/- (KO) mice was the 
consequence of a decrease in afferent sensitivity to urothelial ATP acting through P2X receptors. 
In support of this hypothesis, there have been a number of studies implicating the importance of 
P2X receptors on sensory afferent neurons of the bladder. Vlaskovska et al (2001) identified 
abundant P2X3 immunoreactive nerve fibers in the sub-urothelial plexus. Further studies have shown 
that DRG neurons from P2X2/3 (Dbl
-/- KO) mice have minimal to no response to ATP (Cockayne, Dunn 
et al. 2005) and DRG neurons from P2X3-/- (KO) mice no longer responded to αβMe-ATP (Zhong, 
Dunn et al. 2001), indicating that purinergic responses in sensory neurons are largely mediated by 
P2X2 and P2X3 receptors.  P2X2
-/-, P2X3 
-/-, and P2X2/P2X3 (Dbl
-/- KO) mice were also shown to have 
reduced urinary bladder reflexes and decreased pelvic afferent nerve activity in response to bladder 
distension (Vlaskovska, Kasakov et al. 2001; Cockayne, Dunn et al. 2005). Furthermore, in WT mice, 
the P2X receptor antagonists TNP-ATP and PPADS attenuated distension-induced afferent firing 
(Vlaskovska, Kasakov et al. 2001) whilst αβMe-ATP was seen to potentiate the afferent nerve 
reponse to distension via both low and high threshold fibers (Rong, Spyer et al. 2002). Similar 
experiments performed in an in-vitro rat preparation have shown that intravesical administration of 
αβMe-ATP significantly increased afferent firing which was blocked by TNP-ATP (Yu and de Groat 
2008). 
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Evidence linking TRPV1 and P2X comes from observations that not only do P2X immunoreactive 
nerves convey sensory afferent information, but that they are co-localised on afferents expressing 
TRPV1 (Piper and Docherty 2000; Dang, Bielefeldt et al. 2005). Furthermore, co-immunoprecipitation 
studies have demonstrated the physical association of TRPV1 and P2X3 receptors on DRG neurons 
(Stanchev, Blosa et al. 2009). It is also interesting that P2X3 immunoreactivity on bladder projecting 
neurons is significantly increased in patients with neurogenic detrusor overactivity (Brady, 
Apostolidis et al. 2004) and is significantly reduced in those patients who responded positively to 
intravesical resiniferatoxin, further suggesting there is functional colocalisation between the TRPV1 
and P2X3 receptors on bladder afferent neurons (Brady, Apostolidis et al. 2004). Vlaskovska et al 
(2001) also showed that 10 minutes after a high dose of capsaicin, the afferent nerve response to 
bladder distension was signifcantly attenuated, further supporting this hypothesis.  
Whilst the investigations described above indicate that there has been interest in a link between 
TRPV1 and P2X receptors in mediating sensory signalling, the results in this thesis provide the first 
direct evidence that the TRPV1 receptor is able to influence bladder afferent nerve responses to P2X 
stimulation, a process considered essential to mechanotransduction during bladder distension. It is 
also possible from these results to hypothesise that the enhancement in detrusor overactivity 
symptoms associated with intravesical resiniferatoxin and capsaicin are not only due to 
desensitisation of TRPV1 but a consequence of decreased afferent nerve responses to urothelial ATP. 
In order to draw firm conclusions regarding the ability of the TRPV1 receptor to mediate afferent 
nerve responses to αβMe-ATP, it was first necessary to investigate the role of TRPV1 in αβMe-ATP 
induced detrusor contractions as tension in the bladder wall is a major stimulus for afferent firing. 
 
Is the TRPV1 effect due to a change in detrusor smooth muscle contraction? 
As briefly discussed above, another consideration within these experiments addresses the 
hypothesis that TRPV1 is able to modulate detrusor smooth muscle contraction and that there is an 
interaction between TRPV1 and a specific P2X receptor at the level of  the detrusor. Results from this 
study showed that application of αβMe-ATP induces significant afferent nerve activity as well as a 
concurrent contraction in detrusor smooth muscle. Furthermore, it was shown that when muscle 
contraction was blocked by incubation in a calcium free external solution, a significant component of 
the afferent nerve response to αβMe-ATP remains, albeit small.  
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Two hypotheses can be proposed to explain these results and they are hard to separate. The first is 
that there is a component of the αβMe-ATP afferent response that is secondary to muscle 
contraction and thus removal of detrusor contraction reduces the overall afferent response to 
αβMe-ATP. The second is that by eliminating calcium from the external solution, it reduces the 
overall excitability of the afferent neurons. The effects of P2X stimulation are mediated by the influx 
of cations, predominantly calcium, which results in membrane depolarisation of the afferent 
terminal and generation of an action potential. A loss of extracellular calcium would decrease the 
net cation influx during P2X receptor activation and thus the excitability of the neurons.  
In support for the first of these hypotheses, contraction of the bladder is a well established mediator 
of afferent nerve discharge, and a number of mechanoreceptor subtypes have been identified 
(Zagorodnyuk, Costa et al. 2006; Xu and Gebhart 2008; Zagorodnyuk, Brookes et al. 2009). Therefore 
the next critical question within this study was to assess if the changes in afferent nerve discharge in 
TRPV1-/- (KO) mice were a result of changes in detrusor muscle contractability.  As the bladder is 
filled with saline there is an increase in intravesical pressure as the bladder accommodates the 
increase in volume, and this relationship is referred to as bladder compliance. In experiments with 
TRPV1+/+ (WT) and TRPV1-/- (KO) mice the compliance curves were superimposable, suggesting that 
the change observed in mechanosensitivity is not a result of altered muscle function. The results 
obtained in this thesis mirror those found by Daly et al (2007), and support the hypothesis that 
TRPV1 is involved in mechanosensation and afferent nerve discharge from the bladder during ramp 
distension rather than an action on the detrusor muscle. This was further tested during extraluminal 
applications of αβMe-ATP which stimulated a concurrent detrusor contraction with an increase in 
afferent nerve activity. It was found that neither TRPV1-/- (KO) nor pharmacological blockade with 
capsazepine affected the detrusor contractions, yet afferent responses were attenuated. Thus, more 
evidence is provided for a sensory afferent mediated role of TRPV1 in mechanosensation. Further 
supporting evidence was the continued ability of capsazepine to attenuate the αβMe-ATP induced 
afferent nerve activity in a calcium free krebs solution in which contractile responses were blocked. 
The contribution of detrusor contraction to the TRPV1-mediating modulation of both afferent 
responses to ramp distension and afferent nerve responses to αβMe-ATP can thus be excluded.  
There have been previous reports that genetic deletion or pharmacological blockade of the TRPV1 
receptor alters bladder contraction dynamics and more importantly in relation to mechanosensitivty, 
bladder capacity (Birder, Nakamura et al. 2002; Charrua, Cruz et al. 2009) but others have seen no 
difference in reflex bladder activity, (Dinis, Charrua et al. 2004; Charrua, Cruz et al. 2007; Wang, 
Wang et al. 2008). It is important, however, to establish that capacity in these studies is defined as 
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the volume necessary to evoke a micturition response and thus is influenced by reflex mechanisms, 
particularly in the anaesthetised state. These effects of increased reflex activity could be due to a 
dampening down of TRPV1 mediated afferent inputs to inhibitory mechanisms arising from the 
spinal cord that control micturition.  
There is a significant effect of both pharmacological blockade and genetic deletion of the TRPV1 
receptor on the afferent responses to αβMe-ATP. The results presented here are consistent with a 
model that excludes a role for detrusor smooth muscle and is most likely due to interactions 
between TRPV1 and P2X that are co-expressed on sensory afferent neurons innervating the bladder. 
 
Is the TRPV1 effect due to a change in overall afferent excitability? 
A previous study into the involvement of TRPV1 in intestinal mechanosensitivity showed reductions 
in afferent nerve responses to distention (Rong, Hillsley et al. 2004) and concluded that TRPV1 may 
pre-tune the excitability of these afferents. If this were the case in the bladder, afferent sensitivity to 
various stimuli would be attenuated and a general, rather than specific mechanosensory role for 
TRPV1 would be concluded. In order to test this theory, the nicotinic ionotropic receptor agonist 
DMPP was applied to TRPV1+/+ (WT) and TRPV1-/- (KO) mouse bladders and the afferent response 
was examined and shown to be unaffected. This provides evidence towards a specific functional link 
between the TRPV1 and P2X receptors on bladder afferent nerves mediating responses to distension 
and not a general change in excitability. There is functional evidence for TRPV1 and P2X interaction 
occuring in rat DRG neurons, where calcium dependent cross-desensitization of the ATP response 
was observed following prior desensitisation of TRPV1 with capsaicin application (Piper and 
Docherty 2000). The P2X3 receptor agonist αβMe-ATP also induced less current in the presence of 
the TRPV1 agonist capsaicin than control (Stanchev, Blosa et al. 2009). However, in this study 
capsaicin and αβMe-ATP were administered simultaneously and thus controlled for any potential 
prior desensitisation of the TRPV1 receptor. These studies were not aimed at elucidating bladder 
signalling and thus the DRG neurons were from throughout the thoracic and lumbar regions.  
In support of a subset of afferent neurons showing reduced responses to P2X3 stimulation, Daly et al 
(2007) found that low threshold afferent activity was exclusively attenuated in TRPV1-/- (KO) mice, in 
contrast to the generalised view that capsaicin sensitive afferents are nociceptors. It is generally 
considered that CSPANS are C-fibers responsible for the transmission of noxious stimuli rather than 
physiological signalling. However, it has been shown in rats that there is a larger population of 
unmyelinated C-fiber than Aδ-fiber afferents innervating the bladder of rodents (Vera and Nadelhaft 
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1990; Andersson 2002), and that these fibers respond to slow distension (Morrison 1999) as well as 
at low bladder pressures (Fowler, Griffiths et al. 2008). It has also been shown in mice that these low 
threshold mechanosensitive afferents respond to chemical stimuli (Xu and Gebhart 2008), a 
common characteristic of C-fibers.  
Thus, it is proposed that there is an interaction between the P2X3 and TRPV1 receptors at the level 
of the afferent nerves, and this effect is essential in mediating the afferent nerve responses to ATP 
released from the urothelium during physiological bladder distension.  
 
Examining individal DRG responses to αβMe-ATP 
In order to further test the theory of an afferent mediated role in TRPV1 responses to αβMe-ATP in 
mechanosensation, the responses of DRG neurons from lumbosacral (L6/S2) and thoracolumbar 
(T11/L2) regions were examined in TRPV1+/+ (WT) and TRPV1-/- (KO) mice.   
DRG neurons respond to αβMe-ATP with an increase in intracellular calcium which returns rapidly to 
baseline over 2-3 minutes. This is consistent with receptor desensitisation because a repeat dose of 
αβMe-ATP three minutes after washout induces a significantly attenuated response. DRG neurons 
from WT mice respond to capsaicin with an increase in intracellular calcium, whilst those from 
TRPV1-/- (KO) mice failed to respond to capsaicin, confirming knockout of the functional receptor. 
Unexpectedly, in DRG neurons from TRPV1-/- (KO) mice which responded to αβMe-ATP with an 
increase in intracellular calcium, an equaivalent magnitude of response was seen to that of TRPV1+/+ 
(WT)  mice. This argues against the hypothesis that TRPV1 is responsible for setting the excitability of 
afferents as proposed for afferents supplying the jejunum (Rong, Hillsley et al. 2004). However, while 
the magnitude of the calcium signal was not different, it was observed that the percentage of DRG 
neurons responding to the purinergic agonist αβMe-ATP was significantly reduced in the TRPV1-/- 
(KO). Since receptor expression of a whole host of receptors is developmentally regulated this might 
suggest a role for TRPV1 in determining P2X receptor expression. Alternatively, it could be proposed 
that removal of TRPV1 reduces the sensitivity of the P2X3 receptor upon the afferent terminal to 
respond to purinergic agonism. Thus, it is possible that the responding cells are those which express 
P2X receptors without TRPV1, and the non-responding proportion of DRGs are those which would 
normally coexpress TRPV1 and P2X3, and the lack of functional TRPV1 receptor in these neurons 
renders the P2X3 receptor inactive.  
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The percentage of a mixed population of thoracolumbar and lumbsacral DRGs responding to αβe-
ATP in this study is consitent with other reports (Cockayne, Hamilton et al. 2000; Zhong, Dunn et al. 
2001; Dang, Bielefeldt et al. 2005). As with all cell culture experiments the conditions in which the 
cells are maintained prior to experimentation contributes greatly to the overall effect. This is 
reflected in the variation observed in the percentage of DRGs responding to capsaicin which ranges 
from 50% - 90% (Ueno, Tsuda et al. 1999; Yoshimura, Seki et al. 2003; Dang, Bielefeldt et al. 2005). 
Amongst these capsaicin sensitive neurons there is a distinct population which also respond to 
αβMe-ATP which ranges from 48 - 76% (Ueno, Tsuda et al. 1999; Dang, Bielefeldt et al. 2005) 
depending upon the location of the DRGs. Such relative proportions are consistent with the 40% 
reduction in αβMe-ATP responsive DRGs following TRPV1 knockout seen in this thesis. These results 
also correlate with the results discussed above showing that TRPV1-/- (KO) mice have a reduced, but 
not abolished afferent nerve response to αβMe-ATP in the whole bladder. Although a direct 
mechanism for a reduction in afferent firing following TRPV1-/- (KO) has not been explored in this 
thesis, there are a number of intriguing possibilities. TRP channels have been recently shown to 
modulate the sensitivity of other ion channels (Harrington, Hughes et al. 2011), in this case, other 
TRP channels. This is most likely through extensive phosphorylation of intracellular signalling 
molecules, which in the case of P2X3 has been shown to be regulated by PKC (Giniatullin, Nistri et al. 
2008), calcineurin (King, Chen et al. 1997) and PiP2 (Mo, Bernier et al. 2009; Mo, Peleshok et al. 
2013). Thus it is possible that removal or blockade of the TRPV1 receptor modifies intracellular 
signalling and reduces the sensitivity of P2X3 receptors.   
These results when taken together provide evidence for a role of both P2X and TRPV1 receptors in 
mechanosensation within the bladder via the release of ATP from the urothelium and actions on 
sub-urothelial afferent nerves. The precise interactions that occur are still uncertain but the 
evidence presented here suggests that there is certainly an interaction at the level of the sensory 
afferent nerve terminal which could underlie the effectiveness of intravesical vanilloid treatment. 
 
Does the urothelium contribute to alterations in mechanosensitivity? 
Another potential mechanism by which knockout of the TRPV1 receptor is able to attenuate afferent 
nerve responses during ramp distension is via actions upon the urothelium. The reduced 
mechanosensitivity in the bladder seen in the TRPV1-/- (KO) mice could be a downstream effect of a 
reduction in the release of urothelial factors.   
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The urothelium is considered to be a sensory epithelium, as it contains many receptors/ion channels 
including nicotinic, muscarinic, bradykinin, P2X, P2Y and adenosine receptors (Lee, Bardini et al. 
2000; Chess-Williams 2002; Chopra, Barrick et al. 2005; Yu, Zacharia et al. 2006; Zarghooni, Wunsch 
et al. 2007; Chopra, Gever et al. 2008), as well as a number of TRP channels (Birder, Kanai et al. 2001; 
Stein, Santos et al. 2004; Everaerts, Vriens et al. 2010). In response to mechanical stimulation, the 
urothelium has the ability to release a number of neurotransmitters and peptides including ATP, 
acetylcholine, nitric oxide, prostaglandins (Birder 2010) which are reported to act in both a paracrine 
manner on the underlying interstitial cells and sub-urothelial nerves, but also in an autocrine manner. 
ATP, due its release by distension and actions on bladder sensory nerves (Vlaskovska, Kasakov et al. 
2001) has become the focus of considerable investigations. Augmented release of urothelial ATP has 
recently been implicated in overactive bladder and has been proposed as a biomarker for this 
syndrome (Cheng, Mansfield et al. 2013; Silva-Ramos, Silva et al. 2013). If this is the case, then one 
might hypothesise that a decrease in urothelial ATP might impair sensory function and decrease 
bladder afferent nerve discharge. This was examined as a possible explanation for the alterations in 
bladder mechanosensitivity observed in TRPV1-/- (KO) mice.  
In TRPV1+/+ (WT) mice there was a basal release of ATP from an undistended bladder and a 
significant increase in ATP release during bladder distension. In TRPV1-/- (KO) mice there was no 
change in basal release of ATP from control but a significant attenuation of distension evoked ATP 
release. These results agree with those of others who have previously shown that ATP release is 
significantly reduced in both excised bladder strips and urothelial cells from TRPV1-/- (KO) mice 
(Birder, Nakamura et al. 2002). They also went further in demonstrating that capsaicin was able to 
induce ATP release, an effect blocked by prior incubation with capzasepine. Similar experiments 
have been performed in rat and rabbit, and capsaicin acting through TRPV1 was shown to induce 
ATP release (Sadananda, Shang et al. 2009; Dunning-Davies, Fry et al. 2013). The identification of 
TRPV1 mRNA within the urothelium in this study, albeit in much reduced amounts compared to in 
DRG neurons, shows that urothelial cells have the ability to synthesise the TRPV1 receptor. The exact 
mechanism determining ATP release however is unclear, and the basis for TRPV1 modulation of 
urothelial ATP release is not known. It is important to note that acetylcholine release was not 
effected by TRPV1-/- (KO) indicating urothelial release of ATP and acetylcholine are mediated via 
different mechanisms. Indeed, it has been shown that ATP release is dependent on vesicular 
mechanisms (Knight, Bodin et al. 2002; Birder, Barrick et al. 2003; Collins, Daly et al. 2013) whilst 
acetylcholine is not (Hanna-Mitchell, Beckel et al. 2007). It was also found that in TRPV1-/- (KO) mice 
that there is no change in membrane capacitance during stretch (Birder, Nakamura et al. 2002), 
suggesting that the actions of TRPV1 on ATP release may be up-stream of vesicular exocytosis. As 
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previously explained, the evidence for TRPV1 as a direct mechanosensor is limited, and accordingly 
its role in urothelial signalling is not clear. It has been proposed that the TRPV1 channel could form a 
heteromeric assembly with the mechanosensitive TRPV4 channel (Everaerts, Vriens et al. 2010) 
similar to that observed in vivo with TRPC channels (Schaefer 2005). However, TRPV1 and TRPV4 
channels have been shown to preferentially assemble into homomeric complexes and do not 
combine by chance (Hellwig, Albrecht et al. 2005; Schaefer 2005). This however, does not rule out 
the possibility that TRPV1 might interact with other ion channels or non-related proteins to either 
influence the exocytotic pathways or the function of other mechanosensitive channels within the 
urothelium. 
Indeed, it has previously been shown that antagonism of the TRPV1 receptor is able to inhibit nitric 
oxide release from the bladder (Birder, Kanai et al. 2001; Birder, Nakamura et al. 2002). The 
importance of these results in respect to this study are limited as nitric oxide has been reported to 
either have no role in afferent nerve responses in healthy bladder (Yu and de Groat 2008), or is 
shown to decrease afferent nerve activity (Caremel, Oger-Roussel et al. 2010; Aizawa, Igawa et al. 
2011). Thus, if there was inhibition of nitric oxide release from the bladder urothelium following 
knockout of the TRPV1 receptor, an increase in afferent nerve responses to distension would be 
observed rather than the decrease seen in the current study. It is possible that this pathway 
compensates for a proportion of the functional deficit observed with the abolishment in urothelial 
ATP following TRPV1 knockout, and therefore masks a more significant decrease in the afferent 
nerve response to distension. However, without further experiments, this cannot be confirmed.     
Despite uncertainty behind the mechanism underlying reduced urothelial release of ATP in the 
TRPV1-/- (KO) mouse, it is a consistent finding in both rat and mice and from studies in different 
laboratories. This would imply a role for urothelial ATP within the afferent sensory pathways, and 
may underlie the positive effects on bladder symptoms seen with the instillation of resiniferatoxin 
and Botox.  
 
Functional TRPV1 receptors within the urothelium 
For TRPV1 to sensitise other components within urothelial cells, the receptor must be coupled to 
downstream signalling events including phosphorylation pathways that alter the gating properties of 
various receptors and ion channels including P2X. A rise in intracellular calcium is often the trigger 
for activating these second messenger cascades and monitoring intracellular calcium for example 
with Fura2 is an effective way of following activation events because it can be done in real time. In 
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this respect calcium imaging of PMUCs from TRPV1+/+ (WT) and TRPV1-/- (KO) mice allowed direct 
responses to capsaicin and ATP to be examined. Perfusion of capsaicin onto PMUCs had no effect on 
intracellular calcium, which is hard to explain given the changes in ATP release observed in the 
TRPV1-/- (KO) mouse. Nonetheless, this observation is in line with others who have failed to show 
functional responses to TRPV1 in both isolated mouse and guinea pig urothelial cells (Xu, Gordon et 
al. 2009; Yamada, Ugawa et al. 2009; Everaerts, Vriens et al. 2010). It is interesting that studies in 
which functional responses were absent correlated with low expression of mRNA for the TRPV1 
receptor. In contrast, other studies performed in rats have shown functional TRPV1 receptors on 
urothelial cells (Birder, Kanai et al. 2001; Kullmann, Shah et al. 2009) through an increase in 
intracellular calcium following addition of capsaicin. Species differences could be one explanation. 
However, another possible explanation may be the length of time the cells are maintained in culture 
before undertaking the experiments. All studies failing to report TRPV1 evoked responses used the 
urothelial cells within 48hrs of isolation. Those showing a functional response either do not mention 
the length of time in culture (Birder, Kanai et al. 2001) or it was over 48hrs (Kullmann, Shah et al. 
2009). It is known that culturing primary cells can significantly alter their phenotype. Studies have 
shown the release of NGF from urothelial cells (Pinto, Lopes et al. 2010; Ochodnický, Michel et al. 
2013) and it has been shown that NGF is able to both sensitise and increase membrane expression of 
TRPV1 (Amaya, Shimosato et al. 2004; Zhang, Huang et al. 2005). Thus, it is tenuous, but possible, 
that a longer urothelial cell culture provides the environment for the upregulation of TRPV1 
receptors that underlies their functional response. This is also a potential mechanism whereby 
inflammation and/or damage to the urothelial cell layer can induce TRPV1 and a subsequent 
increase in ATP release which may underlie sensory urgency and pain.   
Following observations that urothelial ATP release was attenuated in TRPV1-/- (KO) mice, the 
response of PMUCs to exogenous ATP was tested using calcium fluorescence. The responses to ATP 
in TRPV1+/+ (WT) and TRPV1-/- (KO) mice had an identical response profile and there was no change 
in the concentration of ATP required to elicit a maximal response. However, what is of particular 
intrigue is that the maximum responses to ATP in urothelial cells from TRPV1-/- (KO) mice were 
significantly higher (≈50%) than the responses from TRPV1+/+ (WT) cells. This is the first study to 
report this augmented response in urothelial cells and requires corroboration. Such augmentation 
might reflect compensatory changes occurring as a result of the TRPV1 knockout. The urothelial 
response to ATP, although not well understood, has been shown to induce further ATP release (Sun 
and Chai 2005) which likely plays a role in the downstream effects of mechanosensation and as such, 
through removal of TRPV1 and a significant attenuation in ATP release during distension, there is an 
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upregulation of purinergic receptors to the membrane which underlie the increased response to 
exogenous ATP.  
The TRPV1 receptor may have two synergistic roles in mediating the mechanosensitivity which when 
knocked out could result in the deficit in mechanosensitivity observed during bladder distension. A 
decrease in the release of ATP from the urothelium, coupled with a decrease in afferent nerve 
sensitivity to ATP could combine to result in a decrease in afferent nerve sensitivity. However, it is 
necessary to mention that the contribution of these pathways to afferent discharge during normal 
bladder distension is only small. However, the relative density of suburothelial P2X3 and TRPV1 
immunoreactive nerves has been shown to increase in disease and thus this pathway may contribute 
a larger proportion of the mechanosensory response to distension during pathophysiological 
conditions.  
 
Conclusions 
The results in this chapter have provided evidence towards the already comprehensive literature 
supporting a role for ATP and P2X receptors in mechanosensitivity within the bladder, specifically its 
actions upon the sensory afferent nerves. The results in this chapter have also presented evidence 
for a significant role of the TRPV1 receptor in mediating bladder responses to P2X agonists, 
particularly during ramp distension. The loss of TRPV1 function resulted in decreased afferent nerve 
responses to ramp distension and following further investigation it was found that genetic deletion 
of TRPV1 or its pharmacological antagonism resulted in a decreased afferent response to P2X 
receptor stimulation.  This was a specific effect on P2X receptor function and was not due to a loss of 
general excitability. This leads to the proposal that the interaction between TRPV1 and P2X 
contributes to mechanosensation within the bladder and that the functional presence of TRPV1 may 
be essential for the effects of endogenous ATP on sensory signalling to be fully manifested. In 
addition, a synergistic interaction of TRPV1 and the purinergic system is evident in the urothelium 
where loss of TRPV1 significantly attenuated stretch evoked ATP release. The present results provide 
a mechanistic basis for the decrease in sensory symptoms seen following resiniferatoxin and 
capsaicin treatment for lower urinary tract symptoms, although the relative contribution of the 
urothelium and the sub-urothelial afferent nerves remains an unknown. Understanding the relative 
role of TRPV1 in urothelial cells Vs DRG neurons may require cell-specific conditional knockouts 
based on cre-loxP technology. 
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CHAPTER 5: THE ROLE OF TACHYKININ 
RECEPTORS IN MECHANOSENSATION 
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5.1 INTRODUCTION 
 
Background of Tachykinin receptors  
The tachykinin family of peptides consisting primarily of substance P, neurokinin A (NKA), and 
neurokinin B (NKB) are principally found within the central and peripheral nervous system.   
All three tachykinins, bind to, and act as full agonists for all three tachykinin receptor subtypes but 
show a defined order of potency such that substance P binds preferentially to NK1, NKA 
preferentially binds NK2, and NKB is more selective for NK3 (Mussap, Geraghty et al. 1993; Regoli, 
Boudon et al. 1994; Maggi and Schwartz 1997).  
 
Tachykinins in the bladder 
Within the bladder, tachykinin neuropeptides are largely contained within capsaicin sensitive 
primary afferent neurons (CSPANS) (Lecci and Maggi 2001; Avelino, Cruz et al. 2002) but it is also 
possible for tachykinins to be present in capsaicin-insensitive neurons, especially following 
inflammation or insult (Neumann, Doubell et al. 1996; Hunter, Myers et al. 2000; Carr, Hunter et al. 
2002). Activation of CSPANS has been shown to trigger the release of tachykinins, and treatments 
which desensitise and disrupt the sensory function of CSPANS has been shown to produce positive 
outcomes in both idiopathic and neurogenic bladder disorders (Brady, Apostolidis et al. 2004; 
Apostolidis, Gonzales et al. 2006) through an increase in bladder capacity, and decrease in 
sensations of urgency and frequency. It has been proposed that these beneficial effects are 
mediated in part by changes in the release of endogenous tachykinins. However, the precise roles 
that tachykinin receptors play within the bladder, and particularly their role in sensory signalling are 
yet to be determined.  
A dual role for CSPANS in sensory signalling was proposed by Maggi et al (1998), whereby in the 
process of CSPAN mediated afferent signalling, there is a concurrent release of neuropeptides from 
the peripheral terminals which leads to an effector response in the periphery as part of the axon 
reflex. This process was termed a sensory ‘efferent’ function and it is these proposed actions, which 
have implicated tachykinins in a role in bladder physiology and pathophysiology. Tachykinin 
containing CSPANS, which are found to innervate the detrusor smooth muscle, but more densely 
innervate the suburothelium of humans (Keast and de Groat 1992; Smet, Moore et al. 1997) and rats 
  
170 
 
(Maggi 1993), thus have the potential to influence a number of bladder structures including the 
detrusor smooth muscle, interstitial cells, urothelium, and sensory afferent nerves. 
CSPANS synthesise and release substance P and NKA (Dalsgaard, Haegerstrand et al. 1985; Hökfelt, 
Pernow et al. 2001) and also express the receptors for these neuropeptides (Brechenmacher, Larmet 
et al. 1998) whilst more recently, NKA has been shown to enhance the excitability of capsaicin 
sensitive DRGs (Sculptoreanu and de Groat 2007). These observations have raised the possibility that 
neurokinins may act in an autofeedback manner to regulate afferent terminal excitability. Indeed, 
tachykinins have been shown to exert significant effects on the excitability of capsaicin sensitive 
lumbo-sacral DRG neurons including an increase in calcium currents (Sculptoreanu and de Groat 
2003) and an increase in action potential frequency in response to sustained depolarisation currents 
accompanied by a decrease in action potential threshold (Sculptoreanu and de Groat 2007). There is 
also an enhancement of capsaicin evoked currents (Sculptoreanu, Aura Kullmann et al. 2008), and it 
has recently been suggested that these effects are mediated in part due to a positive shift in the 
activation curve of low threshold potassium-currents (Sculptoreanu, Artim et al. 2009). As 
mentioned above, nerves immunoreactive for NKA are found in the detrusor muscle (Burcher, E et al. 
2000; Andersson 2002) but more densely populate the sub-urothelium, (Smet, P et al. 1997), and 
thus an autoregulatory mechanism of tachykinins on afferent excitability could have wide ranging 
effects within the bladder, including the transduction of mechanical stimuli during bladder 
distension. 
 
Actions on bladder contraction  
As described briefly earlier, CSPANS innervating the bladder have been shown to have two functions. 
In addition to a known sensory function, they also exhibit an ‘efferent’ component composing the 
release of tachykinins, which can bind to tachykinin receptors on detrusor smooth muscle causing 
contractions.  
There is evidence that endogenous stimuli can induce the release of tachykinins, including muscle 
stretch (Lecci, Giuliani et al. 1998) which provides physiological relevance for tachykinins during 
bladder distension. Stimulation of CSPANS with a non-desensitising dose of capsaicin is also known 
to stimulate the release of tachykinins (Maggi, Patacchini et al. 1991; Lecci, Giuliani et al. 1997), and 
the resultant contractile response of the detrusor smooth muscle can be blocked by prior 
administration of joint NK1 and NK2 receptor antagonists (Maggi, Patacchini et al. 1991) or specific 
NK2 receptor antagonists (Lecci, Giuliani et al. 1997) in the rat. 
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Both NK1 and NK2 receptors are present on detrusor smooth muscle of a number of species but 
there is a large degree of difference in the effects. Bladder contractions via NK1 receptor agonists 
are limited to the rat and guinea-pig (Longmore and Hill 1992) via activation of phospholipase C and 
IP3 (Suman-Chauhan, Guard et al. 1990; Martin, Wheeler et al. 1997), which are also activated by 
NK2 receptors. In many species, NK1 receptors are limited to the smooth muscle and blood vessels 
of both the detrusor and sub-urothelium (Mussap, Geraghty et al. 1993; Burcher, Zeng et al. 2000).  
Within the bladder, the actions of NKA are commonly found on the detrusor smooth muscle. NK2 
receptors are present on detrusor smooth muscle of a number of species, including hamster and 
rabbit (Guard, Pain et al. 1993), guinea pig (Longmore and Hill 1992), sheep (Tucci, Bolle et al. 2001), 
dog (Rizzo and Hey 2000), pig, and human (Giuliani, Patacchini et al. 1993; Burcher, Zeng et al. 2000; 
Templeman, Sellers et al. 2003) and have been shown to elicit powerful bladder contractions. NK2 
mediated detrusor smooth muscle contraction has been linked to IP3 accumulation (Suman-Chauhan, 
Guard et al. 1990; Torrens, Beaujouan et al. 1995; Martin, Wheeler et al. 1997) and rho-kinase has 
also been implicated in NKA induced detrusor contraction in rats (Wibberley, Chen et al. 2003; Quinn, 
Collins et al. 2004). As well as rho-kinase and IP3 accummulation, NKA induced detrusor contraction 
is dependent on extracellular calcium though both receptor mediated and voltage gated calcium 
channels (VGCC) (Quinn, Collins et al. 2004) and it has been previously shown that this component of 
NK2 receptor-mediated bladder contraction largely depends on the activation of nifedipine sensitive 
calcium channels (Maggi, Giuliani et al. 1989). The role of prostanoids is slightly more contentious; 
with a significant effect of prostanoids on the L-type calcium channel component of NK2 mediated 
detrusor contraction in the hamster (Tramontana, Catalioto et al. 2000; Candenas, Lecci et al. 2005), 
whilst blockade of cycloxygenase failed to inhibit tachykinin receptor-mediated detrusor smooth 
muscle contractions in rats, guinea-pigs, dogs and humans (Quinn, Collins et al. 2004; Candenas, 
Lecci et al. 2005). 
Thus, it is possible that tachykinin neuropeptides released from CSPANS in response to muscle 
stretch are able to provide a degree of control to the contraction of the detrusor smooth muscle and 
could provide an endogenous tone to the bladder wall during bladder distension. 
 
Actions on the urothelium 
As described above, the greatest density of tachykinin immunoreactive fibers innervating the 
bladder is found within the suburothelium (Keast and de Groat 1992; Smet, Moore et al. 1997). 
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There is the potential therefore that tachykinins released from terminal varicosities within the sub-
urothelium are able to influence the underlying urothelium and interstitial cells.  
Despite a lack of functional evidence it is considered that the NK2 receptor is also present on the 
urothelium. Bahadory et al (2013) showed expression of NK2 receptor mRNA on urothelial cells 
whilst indirect evidence of a functional NK2 receptor upon the urothelium is presented by 
eradication of an NK2 receptor mediated prostanoid release following urothelial removal 
(Tramontana, Catalioto et al. 2000) and NK2 receptor induced nitric oxide production in cultured rat 
urothelial cells (Candenas, Lecci et al. 2005). It has also been shown that intravesical instillation of 
NKA, but not substance P or NKB into the bladder lumen is able to stimulate micturition in conscious 
rats (Ishizuka, Mattiasson et al. 1995). The authors of this study concluded that the actions of NKA 
on the micturition reflex must be secondary to direct actions upon the urothelium, long before the 
current consensus that the urothelium plays an important role in the control of micturition. Maggi et 
al (1991) also observed facilitation of reflex micturition by intravesical NKA in anaesthetised rats, 
coupled with a reduced bladder capacity and residual volume (Maggi, Giuliani et al. 1991). 
Interestingly, in an in vitro model of guinea pig whole bladder, the instillation of intravesical NKA 
facilitated the occurrence of rhythmic contractile activity (Maggi, Giuliani et al. 1991) which was not 
observed with intravesical instillation of NKA in rats (Ishizuka, Mattiasson et al. 1995).  
A more recent avenue of research has implicated a novel structure in mediating the actions of NKA 
in the bladder. Using porcine bladder strips, NKA was found to directly mediate mucosal 
contractions in the presence of TTX and indomethacin and a role for suburothelial interstitial cells 
was proposed (Sadananda, Chess-Williams et al. 2008).   
 
Role in the micturition reflex 
As described above, intravesical administration of tachykinins has been shown to stimulate the 
micturition reflex (Maggi, Giuliani et al. 1991; Ishizuka, Mattiasson et al. 1995). A number of other 
studies using a variety of techniques have also shown tachykinins can influence the micturition reflex, 
although the role of peripherally mediated tachykinin responses has still not been sufficiently 
explored 
A physiological role for tachykinin receptors in mediating micturition comes from a study in which 83% 
of mutant mice (lacking the preprotachykinin gene) exhibit urinary retention and overflow 
incontinence during cystometrograms (Kiss, Yoshiyama et al. 2001). Also, an NKA induced increase in 
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basal intravesical pressure followed by micturition was observed immediately after intra-arterial 
NKA (Ishizuka, Mattiasson et al. 1995). Bushfield et al (1995) followed a similar protocol with 
intravenous administration of NKA in guinea pigs and also elicited bladder contraction, interestingly, 
this effect was blocked by pretreatment with a desensitising dose of αβMe-ATP and atropine 
combined with hexamethonium suggesting the involvement of reflex mechanisms, and it was 
proposed that activation of preganglionic NK2 receptors could potentiate ATP and ACh release from 
efferent fibers to promote muscle contraction (Bushfield, Metcalfe et al. 1995). Intravenous (IV) 
administration of an NK2 agonist was shown to stimulate a significant increase in afferent nerve 
responses to bladder distension without a change in intravesical pressures (Kibble 1996). In separate 
experiments, an NK2 antagonist administered IV was shown to decrease peak afferent discharge 
rate and increase the intravesical pressure at which it occurred (Kibble 1996), and it was concluded 
that greater levels of receptor stretch are necessary to achieve normal levels of afferent nerve 
discharge in the presence of an NK2 receptor antagonist. There was no mention, however, of 
volumes required to elicit these pressures and it has previously been shown that the NK2 receptor 
antagonist MEN 11420 induces a relaxation of the basal tone of the urinary bladder that is more 
apparent at high volumes of distension (Lecci, Giuliani et al. 1998). 
Studies utilising tachykinin antagonists have explored the role of endogenous tachykinins in the 
peripheral control of micturition in both physiological and pathophysiological states. It has been 
found that there is only a minor contribution of NK1 and NK2 receptors in controlling micturition 
parameters including bladder capacity and the amplitude of micturition contractions during 
cystometry recordings of normal rats (Lecci, Giuliani et al. 1993; Ishizuka, Igawa et al. 1994; Lecci, 
Tramontana et al. 1998). The effect of tachykinin antagonists are revealed in models of bladder 
irritation and outflow obstruction, with a significant role for the NK2 receptor in attenuating 
increases in micturition reflex parameters back towards physiological levels (Lecci, Giuliani et al. 
1993; Ishizuka, Igawa et al. 1994; Lecci, Tramontana et al. 1998).  
These results are consistent with a peripherally mediated release of tachykinins mediating bladder 
overactivity and are consistent with the positive outcomes in both idiopathic and neurogenic 
bladder disorders following desensitisation of CSPANS (Brady, Apostolidis et al. 2004; Apostolidis, 
Gonzales et al. 2006). Indeed there is a significant increase in tachykinin immunoreactivity in the 
sub-urothelium of patients with idiopathic detrusor overactivity (Moore K H 1992; Smet, Moore et al. 
1997) and there is a significant increase in tachykinin immunoreactive fibers, which was not as a 
result of overall increases in nerve density, observed in animal models of chronic inflammation 
(Callsen-Cencic and Mense 1997). 
  
174 
 
Role in pathology 
A number of bladder symptoms have been linked with alterations in the tachykinin containing 
structures of the bladder. As mentioned above, changes in tachykinin related sensory neuron 
innervations have been observed in the sub-urothelium of patients with idiopathic detrusor 
overactivity (Moore K H 1992; Smet, Moore et al. 1997). Spinal cord injury induced hyperreflexia is 
significantly reduced by intravenous administration of an NK2 receptor antagonists (Abdel-Gawad, 
Dion et al. 2001; Abdel-Karim, Barthlow et al. 2005). Atherosclerosis induced ischemia has also been 
shown to significantly increase the frequency of spontaneous bladder contractions in vivo with a 
concurrent increase in NK2 receptor expression (Azadzoi, Radisavljevic et al. 2008) whilst electrical 
field stimulation (EFS)-induced smooth muscle contractions were significantly greater in the ischemic 
tissues and this was selectively reduced by an NK2 receptor antagonist (Azadzoi, Radisavljevic et al. 
2008). In a model of diabetic cystopathy, polypeptide inhibitors of TRPV1 decreased TRPV1 
dependent release of tachykinins from bladder afferents (Philyppov, Paduraru et al. 2012). CSPANS 
are symptom dependently upregulated in interstitial cystitis patients (Liu, Yang et al. 2014) as is NGF 
(Liu, Yang et al. 2014), which is also seen in OAB patients (Tyagi, Tyagi et al. 2013). There is a body of 
evidence which suggests that there is increased expression of tachykinins in response to NGF (Girard, 
Tompkins et al. 2012) and significantly heightened tachykinin CSPAN immunoreactivity following 
increased VEGF in the sub-urothelium (Saban, Davis et al. 2011), both known to increase during 
inflammation. Intravesical VEGF was also found to significantly reduce micturition pressure and 
inter-micturition interval (Malykhina, Lei et al. 2012) which could be related to changes in tachykinin 
immunoreactivity. In NGF overexpressing mice there was a marked increase in the density of CGRP- 
and substance P-positive C-fiber sensory afferents in the suburothelial nerve plexus which was 
accompanied by reduced urinary bladder capacity and increases in the number and amplitude of 
non-voiding bladder contractions (Schnegelsberg, Sun et al. 2010). 
These results provide a link by which inflammation can induce recruitment of CSPANS and an 
increase in bladder content of tachykinins, which are able to potentiate detrusor contraction at the 
periphery, and hyperexcitabilty in the spinal cord through autofeedback regulation of afferent 
terminals.     
The role of tachykinin neuropeptides in mediating responses to bladder irritation has also been 
investigated. The increased c-fos expression seen in spinal neurons following bladder irritation 
(Birder and de Groat 1992) is significantly attenuated with pretreatment with an NK2 antagonist 
(Kiss, Yoshiyama et al. 2001). Intravesical antigen infusion in ovalbumin sensitised guinea pigs 
induced abdominal licking, whilst pre-treatment with a desensitising dose of capsaicin abolished 
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intravesical antigen infusion behaviour (Ruggieri, Filer-Maerten et al. 2000), and an intra-peritoneal 
(IP) injection of NK1 and NK2 but not NK3 antagonists prior to infusion of antigen reduced antigen 
evoked behaviours.  
 
These results suggest there is not only modulation of the micturition reflex and afferent nerve 
activity by tachykinins in the periphery, but there is also a role for tachykinins in the production of 
physiological spinal mediated reflex actions and possibly the sensitisation of spinal afferents during 
spinal insult. Pharmacological research extending back over 25 years has established a complex 
picture of tachykinins in the bladder acting via multiple receptors and intracellular events in various 
cell types to initiate and modulate bladder contraction and so influence micturition. More recently, 
the focus has been on how these mechanisms might be influenced by pathophysiology and so 
contribute to bladder overactivity in patients with chronic inflammation, cystitis and idiopathic 
detrusor overactivity. There remain, however, a number of uncertainties in this area of research. The 
complex interaction between the sensory nerves that are a major source of tachykinins within the 
bladder, and the cellular environment that signal to, and receive signals from, these sensory nerves 
which express tachykinin receptors has thus far proved difficult to discern.  
In particular there is still very little evidence of a tachykinin role in normal bladder function, and the 
studies which have been conducted have failed to determine the precise role of tachykinins within 
the bladder. There has been little experimental differentiation between actions which could be a 
result of direct sensory afferent nerve input to the micturition pathways or alterations in 
mechanosensitivity second to urothelial and detrusor function. As such, it is still unknown if 
alterations in detrusor contraction are the trigger for micturition via release of tachykinins from 
afferent nerve terminals, or if tachykinins are able to directly act on the afferent nerves to stimulate 
reflex micturition.  
This thesis chapter will offer a new approach to the study of tachykinins within the mouse bladder 
and aims to address the paucity of recent functional evidence regarding peripheral regulation of 
tachykinin receptors and assesses the emergence of a sensory role for the urothelium in this process. 
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5.2 EXPERIMENTAL PROTOCOLS 
 
The main methodology is detailed in chapter 2. Here the emphasis is on the specific protocols that 
were employed to address the role of tachykinins in mediating bladder muscle contraction, 
afferent nerve activity, and urothelial receptor function.  
5.2.1 Intravesical pressure and afferent nerve recording.  
Bladder contraction 
In order to measure contractile responses of detrusor smooth muscle and corresponding afferent 
nerve activity, bladders were perfused intravesically with 0.9% saline to a maximum pressure of 
12mmHg. The syringe pump was stopped but the outflow tap remained closed, keeping a set volume 
within a moderately distended bladder. Distension was maintained to allow time for the bladder 
muscle to accommodate this volume (fig 2.4.1) and become stable. Stock solutions of NKA (10nM-
3µM), substance P (1nM-300nM), and the specific NK3 receptor agonist senktide (100pM – 300nM) 
and αβMe-ATP (30µM) in dH20 or DMSO were prepared and added as a 900µl aliquot to the 
experimental bath with a volume of 30ml of krebs buffer. In experiments in which multiple 
applications of agonist were applied in the same experiment, a washout period of 45minutes 
between each dose ensured receptors were not desensitised. 
NK2 antagonist GR159897 (stock @1mg/ml DMSO) (100nM) and Nifedipine (stock@50mg/ml) (1µM) 
were diluted in krebs and applied via the perfusion pump (5ml/min) to the experimental bath for 
30min prior to agonist application. 
 
Ramp distensions 
All ramp distensions in this study were performed at a rate of 30µl/min to a maximal pressure of 
30mmHg. Pilot experiments had established that these conditions were optimal to evoke sustained 
and reproducible detrusor contractions, which were a major focus of this study. As can be observed 
in fig 5.2.1, control distensions of 30µl/min produce reproducible responses to distension. 
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Intravesical administration of drugs  
For intravesical infusion of drugs, either control (0.9% saline + vehicle), NKA (300nM), senktide 
(300nM) or substance P (300nM) were infused into the bladder lumen via the syringe pump. The 
syringe pump provided constant infusion of drug or saline at 30µl/min with the outflow tap open to 
prevent bladder distension and in order to ensure that the full dose of the drug was present in the 
bladder during the following ramp distension. Agonists were infused immediately following bladder 
emptying from control distensions and for a minimum of 7 minutes, whilst antagonists were infused 
intravesically for at least 30minutes prior to, and during the addition of an agonist. 
Periods of control or agonist infusion without bladder distension were analysed for spontaneous 
baseline afferent discharge allowing for the dead space between the syringe pump and the bladder 
which was 120µl, and a latency of response of 4 minutes.    
 
Fig 5.2.1. Pressure/volume and pressure/nerve responses to three repeat distensions at 30µl/min 
prior to the start of an experiment. The compliance and afferent response to distension are 
reproducible.  
 
Extravesical administration of drugs 
Extravesical application of agonists/antagonists for examination of ramp distensions, either control 
(krebs +vehicle), NKA (300nM), senktide (300nM), substance P (300nM) or GR159897 (100nM) were 
applied via the perfusion pump to ensure a steady concentration of compound within the 
experimental bath without the need to stop perfusion during bladder distension.   
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5.2.2 Mediator release 
Mediator release experiments were performed with infusion set at 30µl/min and to a maximal 
pressure of 30mmHg to replicate the protocol for ramp distensions in this study. 
Basal samples of intraluminal contents were taken during a 7 minute infusion of vehicle/agonist 
@30µl/min with the outflow tap open to prevent bladder distension, the outflow tube was placed 
into a sterile Eppendorf tube placed on dry-ice to prevent post-hoc degradation of substrates. 
Immediately following ramp distensions, the syringe pump was stopped and the ending of the 
outflow tap was placed into a sterile Eppendorf tube placed in dry-ice to collect the intravesical 
contents whilst the bladder was left to empty passively.  
Intravesical contents from basal and distension (stretch) in control and drug treated preparations 
were assayed for ATP (Molecular Probes® A22066), ACh (Molecular Probes® A12217) and 
Prostaglandin E2 (Cayman Chemical® 514010) using commercially available kits. Mediator 
concentrations in test samples were calculated from a standard curve of known concentrations with 
blank values subtracted.   
 
5.2.3 qPCR 
qPCR experiments were performed as described in chapter 2. PMUCs were isolated from mice and 
cultured for 24hrs at 37°C. mRNA was harvested, converted to cDNA and RT-qPCR was performed 
using SYBR-Green fluorescence with the primers listed. 
Gene  Sequence ‘5-3’ Product  Position Tm Chromosome 
NK1 Forward GACACTTAGTCTGCCAAGAGC 193bp 3561-3753 58.7 6 
 Reverse CTCCACATGCTGGATAGAGC   57.8  
NK2 Forward GGATGGTGACATGGCTCAGC 117bp 1879-1995 61.1 10 
 Reverse GGACAGCTTGCAGACGTTGG   61.8  
NK3 Forward CCTCATTCTCCTAACCATGCC 205bp 1681-1885 58.1 3 
 Reverse CAGACACCGGATACTTAGAGC   57.6  
Table 5.2.1 Primer sequence, product size, gene loci, and Tm for purinergic receptors investigated in 
this study. 
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5.2.4 Calcium imaging 
The calcium imaging protocol is described in more detail in the major methods chapter.  
Calcium imaging was performed using an excitation wavelength of 510nm light and ratios were 
calculated from emissions at 350 and 380nm with background fluorescence deducted. NKA (stock 
@1mg/ml H2O) (300nM) and Ionomycin (stock @5mg/ml DMSO) (5µM) were diluted from stock into 
HEPES solution and applied using a gravity perfusion system at a rate of 1.5ml/min for 5 minutes. 
Data are represented as a ratio of fluorescent intensity (Rf) (350/380) and also as a percentage of 
Ionomycin fluorescence.  N = number of mice, n = number of cells.      
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5.3 CHARACTERISATION OF BLADDER RESPONSES TO 
EXTRALUMINAL TACHYKININ RECEPTOR AGONISTS  
 
In these experiments, the bladder is partially filled to a pressure of 12mmHg (as described in section 
5.2) in order to observe a rise in intravesical pressure.  
Bath application of the NK2 receptor agonist NKA elicited a concentration-dependent increase in 
intravesical pressure as a result of detrusor smooth muscle contraction, and a concomitant increase 
in afferent nerve firing (fig 5.3.1A). The contractile response consisted of a tonic increase in baseline 
pressure upon which phasic contractile activity was superimposed. The increase in afferent firing 
matched in both magnitude and timecourse the increase in intraluminal pressure. Indeed, on an 
expanding time base (fig 5.3.1B) the phasic increases in pressure and afferent discharge can be seen 
to be temporally linked.  
Bath application of substance P (300nM) and senktide (300nM), which act predominantly via NK1 
and NK3 receptors, also stimulated bladder contraction and a corresponding increase in afferent 
nerve activity but with a much reduced potency to that of NKA (fig 5.3.2). NKA (300nM) elicited 
contraction (6.9±0.7mmHg) and afferent nerve activity (78.1±15.5imp/s-1, n=6) significantly greater 
than that of sub p (300nM) (1.3±0.7mmHg, 4.0±1imp/s-1, p≤0.001 n=4) and senktide (300nM) 
(1.5±0.3mmHg, 12±2imp/s-1, p≤0.001, n=4, one-way ANOVA, Bonferroni multiple comparisons post 
hoc test). The NK2 receptor antagonist GR159897 (100nM) significantly attenuated NKA (300nM) 
induced detrusor muscle contraction (6.9±0.7 Vs 2.8±0.8mmHg, p≤0.001, n=4) and afferent nerve 
activity (53.0±11.5 imp/s-1,n=4, one-way ANOVA, Bonferroni multiple comparisons post hoc test, fig 
5.3.3). An example trace showing GR159897 antagonism of NKA induced muscle contraction and 
afferent activity can be seen in fig 5.3.4. Bursts of afferent nerve activity correlated with rhythmic 
detrusor contractions were partially conserved, but a significant component of the sustained 
pressure and afferent firing was blocked. Nifedipine (1μM) was also able to significantly attenuate 
NKA (300nM) induced peak afferent nerve activity (78.1±15.5 Vs 1.3±0.3imp/s-1, p≤0.001, n=6) and 
detrusor muscle contraction (6.9±0.7 Vs 0.81±0.08mmHg, p≤0.001, n=6, one-way ANOVA, 
Bonferroni multiple comparisons post-hoc test, fig 5.3.3). An experimental trace of NKA induced 
afferent nerve activity and detrusor smooth muscle contraction prior to, and following, incubation 
with nifedipine can be seen in fig 5.3.5. Nifedipine was able to completely abolish NKA induced 
nerve and muscle activity. It is evident, however, that baseline afferent activity remained suggesting 
that spontaneous activity is uncoupled from muscle contraction.  
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These data demonstrate that detrusor muscle contraction and afferent nerve responses within the 
mouse bladder are predominantly NK2 mediated and moreover that the detrusor contraction drives 
the augmentation in afferent discharge. It can be proposed therefore; that the actions of NKA are 
limited to the detrusor muscle and afferent nerve discharge from the bladder towards the CNS is a 
consequence of NK2 receptor mediated contraction only. In order to test this hypothesis, the ability 
of tachykinin agonists to influence detrusor smooth muscle and afferent nerve activity during 
bladder distension was further investigated.  
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Fig 5.3.1 A, Experimental trace of intravesical pressure in response to increasing concentrations of 
NKA (10nM-3µM) applied to the serosal surface of a whole bladder. B, Intravesical pressure and 
afferent nerve responses to NKA (300nM). The phasic bladder contractions and afferent nerve 
activity are temporally linked.  
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Fig 5.3.2 Mean±(SEM) peak afferent firing and intravesical pressure increase in response to 
tachykinin receptor agonists NKA (300nM, n=6), substance P (300nM, n=4), senktide (300nM, n=4), 
(***p≤0.001,  ###p≤0.001 compared to NKA). 
 
Fig 5.3.3 Mean±(SEM) peak afferent firing and intravesical pressure increase in response to NKA 
(300nM, n=6) in the presence and absence of nifedipine (1µM, n=6) and NK2 receptor antagonist 
GR159897 (100nM, n=4), (***p≤0.001,  ##p≤0.01, compared to NKA).  
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Fig 5.3.4 Experimental trace of NKA (300nM) induced afferent nerve activity (imp/s-1) and intravesical 
pressure (mmHg) prior to, and in the presence of the NK2 antagonist GR159897 (100nM). 
 
 
Fig 5.3.5 Experimental trace of NKA (300nM) induced afferent nerve activity (imp/s-1) and intravesical 
pressure (mmHg) prior to, and in the presence of the nifedipine (1µM).  
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5.4 THE EFFECTS OF EXTRALUMINAL TACHYKININ RECEPTOR 
AGONISTS ON AFFERENT NERVE AND DETRUSOR 
CONTRACTION DURING BLADDER DISTENSION 
 
As the bladder fills with saline there is a rise in intraluminal pressure and mechanosensitive afferent 
fibers in the bladder wall activate afferent nerves. The rise in pressure reflects the ability of the 
detrusor muscle to stretch in order to accommodate the increase in volume and gives rise to a 
pressure/volume curve that is an indication of bladder compliance. By examining the effect of 
tachykinin agonists on the pressure/volume relationship and corresponding changes in the 
stimulus/response function of the bladder afferents it is possible to determine the relative effect of 
the various tachykinin receptors on afferent and detrusor activity during bladder distension. All 
compliance curves and nerve/pressure relationships are analysed by two-way ANOVA with 
Bonferroni multiple comparisons post-hoc test.  
With the bladder empty and draining freely extraluminal application of the NK1 receptor agonist 
substance P (300nM) had no immediate effect on afferent discharge. In addition, in the continued 
presence of substance P the response to ramp distension was unchanged. Therefore, there was no 
significant effect on the pressure/volume response profile (p≥0.05, n=6, fig 5.4.2). Moreover, the 
increase in afferent nerve activity that accompanied the increase in intravesical pressure was also 
not significantly different during bladder distension (p≥0.05, n=6, fig 5.4.3). These results show that 
substance P has no significant effect on either muscle compliance or the pressure/nerve response to 
bladder distension. From these results it can be concluded that substance P (and therefore the NK1 
receptor) has no influence on mouse bladder distension responses. 
The same parameters were examined with extraluminal incubation with the NK3 receptor agonist 
senktide (300nM). Senktide (300nM) had no significant effect on muscle compliance (p≥0.05, n=6, fig 
5.4.6), nor afferent nerve discharge in response to bladder distension (p≥0.05, n=6, fig 5.4.7). From 
these results it can be concluded that senktide (and therefore the NK3 receptor) has no influence on 
mouse bladder distension responses. 
In contrast to the NK1 and NK3 receptor agonists, extraluminal incubation with the NK2 receptor 
agonist NKA (300nM) mediates a significant decrease in the compliance of the muscle over the time 
course of bladder distension (p≤0.01, n=6, fig 5.4.9) which was more apparent at low pressures. 
Despite an NKA induced change in detrusor compliance, bath applied NKA (300nM) had no 
significant effect on pressure/nerve relationship during bladder distension (p≥0.05, n=6, fig 5.4.11). 
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The change in detrusor muscle compliance can be seen in the experimental trace of fig 5.4.8. Further 
investigation of the role of the NK2 receptor in bladder compliance showed that bath applied 
incubation with the NK2 receptor antagonist GR159897 (100nM) significantly increases bladder 
compliance over the time course of bladder distension (p≤0.001, n=5, Fig 5.4.10), with the effects 
again occurring at lower bladder pressures. Bath applied GR159897 (100nM) was also able to 
antagonise the actions of NKA (30nM) on compliance confirming an NK2 receptor interaction.  
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Extravesical Substance P 
Fig 5.4.1 Experimental trace showing intravesical pressure (mmHg) and afferent nerve (imp/s¯¹) 
responses to bladder distension prior to, and during substance P (300nM) incubation. 
 
 
Fig 5.4.2 Mean±(SEM) pressure/volume relationship within the bladder when distended with saline at 
a rate of 30µl/min in the presence of extaluminal substance P (300nM), (n=6). 
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Fig 5.4.3 Mean±(SEM) pressure/nerve relationship within the bladder when distended with saline at 
a rate of 30µl/min in the presence of extraluminal substance P (300nM), (n=6). 
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Extravesical Senktide  
 
Fig 5.4.5 Experimental trace showing intravesical pressure (mmHg) and afferent nerve (imp/s¯¹) 
responses to bladder distension prior to, and during senktide (300nM) incubation. 
 
 
Fig 5.4.6 Mean±(SEM) pressure/volume relationship within the bladder when distended with saline at 
a rate of 30µl/min in the presence of extraluminal senktide (300nM), (n=6).  
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Fig 5.4.7 Mean±(SEM) pressure/nerve relationship within the bladder when distended with saline at 
a rate of 30µl/min in the presence of extraluminal senktide (300nM), (n=6). 
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Extravesical NKA 
 
Fig 5.4.8 Experimental trace showing intravesical pressure (mmHg) and afferent nerve (imp/s¯¹) 
responses to bladder distension prior to, and during NKA (300nM) incubation. There is no observed 
contraction due to the initial addition of NKA (300nM) to the bath, as the outflow tap is open and 
there is no pressure inside the bladder.   
 
 
Fig 5.4.9 Mean±(SEM) pressure/volume relationship within the bladder when distended with saline at 
a rate of 30µl/min in the presence of extraluminal NKA (300nM), (**p≤0.01, n=6). 
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Fig 5.4.10 Mean±(SEM) pressure/volume relationship within the bladder when distended with saline 
at a rate of 30µl/min in the presence of extraluminal GR159897 (100nM, n=5) or GR159897 (100nM) 
+ NKA (300nM, n=5), (***p≤0.001 GR159897 Vs control).  
 
 
Fig 5.4.11 Mean(±SEM) pressure/nerve relationship within the bladder when distended with saline at 
a rate of 30µl/min in the presence of extraluminal GR159897 (100nM, n=5) or NKA (300nM, n=6). 
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5.5 NKA INDUCED EFFECTS ON PURINERGIC ACTIVATION 
 
ATP is released from the urothelium during stretch and is hypothesised to mediate bladder 
mechanotransduction via purinoceptors on afferent nerves. To investigate the ability of the 
tachykinin NK2 receptor to modulate purinergic mediated afferent nerve activity in the mouse 
bladder, the effect of extraluminally incubated NKA was investigated on purinergic evoked detrusor 
contraction and afferent nerve activity. A concentration of NKA was chosen (1nM) for which no 
contraction of the smooth muscle occurred.      
Bath application of the purinergic agonist αβMe-ATP (30µM) causes a significant increase in afferent 
nerve activity and concurrent detrusor smooth muscle contraction (fig 5.5.1) which is characterised 
by an initial sharp increase in afferent nerve activity which returns to baseline over 2-3 minutes. 
Application of a sub-contraction threshold dose of NKA (1nM) has no effect on αβMe-ATP (30µM) 
induced afferent firing (p≥0.05, n=6, Fig 5.5.2) but significantly increases the magnitude of detrusor 
smooth muscle contraction throughout the time course of the response (p≤0.01, n=6, two-way 
ANOVA Bonferroni multiple comparisons post-hoc test, fig 5.5.3). A significant potentiation of the 
maximal contraction response to αβMe-ATP is seen with NKA (1nM) (14.5±1.9 Vs 18.0±1.5mmHg, 
p≤0.05, n=6) which is blocked by the NK2 antagonist GR159897 (100nM) (14.5±1.9 Vs 
16.2±0.9mmHg, p≥0.05, n=6, one-way ANOVA, Bonferroni multiple comparisons post-hoc test, fig 
5.5.4). 
These results indicate that although a sub-contraction concentration of NKA is unable to modulate 
afferent nerve responses to αβMe-ATP, and thus is unlikely to influence the indirect component of 
mechanotransduction via urothelial ATP release, there is a mechanism whereby activation of the 
NK2 receptor is able to mediate the purinergic component of detrusor contraction which becomes 
increasingly important during lower urinary tract disorders.  
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Fig 5.5.1 Example trace of αβMe-ATP (30µM) induced afferent nerve activity and detrusor smooth 
muscle contraction in the presence and absence of a sub-contraction concentration of NKA (1nM). 
These experiments were performed in a bladder predistended to 12mmHg in order to accurately 
measure contraction responses.   
 
 
Fig 5.5.2 Mean±(SEM) afferent nerve activity in response to αβMe-ATP (30µM) in the absence and 
presence on NKA (1nM), (n=6). 
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Fig 5.5.3 Mean±(SEM) intravesical pressure in response to αβMe- ATP (30µM) in the absence and 
presence on NKA (1nM), (**p≤0.001, n=6). 
 
 
Fig 5.5.4 Mean±(SEM) peak intravesical pressure  in response to αβMe-ATP (30µM, n=6) in the 
presence of NKA (1nM), (p≤0.05 Vs control, n=6), and NKA (1nM) + GR159897 (100nM).  
 
 
 
 
 
  
196 
 
5.6 THE EFFECTS OF INTRAVESICAL TACHYKININ RECEPTOR 
AGONISTS ON DETRUSOR SMOOTH MUSCLE AND AFFERENT 
NERVE ACTIVITY 
 
The previous sub-sections concentrated on the extra luminal application of tachykinin agonists. 
Under these circumstances the agonists will have access to cellular targets throughout the bladder 
wall. As such, direct effects on the muscle wall may overwhelm any modulating influence following 
actions at the level of the urothelium. Therefore, in order to investigate the ability of the urothelium 
to respond to tachykinin receptor agonists and their ability to influence detrusor smooth muscle 
compliance and afferent nerve activity, tachykinin receptor agonists were perfused intraluminally 
into the bladder in the following experiments. All compliance curves and nerve/pressure 
relationships are analysed by two-way ANOVA with Bonferroni multiple comparisons post-hoc test. 
Similar to extraluminal application, intravesical instillation of substance P (300nM) had no significant 
effect on detrusor smooth muscle compliance (p≥0.05, n=5, fig 5.6.2) throughout the time course of 
bladder distension. There was also no significant effect of substance P (300nM) on the 
pressure/nerve response during the time course of bladder distension (p≥0.05, n=5, fig 5.6.3).  
Likewise, intravesical instillation of senktide (300nM) had no significant effect on the compliance of 
detrusor smooth muscle (p≥0.05, n=5, fig 5.6.5) throughout the time course of bladder distension. 
Intravesical perfusion of senktide (300nM) also had no significant effect on the distension evoked 
pressure/nerve relationship (p≥0.05, n=5, fig 5.6.6).  
In contrast, intravesical perfusion of NKA (300nM) significantly decreased the compliance of the 
detrusor smooth muscle to an increases in intravesical volume throughout the time course of 
bladder distension when compared to control (p≤0.0001, n=6, fig 5.6.7). Intravesical perfusion of the 
NK2 receptor antagonist GR159897 (100nM) alone had no significant effect on bladder compliance 
during bladder distension (p≥0.05, n=6), however, GR159897 (100nM) was able to reverse NKA 
(300nM) induced decreases in bladder compliance (p≥0.05, n=6, fig 5.6.8). 
Analysis of afferent nerve firing showed intravesical perfusion of NKA (300nM) has no significant 
effect on the pressure/nerve relationship during bladder distension (p≥0.05, n=6, fig 5.6.9). 
Intravesical perfusion of either GR159897 (100nM) alone, or GR159897 + NKA (300nM) were also 
without effect on the pressure nerve response during bladder distension (p≥0.05, n=6, 5.6.10). The 
analysis of the pressure/nerve relationship during distension provides essential information 
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regarding the overall state of the bladder, however as fig 5.7.1 shows, this type of analyses masks 
subtle differences when considering afferent nerve firing in response to intravesical NKA and the 
next subsection will delve deeper into the analysis concerned with this.  
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Intravesical Sub P 
 
Fig 5.6.1 Experimental trace showing intravesical pressure (mmHg) and afferent nerve (imp/s¯¹) 
responses to bladder distension prior to, and during intraluminal perfusion with substance P (300nM). 
 
 
 
Fig 5.6.2 Mean±(SEM) pressure/volume relationship of the bladder when distended with either saline 
or substance P (300nM) at a rate of 30µl/min, (n=5). 
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Fig 5.6.3 Mean±(SEM) pressure/nerve relationship within the bladder when distended with either 
saline or substance P (300nM) at a rate of 30µl/min, (n=5). 
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Intravesical Senktide
 
Fig 5.6.4 Experimental trace showing intravesical pressure (mmHg) and afferent nerve (imp/s¯¹) 
responses to bladder distension prior to, and during intraluminal perfusion with senktide (300nM). 
 
 
Fig 5.6.5 Mean±(SEM) pressure/volume relationship of the bladder when distended with either saline 
or senktide (300nM) at a rate of 30µl/min, (n=5). 
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Fig 5.6.6 Mean±(SEM) pressure/nerve relationship within the bladder when distended with either 
saline or senktide (300nM) at a rate of 30µl/min, (n=5). 
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Intravesical NKA 
 
Fig 5.6.7 Mean±(SEM) pressure/volume relationship of the bladder when distended with either saline 
or NKA (300nM, n=6) at a rate of 30µl/min, (****p≤0.0001 Vs Control)  
 
        
Fig 5.6.8 Mean±(SEM) pressure/volume relationship of the bladder when distended with either saline 
or the NK2 antagonist GR159897 (100nM, n=6) or NKA (300nM + GR159897 100nM, n=6) at a rate of 
30µl/min. 
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Fig 5.6.9 Mean±(SEM) pressure/nerve relationship within the bladder when distended with either 
saline or NKA (300nM, n=6) at a rate of 30µl/min. 
                    
 
Fig 5.6.10 Mean±(SEM) pressure/nerve relationship within the bladder when distended with either 
saline, GR159897 (100nM, n=6), or GR159897 + NKA (300nM, n=6) at a rate of 30µl/min. 
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5.7 NKA INDUCED SPONTANEOUS DETRUSOR ACTIVITY 
 
There is a degree of phasic detrusor muscle contraction during normal bladder distension which is of 
low frequency and amplitude. Accompanying these spontaneous detrusor contractions are bursts of 
afferent nerve activity. The pattern of contractile activity and associated afferent discharge were 
significantly altered with the intraluminal perfusion of NKA (300nM, fig 5.7.1). Since these changes 
occur at physiological levels of distension it is feasible that this could impact on sensory 
mechanotransduction within the bladder.  
Intravesical instillation of substance P (300nM) and senktide (300nM) had no significant effect on the 
amplitude or frequency of distension induced spontaneous detrusor contractions compared to 
control (p≥0.05, n=5, fig 5.7.2, 5.7.3). In contrast intravesical instillation of NKA (300nM, n=6) caused 
a significant increase in the amplitude (0.9±0.1 Vs 2.2±0.4mmHg, p≤0.001, n=6) and frequency 
(6.2±1 Vs 22.2±3.7/distension, p≤0.001, n=6, one-way ANOVA, Dunnett’s multiple comparisons post-
hoc test) of spontaneous contractions, which were abolished with prior instillation of GR159897 
(100nM). An experimental trace showing detrusor contractions and bursts of afferent nerve activity 
can be seen in fig 5.7.4 and fig 5.7.5. 
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Fig 5.7.1 Example trace of intraluminal NKA (300nM) induced phasic detrusor contractions with 
accompanying afferent nerve activity during bladder distension. 
  
Fig 5.7.2 Mean±(SEM) amplitude of contractions (mmHg) evoked by bladder distension with 
intravesical substance P (300nM, n=5), senktide (300nM, n=5), NKA (300nM, n=6) and the 
interactions of GR159897 (100nM, n=6), (***p≤0.001 Vs control). 
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Fig 5.7.3 Mean±(SEM) frequency (contractions/distension) of spontaneous contractions elicited by 
bladder distension with intravesical substance P (300nM, n=5), senktide (300nM, n=5), NKA (300nM, 
n=6) and the interactions of GR159897 (100nM, n=6), (***p≤0.001 Vs control). 
 
Fig 5.7.4 Experimental trace showing spontaneous detrusor contractions and accompanying afferent 
nerve activity during bladder distension with intraluminal NKA (300nM).  
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Fig 5.7.5 Spontaneous detrusor contractions and associated afferent nerve activity during bladder 
distension with intraluminal NKA (300nM). Zoom of fig 6.7.4.  
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5.8 SPONTANEOUS AFFERENT ACTIVITY OF THE BLADDER IN 
RESPONSE TO INTRALUMINAL TACHYKININS 
 
In order to investigate the relationship between intraluminal instillation of tachykinins and afferent 
firing with no effect from detrusor contraction, tachykinins were instilled in the bladder lumen and 
the spontaneous afferent discharge was observed.  
Intravesical perfusion of tachykinin agonists substance P (300nM), senktide (300nM), and NKA 
(300nM) had no significant effect on spontaneous afferent activity although there was a trend 
towards an increase with NKA which did not reach statistical significance (fig 5.8.2). The 
experimental trace in fig 5.8.1 shows examples of the relationship between the raw nerve activity 
and the rate histogram of afferent nerve activity imp/s¯¹. No observable differences can be seen.   
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Fig 5.8.1 Experimental traces representing the effects of intravesical instillation of tachykinin 
agonists senktide (300nM), substance P (300nM) and NKA (300nM) on baseline spontaneous 
afferent activity. For each, the upper trace is a rate histogram of nerve activity (imp/s-1) and below is 
the raw nerve activity. 
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Fig 5.8.2 Mean±(SEM) average baseline spontaneous afferent activity recorded over 100s before, and 
following intravesical instillation of tachykinin agonists substance p (300nM, n=5), senktide (300nM, 
n=5), and NKA (300nM, n=6). 
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5.9 NKA INDUCED EFFECTS ON THE UROTHELIUM 
 
The results above indicate that intravesical NKA is able to induce changes in bladder 
mechanosensitivity secondary to changes in detrusor smooth muscle function. It was also found that 
there was no significant effect of intravesical tachykinins on afferent nerve discharge. Thus, there is 
potential for the effects of intravesical NKA to be mediated by a direct effect on the urothelium. For 
this to occur, tachykinin receptors must be present within the urothelial cell layers.  
Quantification of tachykinin receptor mRNA was performed on primary mouse urothelial cells 
(PMUCs) and results are expressed relative to β-actin. Urothelial cells expressed all three of the 
known tachykinin receptors (fig 5.9.1). There was relatively equal expression of both NK1 and NK2 
receptor mRNA, and an approximately two-fold greater expression of NK3 receptor mRNA.  
Identification of the mRNA coding for the tachykinin receptors, together with prior experiments 
showing the ability of intravesically instilled NKA to significantly alter normal bladder function led to 
the proposal that urothelial cells were able to respond directly to NKA. This was investigated by 
examining the ability of NKA to alter mediator release from PMUCs.  
ATP, ACh, and prostaglandin E2 were released into the lumen of the bladder at rest, and in the case 
of ATP, significantly higher amounts were released following bladder distension (fig 5.9.3) (2.3±0.3 
Vs 6.2±1.5nM, p≤0.01, n=6). NKA (300nM) had no significant effect on either basal (2.3±0.3 Vs 
2.1±0.3nM), nor stretch induced (6.2±1.5 Vs 5.8±1.1nM) ATP release (p≥0.05, n=6). Similarly, 
intravesical perfusion of NKA (300nM) had no significant effect on either basal (327±111 Vs 
229±72nM, p≥0.05, n=6), or distension induced (355±129 Vs 247±77nM, p≥0.05, n=6)    
prostaglandin E2 release (fig 5.9.5). However, in contrast, intravesical perfusion of NKA (300nM) 
significantly reduced ACh release at rest (0.33±0.08 Vs 0.07±0.03µM, p≤0.01, n=6), and during 
bladder distension (0.44±0.08 Vs 0.18±0.02µM, one-way ANOVA, Bonferroni multiple comparisons 
post-hoc test, fig 5.9.4)  
This data implies that NKA, acting through NK2 receptors on urothelial cells is able to attenuate the 
release of ACh. To examine this further, calcium imaging experiments were performed on PMUCs. 
Application of NKA (300nM) to PMUCs caused a small but significant rise in intracellular calcium 
levels as reflected by an increase in fluorescent emissions over the course of sustained application 
(fig 5.9.6). The intracellular calcium response to NKA (300nM) was characterised by a slow increase 
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over the course of the response which did not return to baseline until washout. This effect was 
repeatable following wash-out of the agonist. 
NKA (300nM) elicits a significant increase in intracellular calcium equal to 15.6±0.9% of maximal 
Ionomycin (5µM) response (Fig 5.9.7). This is equivalent to 61.7% of the maximum response to 
100µM ATP. 
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Fig 5.9.1 Mean±(SEM) expression  of tachykinin receptor mRNA relative to β-actin (ΔCT/CT) in PMUCs 
(n=3). 
 
 
 
Fig 5.9.2 Gel-electrophoresis of tachykinin receptor mRNA expression in PMUCs following qPCR. All 
three tachykinin receptors expressed a band at the appropriate product size. 
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Fig 5.9.3 Mean±(SEM) intraluminal ATP release from bladders at rest and at a maximum distension 
of 30mmHg with either saline or NKA (300nM), (**p≤0.01 Vs basal, n=6). 
 
Fig 5.9.4 Mean±(SEM) intraluminal acetylcholine release from bladders at rest and at a maximum 
distension of 30mmHg with either saline or NKA (300nM), (**p≤0.01 Vs control, n=6). 
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Fig 5.9.5 Mean±(SEM) intraluminal prostaglandin E2 release from bladders at rest and at a maximum 
distension of 30mmHg with either saline (n=6) or NKA (300nM, n=6).  
 
 
 
Fig 5.9.6 Mean±(SEM) change in intracellular calcium levels of PMUCs to NKA (300nM, N=3, n-61).  
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Fig 5.9.7 Mean±(SEM) peak increase in intracellular calcium of PMUCs following application of NKA 
(300nM, N=3, n=61) and ATP (100µM, N=6, n=124). 
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5.10 DISCUSSION 
 
Tachykinin effects on detrusor smooth muscle and afferent firing 
The first experiments conducted in this chapter were performed in order to determine the effect of 
tachykinins on detrusor smooth muscle contractions. Tachykinin agonists were chosen to identify 
the relative contribution of different tachykinin receptors to the response. Application of the NK2 
receptor agonist NKA caused a significant increase in detrusor smooth muscle contraction which was 
characterised by a fast tonic component, followed by a slower phasic contraction component. These 
results are consistent with a large body of evidence stretching back 3 decades showing NK2-
mediated effects on bladder contraction. NK2 receptors have been shown to be responsible for 
detrusor contraction in a number of species including hamster, rabbit, guinea pig, sheep, dog, pig 
and human (Longmore and Hill 1992; Giuliani, Patacchini et al. 1993; Guard, Pain et al. 1993; Burcher, 
Zeng et al. 2000; Rizzo and Hey 2000; Tucci, Bolle et al. 2001; Templeman, Sellers et al. 2003). The 
NK3 receptor agonist senktide had very little effect on detrusor contraction in these experiments 
and this is reflected in the literature, with NK3 receptors primarily confined to central mechanisms. 
Many other rodent studies, particularly in rat and guinea pig have shown an NK1 receptor 
component of detrusor contraction which is seen with both exogenous application of tachykinin 
agonists (Hall, Flowers et al. 1992; Longmore and Hill 1992) and with antagonism of NK1 receptors 
following capsaicin induced release of endogenous tachykinins from CSPANS (Maggi, Patacchini et al. 
1991; Lecci, Giuliani et al. 1997). However, while substance P and senktide had small effects on 
contraction, this was significantly less than that seen with NKA. This could be due to either a lower 
affinity of these agonists at the NK2 receptor or a small contribution of NK1 and NK3 receptors to 
bladder contractile activity. To distinguish between these two possibilities would require a complete 
pharmacological assessment which was not the priority of the project. Confirming the role of the 
NK2 receptor in detrusor contraction, the selective NK2 antagonist GR159897 significantly 
attenuated NKA evoked contractions. The results observed suggest that, as with human and many 
other species, tachykinin induced contraction of detrusor smooth muscle in the mouse is mediated 
primarily by the NK2 receptor and provide evidence that a mouse model shares similarity to the 
human. NK2 receptor mediated detrusor muscle contractions were abolished by application of the L-
type calcium channel blocker nifedipine. The sensitivity of the NK2 receptor mediated contractile 
response to nifedipine is consistent with Maggi et al’s original findings in 1989. The dependence of 
detrusor smooth muscle on calcium induced calcium release from intracellular stores is well 
established (Quinn, Collins et al. 2004). Other groups have suggested a role for NK2 receptor 
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mediated IP3 formation which may act upstream of calcium entry (Torrens, Beaujouan et al. 1995; 
Martin, Wheeler et al. 1997).  
In association with tachykinin receptor mediated detrusor contraction, there was a significant 
increase in afferent sensory firing, consistent with the hypothesis that tachykinins are able to 
mediate both ‘efferent’ effects and afferent effects. It has been shown that stimulation of NK2 
receptors is able to initiate micturition and the experiments in this thesis went further to investigate 
the effects of NKA mediated afferent nerve activity. It was found that bath application of NKA to a 
predistended bladder caused a significant increase in afferent nerve activity. Substance P and 
senktide were also able to stimulate a significant increase in afferent nerve firing but this was, as 
with detrusor contraction, significantly smaller than that of NKA. The ability of NKA to directly 
stimulate afferent nerves was further explored with the use of nifedipine. As mentioned above, 
nifedipine blocked NKA induced detrusor contraction, and this was accompanied by a complete 
abolishment of NKA induced afferent nerve firing which suggests that the afferent response to NKA 
is related to activation of mechanosensitive endings secondary to detrusor contraction. Only the role 
of the NK2 receptor was tested in this manner, but there was a consistent coordination with 
contraction and afferent activity with NK1 and NK3 receptor agonists substance P and senktide. 
Previous studies have shown that tachykinin receptors, including NK1 and NK2 are able to mediate 
the excitability of DRG neurons including an increase in calcium currents and action potential 
threshold to various stimuli, (Sculptoreanu and de Groat 2007), and also an enhancement of 
capsaicin evoked currents (Zhang, Cang et al. 2007; Sculptoreanu, Artim et al. 2009). Activation of 
NK1, NK2, and NK3, receptors however, have also been shown to induce inward currents in rat DRG 
neurons and the lack of response seen in the whole bladder is somewhat of a mystery. (Yang, Yao et 
al. 2003) 
As tachykinin receptors have been shown to mediate DRG neuron excitability, it was hypothesised 
that tachykinins may also be able to mediate the afferent nerves responsible for mechanosensitivity 
in the bladder which may be key to the contribution of tachykinins in stimulating micturition in a 
number of studies. To test this hypothesis, bath applied agonists were used to examine the role of 
tachykinins in the afferent nerve response to mechanical distension through bladder ramp 
distension and the actions of ATP on bladder afferents.  
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The effects of extraluminal tachykinin receptor agonists on bladder mechanosensitivity 
It was necessary to further investigate the contribution of NK1, NK2 and NK3 receptor mechanisms 
on the interaction between detrusor muscle tone and afferent signalling by determining the effect of 
tachykinin agonists on the response to ramp distension, designed to mimic the effect of normal 
bladder filling. 
Applied extraluminally, the NK3 receptor agonist senktide failed to modify either bladder compliance, 
as revealed from the pressure/volume relationship, or the afferent response to distension. Senktide 
has been previously shown to cause muscle contraction (Lecci and Maggi 2001), however, as 
described above, the small but significant effect of senktide in our own studies could have been via a 
non-NK3 receptor mechanism. Similarly, Lecci et al (2001) failed to determine if the response was 
mediated via actions on other tachykinin receptors. It is worth noting that Lecci et al found the 
contraction responses to senktide showed rapid desensitization. It remains possible that any effect 
of senktide in my studies could have been masked by receptor desensitisation, especially with the 
current perfusion protocol employed in which agonist concentration would rise gradually. 
Nonetheless, considering that senktide only initiated a small contraction and corresponding afferent 
response with a high concentration bolus dose in a predistended bladder, it is unlikely that the 
outcomes of these experiments would have been different if bolus doses were applied during ramp 
distension.  
Substance P applied to the serosal side of the bladder preparation had no effect on either the 
compliance of the smooth muscle or afferent nerve discharge.  These data support the concept that 
substance P does not play a significant role in mediating detrusor smooth muscle contraction in the 
mouse bladder. This is in contrast to other rodent models, including rat and guinea pig (Hall, Flowers 
et al. 1992; Longmore and Hill 1992) which have been shown to respond to NK1 agonists. However, 
these studies were fundamentally different, utilizing either isolated muscle strips (enabling the 
agonist to bind to all the layers of the bladder), or were applied intravenously/intraarterially in vivo, 
and via the vascular system, have access to the entire bladder.  It is possible that other cells, possibly 
interstitial cells mediated NK1 agonist induced detrusor contraction in these studies.  
In contrast to the lack of actions of bath applied substance P and senktide, NKA significantly 
decreased the compliance of the smooth muscle over the time course of the ramp distension. The 
increase in pressure at an equivalent volume is indicative of increased detrusor smooth muscle tone. 
This is consistent with the alterations in micturition patterns seen in a number of studies (Kibble 
1996; Shaker, Tu et al. 1998) which were attributed to tachykinin actions. This is also consistent with 
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our finding that a bolus dose of NKA was able to cause significant contraction of the detrusor. What 
is noticeable though is that the sensory nerve discharge in response to ramp distension was not 
altered relative to the distension pressure, despite being achieved at lower volume. Furthermore, 
the afferent response to distension was not significantly changed following instillation of the NK2 
receptor antagonist GR159897, again providing evidence that the NK2 receptor, and indeed the NK1 
and NK3 receptors are not essential in normal peripheral sensation of bladder volume. Previous 
evidence has shown that it is possible to increase mechanosensitivity to distension via systemic 
application of tachykinins in vivo (Kibble 1996) and that that antagonism of the NK2 receptor 
reduced mechanosensitivity (Kibble 1996). However, in such circumstances it is possible that the 
tachykinin under investigation may have had a sensitising effect on central micturition processes 
independent of a direct peripheral role on bladder sensory afferents. This is suggested by 
experiments that show there is a central action of tachykinins in the spinal cord which are able to 
modulate the micturition reflex (Mersdorf, Schmidt et al. 1992; Ishizuka, Igawa et al. 1994; Lecci, 
Giuliani et al. 1994; Lecci and Maggi 2001) via sympathetic and parasympathetic outflow. There is 
some evidence however, that NKA is able to sensitise calcium channels in peripheral sensory 
neurons (Sculptoreanu and de Groat 2003), as well as enhancing excitability in capsaicin-responsive 
DRG neurons (Sculptoreanu and de Groat 2007). In this respect it is perhaps surprising that 
exogenous NKA did not potentiate the mechanosensitive peripheral sensory neurons in the current 
study. However, these studies on isolated DRG neurons did not select on the basis of bladder 
projection, nor were they able to assess the impact on mechanosensitive ion channels and thus 
interpretation is difficult based on the current observations.   
The NKA induced decrease in bladder compliance was completely attenuated by GR159897 which, 
when applied alone, also significantly increased bladder compliance in normal ramp distensions. 
These results suggest that there is a basal bladder tone during distension, and that endogenous 
tachykinins acting through NK2 receptors could contribute to this, either directly at the level of the 
muscle, or a possible secondary mechanism via the urothelium or interstitial cells. This is supported 
by a previous study showing that an NK2 antagonist was able to cause relaxation of the basal muscle 
tone following distension to a set volume (Lecci, Giuliani et al. 1998) and indirectly via depletion of 
neuropeptides (Lasanen, Tammela et al. 1992). It is possible that during bladder distension, 
mechanosensitive afferents innervating the detrusor smooth muscle are stimulated to release 
neuropeptides such as NKA, which are in turn able to act on the muscle (Morrison 1999). The 
difference in the compliance curve was evident by the time the bladder pressure had reached 10-
15mmHg which represents a physiological level of distension during the more compliant part of the 
pressure/volume curve. This would imply that low threshold afferents are activated at this stage and 
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not higher threshold nociceptive fibers, contradicting the general view that the neuropeptide 
containing C-fiber afferents are activated only at high threshold. However, in rats, greater than 70% 
of bladder DRG neurons appear to contain multiple neuropeptides (Fowler, Griffiths et al. 2008). In 
the rat there is also a greater proportion of unmyelinated C-fiber (TRPV1 expressing) bladder 
afferents than Aδ-fiber afferents (Vera and Nadelhaft 1990; Andersson 2002), and these fibers have 
been shown to respond to slow distension (Morrison 1999) as well as low bladder pressures (Fowler, 
Griffiths et al. 2008).  
It is hard to interpret a direct role of tachykinins on mechanosensitivity from these results because 
not only are stretch sensitive afferents activated by the process of bladder distension but tachykinins 
are also able to induce a direct bladder contraction and a change in compliance, and this can make 
interpretation of the cause of these responses difficult.  
The concept of NKA induced potentiation of afferent nerve activity and detrusor smooth muscle 
contraction was tested further by examining the interaction with ATP. These experiments examined 
P2X sensitive afferents, which have been proposed to be important in mechanosensation of the 
bladder via urothelial release of ATP (Vlaskovska, Kasakov et al. 2001; Cockayne, Dunn et al. 2005). 
αβMe-ATP induced afferent firing was unchanged by a sub-threshold dose of NKA, suggesting that 
low doses of NKA are not able to sensitise afferent nerves to purinergic stimulation. However, the 
purinergic component of detrusor contraction was significantly potentiated. The mechanism 
underlying this potentiation is unclear but liberation of intracellular calcium and sensitisation of 
second messenger pathways is a possibility. This theory is in part supported by experiments in which 
there was an increase in ATP induced calcium mobilisation in detrusor smooth muscle from aged 
animals, associated with an enhanced purinergic mediated contractions (Gomez-Pinilla, Pozo et al. 
2011). In theory these cellular modifications could occur as a result of increased tachykinin release 
from CSPANS. It is also proposed that a subthreshold dose of NKA mimics the enhancement of 
tachykinin immunoreactivity seen in disease/inflammation (Moore K H 1992; Callsen-Cencic and 
Mense 1997; Smet, Moore et al. 1997; Schnegelsberg, Sun et al. 2010), and considered responsible 
for the increase in the atropine insensitive component of detrusor contraction observed in humans 
with bladder pathologies (Yoshida, Homma et al. 2001). This theory is consistent with an ‘efferent’ 
function of tachykinins, and an upregulation of tachykinin sensitive nerves in animal models of 
chronic inflammation and idiopathic detrusor overactivity in humans (Moore K H 1992; Callsen-
Cencic and Mense 1997; Smet, Moore et al. 1997). There have been no previous studies examining 
the specific effect of tachykinins on the purinergic component of contraction but EFS studies have 
generally concluded that although tachykinins may have a role in the NANC component of 
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contraction, it is not associated with the purinergic component (Meini and Maggi 1994; Azadzoi, 
Radisavljevic et al. 2008). However, the focus of these studies was antagonism of contraction rather 
than its potentiation.  
 
The effects of Intravesical tachykinin receptor agonists on detrusor smooth muscle and afferent 
nerve activity 
As alluded to above, application of tachykinin agonists to the serosal side of the bladder and the 
effects it may have on mechanosensitivity may be masked by contraction of the detrusor by direct 
actions of NK2 receptors. In order to try and remove the direct detrusor contraction component, 
tachykinins were also applied intravesically as this approach has previously been able to stimulate 
micturition reflexes. 
Neither intravesical senktide nor substance P had any effect on either detrusor smooth muscle 
compliance, or afferent nerve discharge. These results are consistent with previous experiments in 
rats which failed to identify a response to NKB (Ishizuka, Mattiasson et al. 1995). It is interesting 
however, that substance P failed to stimulate changes in compliance or afferent nerve activity. These 
results add to the increasing evidence that the NK1 receptor is not essential for mediating the 
peripheral tachykinin responses in the bladder and that NK1 receptors on sub-urothelial afferent 
nerves are not activated by intravesical substance P. Intravesical instillation of substance P in rats 
failed to stimulate micturition (Ishizuka, Mattiasson et al. 1995) corroborating the current results.  
Intravesical perfusion of the NK2 receptor agonist NKA induced a significant decrease in smooth 
muscle compliance which was blocked by GR159897, with the bladder exhibiting significant 
increases in intravesical pressure at much lower volumes, yet the afferent nerve response to 
distension remained unchanged. Although there was no overall variation in afferent nerve activity in 
relation to an increase in intravesical pressure, a significant change in transient afferent nerve 
activity was observed with a potentiation of phasic detrusor contractions during distension. 
A maximal pressure of 30mmHg was used in these experiments to ensure reproducibility of 
spontaneous activity during ramp distension, which was not always observed at faster filling rates 
and higher pressures. It has been reported previously (Maggi, Giuliani et al. 1991; Ishizuka, 
Mattiasson et al. 1995) that in an in vitro model of guinea-pig whole bladder, intravesical instillation 
of an NK2 agonist facilitated the occurrence of rhythmic contractile activity. Spontaneous contractile 
activity was potentiated in the current experiments also, but went further to examine the associated 
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afferent nerve discharge. Both the magnitude and the frequency of spontaneous detrusor activity 
were significantly increased with intravesical NKA and the effect was deemed specific to the NK2 
receptor since it was completely attenuated by GR159897. Neither senktide, nor substance P had 
any effect on spontaneous detrusor activity. A striking feature of the current experiments was the 
concurrent bursts of afferent nerve activity that were coupled to the detrusor contraction which 
were significantly greater than control and were more apparent at low/more physiological levels of 
bladder pressure. It has been shown that sensory afferent nerve activity is an essential stimulus for 
micturition, but the significance of phasic afferent activity such as this has yet to be proven. 
However, a correlation between small detrusor contractions termed micromotions and increased 
sensation has been observed in human patients with increased bladder sensation  during the filling 
phase of cystometry (Drake, Harvey et al. 2005) and a number of studies have reported increased 
non-voiding contractions in animal models of cystitis induced bladder hyporeflexia (Charrua, Cruz et 
al. 2007; Wang, Wang et al. 2008). The firing of afferent nerves associated with these spontaneous 
detrusor contractions at low levels is equivalent to distension induced afferent firing occurring at 
much greater bladder pressures under normal ramp distension. It is thus hypothesised, that this 
phasic bursting of sensory afferents is an adequate stimulus to facilitate the micturition reflex 
observed in previous experiments which did not record afferent activity, and these results provide a 
mechanism whereby increases in tachykinin levels can result in the development of OAB and bladder 
pain symptoms. Spontaneous contractions which increase the pressure in the bladder up to the 
point at which afferent firing generates physiological sensations to void would occur at a much 
reduced volume (Igawa, Zhang et al. 2004).  
These results indicate two things, firstly, that NKA, acting on NK2 receptors upon the urothelium is 
able to modulate detrusor smooth muscle compliance, and secondly, that the actions of intravesical 
NKA, and the direct downstream effects exclude actions on the sensory afferent nerves in the 
normal bladder as there is no direct effect of NKA on mechanosensitivity. It could be considered that 
NKA is able to penetrate the urothelium and act directly on the detrusor smooth muscle, however, 
previous studies using a similar methodology in both rats and guinea pigs, where detrusor 
contraction is mediated by both NK1 and NK2 (Hall, Flowers et al. 1992; Longmore and Hill 1992), 
found only NKA can stimulate micturition when given intravesically (Maggi, Giuliani et al. 1991; 
Ishizuka, Mattiasson et al. 1995), and only an NK2 selective antagonist can attenuate this response. 
These results pertain to the earlier suggestion, that intravesical NKA stimulates micturition, a 
decrease in bladder compliance, bladder capacity and residual volume, and rhythmic contractile 
activity via a different method to serosal application or intra-arterial/intravenous application of 
tachykinin agonists, and this route is most likely via stimulation of the urothelium. Another point of 
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interest is that intravesical instillation of the NK2 antagonist blocked NKA responses but the 
antagonist alone did not have an effect on either phasic detrusor contraction or afferent nerve 
activity. It is possible that an endogenous role for tachykinins via this pathway is limited under 
physiological conditions but could become more influential during disease, especially those involving 
inflammation affecting the urothelial layer.  
Further evidence of a role for the urothelium in mediating the alterations in detrusor muscle 
contraction and subsequent sensory discharge was tested by investigating the ability of NKA to 
influence the release of urothelial mediators, and the ability of intravesical tachykinins to induce 
changes in afferent nerve activity whilst the bladder was at rest.  
Firstly, intravesical infusion of all three tachykinin agonists, NKA, substance P, and senktide were 
without effect on baseline afferent activity of the bladder. The results again show that there is a no 
direct effect of tachykinins on sensory afferent nerves in the suburothelium. These experiments 
nonetheless provide an insight into the action of tachykinins within the bladder, and how they might 
influence detrusor smooth muscle contraction. The urothelium of the bladder, aside from its barrier 
function has an essential role as a mechanosensor, releasing in response to stretch, a number of 
neurotransmitters, including but not limited to acetylcholine, ATP, prostaglandins, peptides, nitric 
oxide, NGF, and cytokines. It is possible, that the effects seen by intravesical instillation of 
tachykinins occur as a result of changes to distension induced mediator release, and are therefore 
only seen during ramp distension of the bladder. 
The urothelium of the bladder has many proposed functions, but its primary and most established 
role is as a barrier to the contents of urine. It could be loosely proposed, therefore, that instillation 
of an agonist into the bladder lumen will interact only with the cells in the immediate vicinity of the 
urothelium, and that any other effects seen, such as those observed with changes in bladder 
compliance and the amplification of spontaneous activity and afferent nerve activity, will be 
downstream of urothelial activation. Measurements of ATP, acetylcholine and PGE2 were made 
before bladder distension and following ramp distension at 30µl/min to a maximal pressure of 
30mmHg. Consistent with previous literature (Birder, Nakamura et al. 2002; Hanna-Mitchell, Beckel 
et al. 2007; Sadananda, Shang et al. 2009; Tanaka, Nagase et al. 2011) it was found that the bladder 
has a tonic release of acetylcholine and ATP, as well as PGE2. It was also shown that ramp bladder 
distension induces a significant increase in both ATP and acetylcholine, but not PGE2. Intravesical 
instillation of NKA had no effect on ATP or PGE2 release at rest or during bladder distension, but 
acetylcholine release was significantly reduced during basal and also distension conditions yet there 
was no effect on the change in the ability of stretch to release acetylcholine. It has been previously 
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shown that NKA has no effect on ATP release from urothelial cells (Cheng, Mansfield et al. 2011) but 
this is the first study to investigate the effects of other mediators. 
There is a network of interstitial cells identified within the bladder which have been proposed to be 
intermediates in sensory transduction pathways. These cells have been shown to mediate 
spontaneous detrusor contraction (Biers, Reynard et al. 2006) through gap junctions (Ikeda, Fry et al. 
2007), and application of Imatinib or other tyrosine kinase inhibitors has been shown to reduce 
spontaneous detrusor contractions (Biers, Reynard et al. 2006). It is therefore proposed that the 
actions of NKA on urothelial cells, and their subsequent alterations in mediator release alter the 
functional dynamics of the interstitial cells and thus the underlying detrusor smooth muscle. 
Interstitial cells have been shown to express purinergic (Sui, Wu et al. 2006; Li, Xue et al. 2013) and 
muscarinic receptors (Johnston, Carson et al. 2008) and generate large depolarizing responses to 
ATP (Wu, Sui et al. 2004). An important role for P2Y receptors has been shown (Sui, Wu et al. 2006; 
Fry, Young et al. 2012) and thus a role in processing ATP-mediated sensory activation (Liu, Takahashi 
et al. 2009) is also a possibility. It could be possible that with multiple inputs to interstitial cells from 
mediators released from the urothelium, that downregulation of the acetylcholine/muscarinic 
component leaves only purinergic excitation which may mediate a phenotypic switch in spontaneous 
detrusor contractions. Indeed, in overactive bladder there is an increase in interstitial cell number in 
both humans and rats (Ikeda, Fry et al. 2007; Roosen, Datta et al. 2009) which is also associated with 
an increase in ATP release from the urothelium, and as mentioned previously, an increase in 
tachykinin immunoreactivity in CSPANS which are known to innervate the urothelial layers. An intact 
urothelium has also been shown to be necessary for normal interstitial cell function (Ikeda and Kanai 
2008), whilst interstitial cells were augmented by ATP (Sui, Wu et al. 2008) and which lead the 
author to suggest that intrinsic (spontaneous) activity of the bladder is of urothelial origin (Ikeda and 
Kanai 2008).  
 
Urothelially mediated responses 
In order to test the hypothesis that intraluminal NKA is able to act on urothelial cells, it was 
necessary to show that tachykinin receptors are not only present upon urothelial cells, but are also 
functional.  
NK1, NK2 and NK3 receptor mRNA was present within PMUCs, providing some credence to the 
theory that NKA is able to act on urothelial cells. Although it is not direct evidence for tachykinin 
receptor expression, the presence of all three tachykinin mRNAs suggests that the framework is 
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there for the cells to express these receptors and it could be the case that these receptors are more 
highly expressed during inflammation and disease, just as is seen in afferent sensory neuron 
immunoreactivity. Particularly intriguing is the high levels of NK3 receptor mRNA yet studies have 
not found a role for this receptor in the periphery. Despite the more prolific expression of the NK3 
receptor within the urothelium, the NK2 receptor was focussed on as evidence up to this point 
suggested that NK2 was more functionally relevant.  
The final experiments performed confirmed that functional NK2 receptors exist on the urothelium, 
and through calcium imaging of PMUCs it was shown that they respond to repeated application of 
NKA with a sustained and repeatable calcium response. These results also confirm the hypothesis 
that intravesical NKA is able to stimulate NK2 receptors on urothelial cells and this could be the 
initial stage in a process in which urothelial activation by tachykinins contributes to the maintenance 
of the micturition reflex through changes in mediator release and interactions with the underlying 
structures of the bladder wall, including interstitial cells, detrusor smooth muscle and afferent 
nerves. Other studies have previously alluded to the presence of tachykinin receptors on urothelial 
cells, but these results are the first to confirm that there are functional NK2 receptors upon the 
urothelium and their response could mediate downstream mechanosensation. 
 
Conclusion 
The role of tachykinins in the peripheral control of mouse bladder urothelium, detrusor smooth 
muscle, and afferent sensory nerves have been outlined above. This study agrees with previous 
findings suggesting that the NK1 and NK3 receptors have little function within the normal mouse 
bladder and that the NK2 receptor is shown to have a role in smooth muscle contraction.  
This study has gone further than previous reports by employing various techniques in an attempt to 
determine the precise mechanosensitive role of tachykinins within the bladder. It is the first study of 
its kind to link previous functional evidence of increased bladder contractions and micturition by 
examining the role of tachykinins on afferent nerve excitability in the mouse, particularly in response 
to physiological bladder distension. This study is also the first to show that functional NK2 receptors 
exist on the urothelium and that through agonist binding, they are able to alter the afferent 
sensations associated with the micturition reflex.  
The importance of these results in normal bladder function have been shown to be limited, however, 
there is significant potential for tachykinin mediated responses to play an essential role in bladder 
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disease states. Thus far it has been shown that there is increased tachykinin immunoreactivity and 
increased CSPAN immunoreactivity in bladder disease providing a mechanism whereby additional 
tachykinins can be released from the peripheral endings in the vicinity of the urothelium and 
interstitial cells and therefore has the potential to modulate afferent excitability.  
It would also be interesting to investigate if tachykinin receptor expression increases with 
inflammation and cystitis in the urothelium, as it has been observed that NK2 receptors in the 
urothelium respond to tachykinins and this activation can lead to potentiation of rhythmic 
contractions and afferent nerve activity, and could provide a novel route in which to target bladder 
symptoms. 
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CHAPTER 6: GENERAL DISCUSSION 
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This thesis describes a body of work investigating various pathways and receptors involved in 
bladder mechanosensitivity using a variety of techniques which converge on the hypothesis that 
sensory afferent function is a key modulator of the micturition reflex in both health and disease. The 
importance of sensory pathways in governing the micturition reflex has highlighted them as a target 
for the treatment of overactive bladder and interstitial cystitis.  
Overactive bladder syndrome (OAB) is defined by the ICS committee as ‘urgency, with or without 
urge incontinence, usually with frequency and nocturia (Abrams, Cardozo et al. 2002) and is believed 
to affect approximately 16-17% of the adult population (Milsom, Abrams et al. 2001) with a number 
of contributing risk factors including age, child birth, and increased BMI (Rortveit, Daltveit et al. 2003; 
Maserejian, Minassian et al. 2014),  
The aetiology of OAB is still unknown but is considered to be multifactoral. A major concept now 
under intense investigation is that of abnormal afferent firing from the bladder wall. This is based on 
the observations that urge and frequency of micturition are symptoms associated with the filling 
phase of the micturition reflex rather than during voiding. This has been considered in respect to 
increased spontaneous activity of the detrusor smooth muscle (Andersson 2010) upregulation of C-
fiber afferent activity and subsequent plasticity (Ouslander 2004), as well as increased activation of 
sensory C-fiber afferents in the sub-urothelium. There is also a growing consensus that release of a 
number of chemical mediators, in particular ATP, from non neuronal sources such as the urothelium 
and acting on the afferent nerves innervating both the urothelium and sub-urothelium is a 
substantial contributing factor to OAB symptoms.  
Understanding the complex sensory mechanisms which initiate the micturition reflex could provide 
novel targets for the development of more effective pharmacotherapy for bladder disorders. The 
aim of this work was to directly investigate the mechanisms underlying mechanosensation within 
the bladder using an in vitro mouse model that enables the recording of afferent nerve activity and 
intravesical pressure together with cell based assays using primary cultures of pelvic DRG and 
urothelial cells. This final discussion will focus on the control of mechanosensation and how the 
results found in this thesis contribute to our overall understanding of this process. 
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Mechanosensitivity 
Mechanosensitivity, the process by which sensory afferent nerves convey information regarding the 
state of bladder filling, is a crucial determinant in the initiation of the micturition reflex. Relaxation 
of the bladder during the storage/filling phase of micturition is required to maintain low intravesical 
pressure. Sensory afferent firing from the bladder is coordinated in the spinal cord and stimulates 
inhibitory sympathetic input to the detrusor smooth muscle causing relaxation, as well as an 
inhibitory effect on bladder ganglia to inhibit excitatory parasympathetic inputs to the bladder. The 
switch from urine storage to voiding occurs when sensory afferent activity reaches a critical 
threshold, and central mechanisms cause a switch in the autonomic outflow resulting in 
parasympathetic excitation and sympathetic inhibition. Despite this, the current pharmaceuticals for 
OAB are designed to modulate cholinergic pathways with a view to suppressing parasympathetic 
drive, as opposed to targeting the sensory process mediating this response. 
What remains unclear however, is the mechanisms that regulate the sensory afferent discharge 
from the bladder, and most importantly, determining how this can be effectively targeted to 
improve the urgency, frequency and pain symptoms of OAB and IC. 
The detection of bladder stimuli by afferent nerves is inherently linked to the feelings which progress 
from an urge to void, followed by discomfort, and finally pain associated with an abnormally full 
bladder. Normal bladder function relies on several different afferent subtypes, in different layers of 
the bladder wall and following different pathways to the spinal cord.  
There are typically considered to be two structurally distinct populations of bladder afferents; those 
with terminal receptive fields in the detrusor smooth muscle, and those in the vicinity of the 
urothelium (Zagorodnyuk, Brookes et al. 2010). The structural location of these two populations of 
afferents reflects the two current theories for how mechanosensation is triggered. The first theory is 
that initiation of afferent firing is caused by mechanical deformation of the urothelial layer and 
detrusor smooth muscle. This type of mechanosensitivity is dependent on the distortion of 
mechanically gated ion channels on peripheral varicosities innervating both the muscle layer and the 
sub-urothelial layer (Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). These respond to 
either muscle stretch and act as in-series tension receptors or to distortion of the urothelium by 
experimental stoking. The second theory is that of an indirect mechanosensation mechanism 
through the release of mediators from the urothelium which either directly activate sub-urothelial 
afferents or have a modulating influence over their mechanosensitivity. This latter concept suggests 
that the urothelium acts as a sensory web, a notion that has recently been gaining popularity. 
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Bladder distension evokes the release of a number of mediators that act on chemosensitive afferent 
endings which express a number of receptors that trigger changes in excitability, for example TRP 
channels and purinergic receptors (Rong, Spyer et al. 2002; Zagorodnyuk, Costa et al. 2006; Daly, 
Rong et al. 2007; Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). There is, of course, likely 
to be a contribution of both these pathways in the control of reflex micturition and a blurring 
between the classifications of afferents, particularly in disease, where there is sensitisation of 
mechanosensitive afferents, and the recruitment of silent afferents that enhance the sensory signals 
flowing from the bladder towards the CNS (Häbler, Jänig et al. 1990; Shea, Cai et al. 2000; Rong, 
Spyer et al. 2002; Xu and Gebhart 2008). 
These two concepts provide a simplistic view of mechanosensation in the bladder as can be seen in 
fig 6.1.2. The role of the urothelium is becoming increasingly apparent, as both a transducer of 
tension and in the release of neurotransmitters from the distending bladder, and as such is currently 
considered a major sensory structure. However, other cells in the bladder wall have been proposed 
to contribute to mechanosensitivity, particularly interstitial cells, which may act as intermediaries 
responding to mediators released from the urothelium and have a modulating influence over 
smooth muscle contractility and afferent excitability (Wiseman, Fowler et al. 2003; Davidson and 
McCloskey 2005; Fry, Sui et al. 2007) 
A major focus of this thesis has been to investigate these mechanosensitive mechanisms and 
attempt to distinguish the actions of the urothelium from those of the afferent nerves and detrusor 
smooth muscle in order to provide a clearer picture of the control of bladder sensation.  
 
Mechanosensation mediated by stretch/tension 
Increased tension on the detrusor smooth muscle either via mechanical stretch or active 
contractions that causes an increase in intravesical pressure has been shown in this thesis to be a 
major stimulus of sensory nerve activity. However, the precise relationship between the muscle and 
afferent ending is difficult to determine because of the complex network of internal structures 
contributing to a multifaceted afferent response. 
Afferent nerve recording experiments performed in this thesis employed ramp distension of the 
bladder to better mimic the slow filling of the bladder and accompanying rise in intraluminal 
pressure that occurs physiologically. It is observed that afferent nerve activity is inextricably linked to 
changes in intraluminal pressure. This is similar to other studies inducing bladder distension in vitro 
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(Vlaskovska, Kasakov et al. 2001; Rong, Spyer et al. 2002; Daly, Rong et al. 2007) as well as bladder 
stretch in vitro (Zagorodnyuk, Costa et al. 2006; Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 
2008) where a distinction between low and high threshold afferents has been made. In those studies, 
a larger proportion of the afferent response was attributed to low rather than high threshold 
mechanoreceptors, particularly within the physiological ranges of distension (Igawa, Zhang et al. 
2004). 
An important consideration in this thesis was the relationship between afferent firing and bladder 
compliance which became even more apparent upon comparing the two bladder filling rates used in 
this thesis, 30µl/min and 100µl/min. As described in chapter 4, an infusion rate of 100µl/min has 
been used in a number of previous studies (Vlaskovska, Kasakov et al. 2001; Rong, Spyer et al. 2002; 
Cockayne, Dunn et al. 2005; Daly, Rong et al. 2007) investigating afferent nerve responses to bladder 
distension and has been considered as a standard for these experiments. The effects of tachykinins 
were studied using a slower fill rate of 30µl/min in order to maintain consistent phasic detrusor 
contractions. Further analysis of bladder distension at the two filling rates from all experiments 
revealed a significant difference in the compliance and afferent response profiles (fig 6.1.1). A 
significant increase in the compliance of the muscle is observed with a slower filling rate, allowing a 
larger volume before reaching a set pressure and a reduction in the afferent response to given 
pressures. These results support the idea of in-series tension receptors within the bladder and that 
at a slower rate of filling, the structures have the ability to accommodate the volume more 
effectively and less tension is produced in the bladder wall. 
 
Fig 6.1.1 Mean±(SEM) pressure/volume and pressure/nerve relationships of bladders distended with 
saline at either 30µl/min (n=50) and 100µl/min (n=40).  
 
An infusion rate of 30µl/min is considered to be more within the physiological range of mouse 
bladder distension and rates between 20-30µl are commonly used during cystometry recordings in 
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mice (Andersson 2011). It would be my recommendation that future studies examining physiological 
bladder function be performed at reduced infusion rates, to ensure the bladder is allowed to 
accommodate the increase in volume without unphysiological levels of stretch in the bladder wall. It 
is possible that a faster infusion rate provides information regarding nociceptive afferent firing from 
the bladder.  
The role of tension receptors and their ability to mediate afferent nerve excitability was especially 
apparent with the spontaneous detrusor contractions that occur during ramp distension. Even small 
changes in intravesical pressure directly coupled to detrusor contraction, in the range of 1-2mmHg, 
were able to induce large transient increases in afferent nerve activity. These contractions were of 
myogenic origin since they persisted in the presence of tetrodotoxin (fig 2.6.4). Phasic detrusor 
activity in whole bladder preparations has previously been shown in the guinea pig, and it was 
revealed, using a novel electrode displacement technique, that these phasic detrusor contractions 
were associated with localised stretch of the bladder wall (Drake, Harvey et al. 2003; Drake, Harvey 
et al. 2005). If the detrusor is overactive and is producing large spontaneous contractions and 
localised stretch of the bladder wall, this would result in an exaggerated sensory afferent discharge 
from the periphery, and rapidly reach the threshold for micturition at lower bladder volumes thus 
causing symptoms such as urge and discomfort. This is a potential mechanism underlying increases 
in micturition frequency in animal models of bladder cystitis which are associated with increases in 
the frequency of reflex (non-voiding) bladder contractions (Charrua, Cruz et al. 2007; Wang, Wang et 
al. 2008). Furthermore, a greater prevalence of phasic detrusor activity has been correlated to 
patients with increased sensation during filling cystometry (Drake, Harvey et al. 2005). Despite the 
phenotype in this case being increased contractions of the detrusor, the trigger for this could 
potentially arise from the urothelium as was shown in the experiments employing intravesical 
instillation of NKA, and could include a contribution from interstitial cells. Indeed, it has been shown 
that removal of the urothelium significantly inhibits stretch sensitive muscle/urothelial afferents 
(Zagorodnyuk, Gibbins et al. 2007) and these endings are also able to respond to ATP.  
The data are in agreement with a considerable body of literature showing that a major proportion of 
bladder pelvic nerve mechanosensation occurs via the muscular and muscular/urothelial stretch 
sensitive afferents in the mouse, rat, guinea pig and cat (Häbler, Jänig et al. 1993; Sengupta and 
Gebhart 1994; Su, Sengupta et al. 1997; Shea, Cai et al. 2000; Zagorodnyuk, Costa et al. 2006; 
Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). This was further explored using a number 
of pharmacological tools found to stimulate sensory afferent firing which were directly coupled with 
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contraction of the muscle. This was most apparent using NKA, which via NK2 receptors induced 
afferent activity that was abolished following elimination of the contractile response. 
In contrast, P2X receptor stimulation of afferent nerves with αβMe-ATP evoked a significant increase 
in afferent nerve discharge even in the absence of muscle contraction. In the presence of calcium, 
αβMe-ATP induced a sharp contraction of smooth muscle and an even greater afferent nerve 
discharge than that in calcium free medium. This suggests that there are two distinct pathways 
responding to P2X receptor stimulation, a direct activation of P2X receptors on sensory afferent 
endings, and an indirect afferent response as a result of P2X dependent contraction of detrusor 
smooth muscle and the subsequent activation of mechanically gated afferents.  
 
Fig 6.1.2 Theoretical model depicting interactions between urothelial cells, interstitial cells, and 
detrusor smooth muscle during bladder distension, and the control of afferent nerve firing. Stretch of 
urothelial cells can release mediators that target bladder nerves and interstitial cells; urothelial cells 
can also be targets for neurotransmitters released from suburothelial nerves or through autocrine 
mechanisms. Afferent nerves can be activated by direct or indirect mechanotransduction. 
Abbreviations: Ach, acetycholine; ATP, adenosine triphosphate; ADP, adenosine diphospahte; CX43, 
connexion 43 gap junction protein; CSPAN, capsaicin sensitive primary afferent neuron; iCa2+, 
intracellular calcium; NKA, neurokinin A; NK2, tachykinin 2 receptor; P2X and P2Y, purinergic 
receptors; TRPV1, transient receptor potential vanilloid 1; UTP, uridine triphosphate; UDP, uridine 
diphoshate. 
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Mechanosensation not mediated by stretch/tension 
A number of studies have identified a component of the afferent nerve response that is not a result 
of bladder stretch/tension. Xu and Gebhart (2008) identified a proportion of pelvic afferents that did 
not respond to stretch and had virtually no response to stroking or probing, which they called 
urothelial afferents. A similar subclass of afferents was reported to be present in the guinea pig 
bladder (Zagorodnyuk, Gibbins et al. 2007) which were proposed to act as chemoreceptors. These 
afferents showed reduced responses following removal of the urothelium, and this was proposed to 
be as a consequence of removing ATP release from the urothelium. However, these studies did not 
assess the role of these afferents in response to the physiological stimuli of bladder filling. It is these 
urothelial afferent fibers which are believed to be responsible for the functionally distinct sensitivity 
to αβMe-ATP and capsaicin which are reported to make up approximately 10% of the total afferent 
innervations (Zagorodnyuk, Gibbins et al. 2007; Xu and Gebhart 2008). The TRPV1 receptor is not 
considered to be mechanically gated. Nevertheless, as discussed in chapter 4, the afferent response 
to ramp distension was attenuated in the TRPV1-/- (KO) mice, and was proposed to arise from these 
urothelial endings. Further evidence for this comes from the observation that afferent responses to 
αβMe-ATP were significantly attenuated both in the TRPV1-/- (KO) mice, and following 
pharmacological antagonism of TRPV1, yet the amplitude of the detrusor muscle contraction was 
unchanged. This is evidence that the two distinct P2X receptor pathways described above (direct and 
secondary to contraction) can operate independently of each other. TRPV1 receptor function 
appears not to be related to direct mechanosensitivity induced by muscle contraction, but is coupled 
to the afferent mechanisms responsible for αβMe-ATP induced afferent sensitivity that is 
independent of muscle contraction. This is further indicated by the observation that in TRPV1-/- (KO) 
mice there was no change in bladder compliance during distension but afferent nerve firing was 
significantly attenuated. This again is evidence that these two mechanosensitive pathways can 
function independently, although the relative contribution of this urothelial component of 
mechanosensation appears much smaller than that from the muscle.  
Further evidence for this distinct purinergic based afferent response that is independent  of detrusor 
contraction can be found from previous studies using P2X knockout mice, although the contribution 
of the urothelial component is hard to quantify given the way the data is presented (Vlaskovska, 
Kasakov et al. 2001). This is because while afferent activity was significantly attenuated in the P2X3
-/- 
(KO) mice, this was accompanied by a significant change in muscle function (Vlaskovska, Kasakov et 
al. 2001). The volume required to elicit maximum pressure was almost double that seen in the WT 
mouse, with a corresponding increase in the time taken to achieve this pressure, thus indicating that 
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the compliance of the smooth muscle had changed, and with it, the level of afferent firing. 
Significant changes in bladder volumes as well as decreases in non-voiding contractions were 
observed in another study using  P2X3
-/- (KO) mice (Cockayne, Hamilton et al. 2000) which also found 
no significant change in the pressure required to elicit micturition. This tends to confirm the view 
that pressure or bladder wall tension is a major stimulus for afferent evoked micturition. 
Further studies by Cockayne et al (2005) compared directly the relationship between afferent nerve 
firing and intravesical pressure in single and double knockouts of P2X2 and P2X3 receptors since these 
receptors often form heteromeric assemblies (North 2002). A significant change in detrusor muscle 
function was observed, but analysis of the afferent nerve/pressure response curves indicated that 
whole nerve and single unit nerve firing in response to distension was significantly attenuated 
(Cockayne, Dunn et al. 2005). In these experiments, as with my own studies examining multiunit 
afferent responses in TRPV1-/- (KO) mice, approximately 80% of distension induced firing persisted in 
the knockouts (Cockayne, Dunn et al. 2005). Based on these findings it is my opinion that the P2X2/3 
receptors on bladder afferent nerves contribute only a portion to the normal physiological response 
to distension and that this proportion of the response arises from urothelial afferents that are 
tension insensitive. Due of the similar level of afferent attenuation in both the TRPV1-/- and P2X2/3
-/- 
mouse it is tempting to speculate that the proportion of urothelial afferents contributing to the 
distension response is the same in both studies. Thus, I would propose that ATP is progressively 
released from the urothelium during distension with subsequent activation of purinergic receptors 
on urothelial afferents also expressing the TRPV1 receptor (Ferguson, Kennedy et al. 1997; 
Vlaskovska, Kasakov et al. 2001). Reduced ATP release from the urothelium in TRPV1-/- (KO) mice 
would also contribute to blunted afferent sensitivity in these animals. 
The functional role of these distension insensitive but purinergic and capsaicin sensitive afferents is 
unclear. A large proportion of capsaicin sensitive afferents have been shown to colocalise with 
purinergic receptors and these are reported to respond both to high and low distension threshold 
(Rong, Spyer et al. 2002; Daly, Rong et al. 2007; Zagorodnyuk, Brookes et al. 2010). It is likely, despite 
contributing only a moderate proportion of the overall response to distension, that these afferents 
are essential to the normal micturition reflex. Due to their localisation within the bladder close to 
the urothelium, they are also in prime position to respond to factors released from the urothelium, 
including ATP. These endings may also be particularly important in bladder disorders when 
sensitisation of afferent pathways occurs. This view is supported by the observed upregulation of 
TRPV1 sensitive afferents seen in disease, and the corresponding symptomatic improvement 
following intravesical resiniferatoxin treatment (Apostolidis, Brady et al. 2005; Apostolidis, Popat et 
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al. 2005). As tachykinin neuropeptides are primarily contained within CSPANS, tachykinin 
immunoreactivity is significantly increased in the sub-urothelium of patients with idiopathic detrusor 
overactivity (Moore K H 1992; Smet, Moore et al. 1997), and tachykinins have been shown to 
enhance excitability in capsaicin-responsive DRG neurons (Sculptoreanu and de Groat 2007) but not 
alter the mechanosensitive response to distension, it is still possible that a proportion of the positive 
effects elicited by resiniferatoxin on bladder disorders is mediated by depletion of tachykinins from 
peripheral terminals.    
My findings during the course of this PhD study are that in the normal bladder the majority of the 
afferent response is related to intravesical pressure/bladder wall tension, but there is also a 
proportion that is tension insensitive.  
 
The role of the urothelium 
The concept of bladder afferent nerves responding to ATP is well established and is considered to be 
mediated via release from the urothelium. Results obtained showing that baseline afferent firing 
increases following the intravesical instillation of αβMe-ATP is consistent with that view and 
prompted a series of investigations in which receptor expression and mediator release was directly 
investigated.  
I was therefore able to show by RT-qPCR that the urothelium expresses purinergic receptors and 
furthermore in functional studies, provide evidence towards an indirect role for the urothelium in 
sensory signalling. These studies contribute to the growing view that the urothelium is not a simple 
barrier but plays a role as a sensory structure.  
As was shown in chapters 4 and 5 of this thesis, a number of mediators including acetylcholine, ATP 
and PGE2 are released from the urothelium and of these; the release of ATP is the most sensitive to 
bladder distension. Other studies have also shown nitric oxide release (Birder, Nakamura et al. 2002), 
but this was not explored in the current study. ATP is released from the urothelium during distension 
and has a number of proposed roles. Vesicular release of ATP during stretch is found to be essential 
to maintaining the barrier function of the urothelium as the bladder expands (Wang, Lee et al. 2005). 
This autofeedback mechanism allows membrane trafficking during stretch and relaxation (Wang, Lee 
et al. 2005). In addition, the presence of functional purinergic receptors within the underlying 
structures of the bladder including the detrusor smooth muscle, interstitial cells, and tension 
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insensitive afferent nerve fibers indicates that non-neuronal ATP has a major role to play in the 
bladder.   
The level of distension-evoked ATP release increases significantly with age (Yoshida, Homma et al. 
2001; Collins, Daly et al. 2013), a known risk factor for all lower urinary tract symptoms. ATP is also 
increased in a number of disease models including spinal cord injury, cyclophosphamide induced 
inflammation, and feline interstitial cystitis (Sun and Chai 2002; Khera, Somogyi et al. 2004; Smith, 
Vemulakonda et al. 2005; Smith, Gangitano et al. 2008). Instillation of a number of current 
therapeutic agents including DMSO, heparin, and Botox, into the bladder results in a significant 
reduction in distension-evoked ATP release and is associated with an improvement in lower urinary 
tract symptoms. ATP release is also altered in human luminal samples from patients with OAB and 
has been proposed as a biomarker for OAB detection (Cheng, Mansfield et al. 2013; Silva-Ramos, 
Silva et al. 2013). 
Evidence supporting a significant role for the urothelium in mechanotransduction comes from a 
number of experiments performed in this thesis. Firstly, deletion of the TRPV1 receptor abolishes 
distension evoked ATP release from the urothelium and contributes to the sensory deficit observed 
during bladder distension in the TRPV1-/- (KO) mouse. TRPV1-mediated ATP release in urothelial cells 
has been reported by a number of authors (Birder, Kanai et al. 2001; Sadananda, Shang et al. 2009; 
Dunning-Davies, Fry et al. 2013) but as TRPV1 is not thought to directly activate mechanically gated 
channels, the mechanisms responsible for these actions are uncertain. Data from both calcium 
imaging experiments and biochemical release assays provide evidence for the underlying 
mechanisms of distension-induced ATP release which is consistent with previous data on the effect 
of pharmacological manipulation of vesicular release (Birder, Barrick et al. 2003; Matsumoto-Miyai, 
Kagase et al. 2009; Matsumoto-Miyai, Kagase et al. 2011; Collins, Daly et al. 2013). Moreover, Birder 
et al (2002) did not see an increase in membrane capacitance in TRPV1-/- (KO) mouse bladders upon 
distension suggesting that the actions of TRPV1 may be upstream of vesical fusion (Birder, Nakamura 
et al. 2002). These results are consistent with Wang et al (2005) who proposed that vesicular ATP 
release is essential to the maintenance of the urothelial barrier, and thus a loss of ATP release would 
render the barrier more permeable. Purinergic receptors have also been identified on the 
suburothelial interstitial cells where they make close contact with afferent endings (Wiseman, 
Fowler et al. 2003), and are able to depolarise afferents in the surrounding area up to several 
hundred microns away (Sui, Wu et al. 2004). With this evidence, it is possible that the activation of 
suburothelial cells is able to create a functional link between urothelial ATP and afferent neurons 
and has the potential to influence their excitability.  
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The specificity of ATP in mediating direct afferent nerve transduction was made apparent by studies 
utilizing intravesical infusion of NKA. Intravesical NKA had no effect on ATP release, either in the 
basal state, or during bladder distension, and was not able to influence spontaneous afferent 
excitability. However, NKA was able to significantly reduce ACh release by a mechanism that has yet 
to be determined. As afferent nerve activity was not directly affected this suggests that urothelial 
ACh is not a major stimulus for suburothelial afferent nerves and that ATP is the major player. 
Intravesical NKA was however, able to significantly alter the overall afferent response to distension 
through a novel pathway that could potentially involve suburothelial interstitial cells. In this 
hypothesis, the interstitial cells provide a functional link between the mediators released from the 
urothelium and the contractile properties of the detrusor smooth muscle. Interstitial cells have been 
shown to express both purinergic (Cheng, Scigalla et al. 2011; Li, Xue et al. 2013) and muscarinic 
receptors (Johnston, Carson et al. 2008). It is proposed that under normal conditions, the role of ACh 
acting on interstitial cells is to tonically inhibit contraction of the bladder as it fills. A decreased 
release of urothelial ACh could therefore allow the bladder to develop more frequent and higher 
amplitude spontaneous contractions that are coupled to bursts in afferent nerve activity. This is 
counterintuitive since muscarinic blockers are the mainstay of current therapy for OAB (Abrams and 
Andersson 2007). However, this action is likely to be mediated at the level of smooth muscle which 
expresses M2 and M3 receptors, without which parasympathetically mediated bladder contractions 
are lost (Chess-Williams, Chapple et al. 2001). In this respect, it has been shown that ACh 
significantly inhibited the afferent response to bladder distension while concurrently reducing 
bladder compliance in mice (Daly, Chess-Williams et al. 2010). Thus, it is hypothesised that 
tachykinins can stimulate phasic contractile activity by inhibiting ACh release, via a process of 
disinhibition. Under normal physiological conditions there is the potential for multiple mechanisms 
involving muscle contractility and urothelial release mechanisms acting on tension-sensitive and 
tension-insensitive afferents driving sensory afferent activity. The balance of these mechanisms may 
alter in a number of bladder diseases leading to increases in reflex bladder contractility and sensory 
signalling.  
A potential role for interstitial cells in the control of detrusor smooth muscle and afferent nerve 
activity has been discussed on a number of occasions although this thesis has not examined their 
role directly.  Nonetheless, there are a number of bladder conditions in which ATP release is thought 
to increase, accompanied by increases in reflex bladder activity (Smith, Vemulakonda et al. 2005; 
Smith, Gangitano et al. 2008) which are reported to involve interstitial cells. Human interstitial cell 
cultures have been shown to respond to nanomolar concentrations of ATP and P2Y receptors have 
been implicated in mediating spontaneous and electrical activity of guinea-pig interstitial cells to ATP 
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(Sui, Wu et al. 2006). ATP induces an intracellular Ca2+ transient (Wu, Sui et al. 2004; Cheng, Scigalla 
et al. 2011; Li, Xue et al. 2013) which propagates through the interstitial cell network (Fry, Sui et al. 
2007), and similar to that of gastrointestinal tract, is hypothesised to coordinate myogenic 
contractions.  
Non-neuronal ATP released from the bladder is likely to have an important role in the control of 
sensory afferent discharge. It is not likely to provide a direct mechanism controlling a large 
proportion of the afferent response but its ubiquitous expression and functional properties suggest 
that the coordination of ATP release from the urothelium and action on interstitial cells, afferent 
nerves and detrusor smooth muscle, is crucial to normal voiding reflexes and changes are a key 
marker in disease states.  
As the importance of ATP release in sensory afferent firing becomes apparent, and the ability of the 
urothelium to autoregulate ATP release becomes established, the possibility of new drugs that 
target purinergic receptors becomes feasible. Moreover, the results showing that these receptors 
are present on the urothelium and that they modulate intracellular calcium concentration, an 
essential intracellular event linked to distension evoked ATP release (Matsumoto-Miyai, Kagase et al. 
2009; Matsumoto-Miyai, Kagase et al. 2011; Dunning-Davies, Fry et al. 2013), suggests the 
urothelium itself could be a therapeutic target. One advantage of the urothelium as a target for 
pharmaceutical agents is that drugs acting from the luminal side of the bladder have limited access 
to systemic and CNS mechanisms and therefore carry a reduced risk of side effects, the most 
commonly cited reason for a discontinuation rate of 75% of patients after 12 months with 
antimuscarinics (Wagg, Compion et al. 2012; Veenboer and Bosch 2013)(Wagg 2012, Veenboer 
2013). 
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Conclusion 
As with any avenues of scientific research, the work in this thesis has generated a number of 
questions and interesting avenues for future investigation. The major stimulus for afferent signalling 
is bladder distension which results in an increase in transmural tension. However, my findings have 
shown that intravesical application of agonists acting at the level of the urothelium has the potential 
to alter this dynamic process. The development and use of isolated cell models has been key in 
determining the molecular mechanisms underlying urothelial stimulation and responses. However, 
by applying these principles to the whole bladder it has been possible to evaluate the impact of the 
cellular events for overall sensory signalling. In this regard, determining the physiology of the 
urothelium and its interactions with associated cells would be, in my opinion, the key to determining 
therapeutic targets for the treatment of overactive bladder.   
One potential target for urothelially released ATP are the bladder afferent nerves which express P2X2 
and P2X3 receptors. These are ligand-gated ion channels that are fast acting and undergo rapid 
desensitisation following agonist binding (Virginio, MacKenzie et al. 1999; North 2002). This was 
shown to be the case in experiments carried out in this thesis, whereby application of αβMe-ATP to 
thoraco-lumbar and lumbo-sacral DRG neurons induced marked increases in intracellular calcium on 
the first application, but subsequent responses were significantly attenuated, a result which has 
been observed before using whole cell patch clamp electrophysiology (Cockayne, Hamilton et al. 
2000; Cockayne, Dunn et al. 2005). Considering that the mechanosensitive role of P2X3 receptors on 
bladder afferent nerves is presumed to be through ATP released from the urothelium, and this 
release of ATP has been shown to be both continual and to increase in concentration during bladder 
stretch (Vlaskovska, Kasakov et al. 2001), it is likely that receptor desensitisation is a limiting factor in 
sensory signalling.  Nevertheless a role for urothelially released ATP and its metabolites is most 
certainly important in mechanosensation, but the idea that P2X3 receptors upon the afferent nerves 
are the mediators of significant mechanosensation is over simplified. As this thesis has 
demonstrated, other purinergic receptor mechanisms are likely involved, interacting with various 
cell types and other mediators to offer a dynamic afferent sensitivity.  
The results of this thesis support the concept for a role whereby the urothelium releases a number 
of agents including ATP which play a coordinated role to influence detrusor muscle contraction, 
afferent nerve activity, and bladder compliance. The use of experimental techniques that provide 
information regarding afferent nerve activity are essential to determining the physiological roles of 
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the bladder, as this is the major stimulus for the initiation of the micturition reflex. Understanding 
how these mechanisms are influenced in disease is the next challenge. 
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